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FSP Section 11,000
Checklists and Illustrative Financial 
Statements for Health Care Organizations
Description
.01 Health care organizations may be classified by sponsorship or legal structure within the following 
broad categories:
Not-for-profit business-oriented: These are essentially self-sustaining from fees charged for goods and 
services. The fees charged by such organizations generally are intended to help the organization 
maintain its self-sustaining status rather than to maximize profits for the owner's benefit. Such 
organizations often are exempt from federal income taxes and may receive contributions of relatively 
small amounts from resource providers that do not expect commensurate or proportionate pecuniary 
returns.
Not-for-profit non-business-oriented: These are voluntary health and welfare organizations as defined 
in FASB Statement of Financial Accounting Standards (SFAS) No. 117, Financial Statements of Not-for- 
Profit Organizations. Such organizations are within the scope of the AICPA Audit and Accounting 
Guide Not-for-Profit Organizations rather than that of the Health Care Organizations Guide.
Governmental: Often called public health care entities, the entities are owned and operated by federal, 
state, city, or county governments or other political subdivisions.
Investor- (or operator-) owned: These organizations operate as stock corporations, partnerships, or sole 
proprietorships.
.02 Health care organizations include, but are not limited to, the following:
• Clinics, medical group practices, individual practitioners and practice associations, and other ambu­
latory care organizations
• Continuing care retirement communities (CCRCs)
• Health maintenance organizations and similar prepaid health care plans
• Home health agencies
• Hospitals
• Nursing homes that provide skilled, intermediate, and less intensive levels of health care
• Parent companies, holding companies, and other organizations that primarily plan, organize, and 
oversee health care services
Applicability of This Checklist
.03 This checklist, and the illustrative financial statements included herein, follow the guidance con­
tained in the AICPA Audit and Accounting Guide Health Care Organizations (with conforming changes as of 
May 1, 1999), referred to as "the Guide." The checklist and illustrative financial statements should be 
used for not-for-profit business-oriented and investor-owned health care organizations. Not-for-profit health care
1
providers that receive federal financial assistance may be required to have an audit conducted in accordance 
with Office of Management and Budget (OMB) Circular A-133, Audits of States, Local Governments, and 
Non-Profit Organizations. Section 11,300 includes guidance for auditors' reports for audits performed under 
OMB Circular A-133.
.04 Although the Guide also applies to state and local government-owned health care providers, this 
checklist does not include disclosures or sample financial statements of government-owned providers. Chapter 
1 of the Guide discusses the application of generally accepted accounting principles (GAAP) to governmental 
health care providers.
.05 In addition, this checklist does not apply to not-for-profit non-business-oriented health care organiza­
tions. For these types of organizations, follow the guidance in the AICPA Audit and Accounting Guide 
Not-for-Profit Organizations, and the AICPA's disclosure checklist entitled Not-for-Profit Organizations.
Legislation and Regulation
.06 Significant aspects of health care organization operations are affected by government legislation and 
regulation with many states adopting laws governing the granting of licenses, as well as scope of services to 
be rendered. In addition, many independent organizations and governmental agencies, including Medicare 
and Medicaid, evaluate programs and services of health care organizations to determine compliance with 
set standards.
Basic Financial Statements
.07 The financial reporting for not-for-profit business-oriented organizations and investor-owned health 
care enterprises generally is consistent except for transactions that clearly are not applicable. For example, 
not-for-profit business-oriented organizations, by their nature, do not have shareholders' equity. On the 
other hand, investor-owned health care enterprises typically do not receive contributions. Throughout this 
checklist, disclosure/presentation questions are preceded by certain symbols. Not-for-profit business- 
oriented organizations should complete all disclosure items denoted with a star (★). Investor-owned health 
care enterprises should complete all disclosure items denoted with a diamond (♦).
.08 The basic financial statements of health care providers generally consist of a statement of financial 
position or balance sheet, a statement of activities or income statement or statement of operations, a statement 
of changes in net assets (equity), a statement of cash flows, and notes to the financial statements. The titles 
of the financial statements will depend upon the business form of the provider (i.e., not-for-profit, investor- 
owned, etc.). See the chart below.
Basic Financial Statements
* May be combined with the Statement of Operations.
Not-for-Profit
Business-Oriented Organization Investor-Owned Organization
Balance Sheet/Statement of Financial Position Balance Sheet
Statement of Operations/Statement of Activities Statement of Operations/Income Statement
Statement of Changes in Net Assets (Fund Balance)* Statement of Changes in Equity*
Statement of Cash Flows Statement of Cash Flows
Note: This publication was extracted from sections 11,000 through 11,500 of the AICPA Financial Statement 
Preparation Manual (FSP).
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FSP Section 11,100 
Instructions
Purpose
.01 The checklists and illustrative financial statements included in this section have been developed by 
the staff of the Accounting and Auditing Publications Team of the AICPA as nonauthoritative technical 
practice aids to be used as a memory jogger to aid in the audit of financial statements of health care 
organizations.
The checklists have been updated to include guidance relevant to health care organizations 
contained in official pronouncements through:
• FASB Statement of Financial Accounting Standards No. 137, Accounting for Derivative 
Instruments and Hedging Activities—Deferral of the Effective Date of FASB Statement No. 
133
• FASB Interpretation No. 43, Real Estate Sales
• FASB Technical Bulletin No. 97-1, Accounting under Statement 123 for Certain Employee 
Stock Purchase Plans with a Look-Back Option
• AICPA Statement on Auditing Standards No. 90, Audit Committee Communications
• AICPA Statement of Position 00-1, Auditing Health Care Third-Party Revenues and 
Related Receivables
• AICPA Audit and Accounting Guide Health Care Organizations (with conforming 
changes as of May 1, 1999)
• AICPA Practice Bulletin No. 15, Accounting by the Issuer of Surplus Notes
• FASB EITF consensuses adopted up to and including the March 2000 Emerging 
Issues Task Force (EITF) meeting
The checklists and illustrative financial statements should be modified, as appropriate, for 
subsequent pronouncements. In determining the applicability of a pronouncement, its effective 
date should also be considered.
Instructions
.02 The checklists consist of a number of questions or statements that are accompanied by references to 
the applicable authoritative pronouncements. The checklists provide for checking off or initialing each 
question or point to show that it has been considered. Users should check: "yes" if the disclosure has been 
appropriately made, "no" if the disclosure has not been made, or "n/a" if the disclosure is not applicable to 
the organization. The auditor should consider the effect of a "no" answer on his/her report. A "no" answer 
that is material to the financial statements may warrant a departure from an unqualified opinion. (See paragraphs 
20-63 of SAS No. 58, Reports on Audited Financial Statements, as amended [AICPA, Professional Standards, vol. 
1, AU sec. 508.20-.63].) If a "no" answer is checked, the authors recommend that a note be made in the right
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margin to explain why the disclosure was not made (for example, if the disclosure was not made because it 
was not material to the financial statements, write "not material" in the right margin). The right margin may 
be used for other remarks or comments as appropriate, including cross-referencing to applicable workpapers 
where the support to a disclosure may be found. Use of the checklists requires the exercise of individual 
professional judgment and may likely require some modification based on the circumstances of individual 
engagements.
.03 This checklist is applicable to not-for-profit business-oriented and investor-owned health care organiza­
tions. While financial reporting for these types of organizations is generally consistent, there are requirements 
that apply to only not-for-profit business-oriented organizations and those that apply to only investor-owned 
enterprises. Symbols have been used to indicate the applicability of presentation and disclosure requirements 
to these types of organizations. Not-for-profit business-oriented organizations should complete all disclosure 
items denoted with a star (★). Investor-owned organizations should complete all disclosure items denoted 
with a diamond (♦).
.04 The checklist is not a substitute for the authoritative pronouncements. Users of the checklists and 
illustrative financial statements are urged to refer directly to applicable authoritative pronouncements 
when appropriate. The checklists and illustrative financial statements do not include all disclosures and 
presentation items promulgated nor do they represent minimum requirements. Disclosures prescribed 
by pronouncements deemed remote for health care organizations are not included in this document. The 
checklists and illustrative financial statements are "tools" and in no way represent official positions or 
pronouncements of the AICPA.
.05 If you have further questions, call the AICPA Technical Hotline at 1-888-777-7077.
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FSP Section 11,200
Financial Statements and
Notes Checklist
.01 This checklist has been developed by the staff of the Accounting and Auditing Publications Team of 
the AICPA as a nonauthoritative practice aid. The checklists and illustrative financial statements do not 
include all disclosures and presentation items required by GAAP; as a result, pronouncements deemed 
unlikely to be encountered in financial statements of health care providers are not included.
.02 Explanation of References:
★ = Disclosure applicable for not-for-profit organizations
♦ = Disclosure applicable for investor-owned organizations
AAG = AICPA Audit and Accounting Guide Health Care Organizations (with conform­
ing changes as of May 1, 1999)
AC = Reference to section number in FASB Accounting Standards—Current Text
APB = Accounting Principles Board Opinion
ARB = Accounting Research Bulletin
AU = Reference to section number in AICPA Professional Standards (vol. 1)
EITF = FASB Emerging Issues Task Force consensus
FASBI = FASB Interpretation
SAS = AICPA Statement on Auditing Standards
SFAS = FASB Statement of Financial Accounting Standards
SOP = AICPA Statement of Position
TB = FASB Technical Bulletin
.03 Checklist Questionnaire:
This checklist is organized into the sections listed below. Carefully review the topics listed and consider 
whether they represent potential disclosure items for the health care provider. Place a check mark by the 
topics or sections considered not applicable; these sections need not be completed. For example, if the entity 
does not have any extraordinary items, place a check by "Extraordinary Items" and skip this section when 
completing the checklist.
Place   by
Sections Not Applicable
• General
A. Titles and References
B. Comparative Financial Statements
• Statement of Financial Position/Balance Sheet
A. General
B. Cash and Cash Equivalents
C. Investments
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Place  by
Sections Not Applicable
D. Receivables _________
E. Beneficial Interests in Assets Held by Others _________
F. Property and Equipment, Supplies, and Other Assets _________
G. Current Liabilities, Notes Payable, and Other Debt _________
H. Other Liabilities and Deferred Credits _________
I. Lessor Leases _________
J. Lessee Leases _________
K. Net Assets _________
L. Restricted Resources _________
M. Agency Transactions _________
• Statement of Activities/Income Statement/Statement of 
Operations/Statement of Changes in Net Assets
A. General _________
B. Revenue _________
C. Income Taxes _________
D. Discontinued Operations _________
E. Extraordinary Items _________
F. Unusual or Infrequent Items _________
G. Advertising Costs _________
H. Donated or Contributed Services _________
I. Donated Materials and Facilities _________
J. Fund Raising _________
K. Contributions/Pledges _________
L. Expenses _________
M. Wills _________
N. Endowments _________
O. Earnings Per Share _________
P. Comprehensive Income _________
• Statement of Cash Flows
• Other Financial Statement Disclosures
A. Accounting Changes _________
B. Accounting Policies _________
C. Business Combinations _________
D. Commitments and Contingencies _________
E. Costs to Exit an Activity _________
F. Derivatives _________
G./G 1. Financial Instruments _________
H. Nonmonetary Transactions _________
I. Pension and Other Postretirement Benefit Plans _________
J. Related Organizations and Economic Dependency _________
K. Risks and Uncertainties _________
L. Segment Information _________
M. Subsequent Events _________
N. Managed Care Organizations—Adoption of NAIC's Codification of SAP _________
• Continuing Care Retirement Communities (CCRCs)
A. Refundable Advance Fees _________
B. Fees Refundable to Residents Only From Reoccupancy
Proceeds of a Contract Holder's Unit _________
C. Nonrefundable Advance Fees _________
6
Place   by
Sections Not Applicable
D. Obligation to Provide Future Services and Use of Facilities 
to Current Residents
E. Costs of Acquiring Initial Continuing-Care Contracts
F. Other
• OMB Circular A-133 Presentation Requirements
• Exhibit A—Stock-Based Compensation
• Auditors' Reports
• Auditors' Reports on Audits Performed Under Government Auditing 
Standards and Under OMB Circular A-133
Yes No
General
A. Titles and References
★♦1. Are the financial statements suitably titled? ____
[SFAS 62, par. 7 (AU 623.07)]
2. Does each statement include a general reference that the notes are an
integral part of the financial statement presentation? ____
[Generally Accepted]
★ 3. Do the basic financial statements of the health care organization 
include:
a. Statement of financial position (balance sheet)? ____
b. Statement of activities (statement of operations/income statement)? ____
c. Statement of cash flows? ____
d. Statement of changes in net assets (equity)? [Note that this state­
ment may be combined with the statement of activities.] ____
[SFAS 117, pars. 1 and 6 (AC No5.104); AAG, par. 1.05]
B. Comparative Financial Statements
1. Has presentation of comparative statements been considered? ____
[SFAS 117, par. 69; ARB 43, Ch. 2A, pars. 1 and 2 (AC F43.101 and 
.102)]
★♦2. If comparative statements are presented, are the notes and other 
disclosures included in the financial statements of the preceding 
year(s) repeated, or at least referred to, to the extent that they continue
to be of significance? ____
[ARB 43, Ch. 2A, par. 2 (AC F43.102)]
3. If changes occurred in the manner of or basis for presenting corre­
sponding items for two or more periods, are appropriate explanations
of the changes disclosed? ____
[ARB 43, Ch. 2A, par. 3 (AC F43.103)]
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N/A
★ 4. If comparative annual financial statements are presented for earlier 
periods, are those financial statements reclassified (or restated) to 
reflect retroactive application of the provisions of SFAS 116 and SFAS 
117?
[SFAS 116, par. 30; SFAS 117, par. 31]
Statement of Financial Position/Balance Sheet
A. General
★♦1. For classified statements of financial position/balance sheets, are 
assets and liabilities segregated into current and noncurrent classifi­
cations, with totals presented for current assets and current liabilities? ____
[ARB 43, Ch. 3A, par. 3; SFAS 78, pars. 5 and 13 (AC B05.102-.109B);
SFAS 6, par. 15 (AC B05.118); FASBI 8, par. 3 (AC B05.117); TB 79-3, 
par. 2 (AC B05.501-.503); SFAS 117, par. 12 (AC No5.110)]
2. Are assets not expected to be realized during the current operating
cycle classified as noncurrent? ____
[ARB 43, Ch. 3A, pars. 5 and 6 (AC B05.106 and .107)]
★ 3. Does the statement of financial position/balance sheet report total
assets, liabilities, and net assets as well as separate amounts for each 
of three classes of net assets with captions used to describe their
meaning as explained in SFAS 117? ____
[SFAS 117, pars. 10,13, and 100 (AC No5.108, .111, and .131, fn. a)]
★ 4. Does the entity provide information about liquidity by one or more
of the following presentations:
a. Sequencing assets according to their nearness of conversion to
cash and sequencing liabilities according to the nearness of their 
maturity and resulting use of cash? ____
b. Classifying assets and liabilities as current and noncurrent? ____
c. Disclosing in notes to financial statements relevant information 
about the liquidity or maturity of assets and liabilities, including
restrictions on the use of particular assets? ____
[SFAS 117, par. 12 (AC No5.110)]
5. Are valuation allowances for assets shown as deductions from their
related assets with appropriate disclosure? ____
[APB 12, par. 3 (AC V18.102)]
★♦6. Is the need for disclosure of the impact of a new FASB Statement, 
issued but not yet effective where restatement of prior periods is
required, considered? ____
[SAS 1, secs. 9410.13-.18 (AU 9410.13-.18)]
B. Cash and Cash Equivalents
★♦1. Is restricted cash appropriately segregated from cash available for
current operations? ____
[ARB 43, Ch. 3A, par. 6 (AC B05.107); AAG, par. 3.01]
2. Are restrictions on cash (such as for plant acquisition, debt reduction
or working capital maintenance) appropriately disclosed? ____
[SFAS 5, pars. 18 and 19 (AC C59.120)]
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Yes No N/A
Yes No N/A
  3. Are personal funds of patients, residents and others under an agency 
arrangement reported as unrestricted assets and corresponding li­
abilities in the balance sheet/statement of financial position?
[AAG, par. 3.02]
★♦4. If a concentration of credit risk arises from deposits in excess of 
federally insured limits, is it disclosed?
[SFAS 105, par. 20 (AC F25.115)]
Note: SFAS 133, Accounting for Derivative Instruments and Hedging Activi­
ties, as amended by SFAS 137, Accounting for Derivative Instruments and 
Hedging Activities—Deferral of the Effective Date of FASB Statement No. 133, 
which is effective for all fiscal quarters of fiscal years beginning after June 
15, 2000, supersedes SFAS 105. If SFAS 133 has been adopted, refer to the 
disclosure requirements listed in the Other Financial Statement Disclo­
sures section G1 of this checklist.
On March 3, 2000 the FASB issued an exposure draft, Accounting for Certain 
Derivative Instruments and Certain Hedging Activities, that would amend 
SFAS 133. Readers should be alert to the issuance of a final standard.
5. If the organization has material bank overdrafts or material balance 
of undelivered checks as of the statement-of-financial-position/ 
balance-sheet date, are:
a. Bank overdrafts presented as a separate caption within current 
liabilities?
b. Undelivered checks classified as accounts payable?
[Generally Accepted]
6. Are internally designated funds reported separately from externally 
designated funds?
[AAG, par. 3.01]
7. Is the policy for determining cash equivalents disclosed?
[SFAS 95, par. 10 (AC C25.108)]
C. Investments
1. Are investments reported as current or noncurrent assets in conform­
ity with GAAP?
[AAG, par. 4.14]
★♦2. Are the appropriate disclosures made for investments in common 
stock accounted for by the equity method?
[APB 18, par. 20 (AC I82.110)]
3. Are other investments (such as real estate) reported at amortized cost, 
or at lower of cost or market if an impairment in value is deemed to 
be other than temporary?
[AAG, par. 4.02]
♦ 4. Are debt and equity securities classified as (a.) held-to-maturity, (b) 
available-for-sale, or (c) trading?
[SFAS 115, par. 6 (AC I80.103)]
9
Yes
Note: SFAS 133, Accounting for Derivative Instruments and Hedging Activi­
ties, modifies the disclosure requirements of SFAS 115, paragraphs 19, 20, 
21, and 22. SFAS 133, as amended by SFAS 137, Accounting for Derivative 
Instruments and Hedging Activities—Deferral of the Effective Date of FASB 
Statement No. 133, is effective for all fiscal quarters of fiscal years beginning 
after June 15, 2000. If SFAS 133 has been adopted, replace Questions 5, 6, 
7, 9, and 10 below with those shown in the Other Financial Statement 
Disclosures section G1 of this checklist.
On March 3, 2000 the FASB issued an exposure draft, Accounting for Certain 
Derivative Instruments and Certain Hedging Activities, that would amend 
SFAS 133. Readers should be alert to the issuance of a final standard.
♦ 5. For debt and marketable equity securities classified as available-for-
sale or held-to-maturity, are the following disclosures made, by 
major-security type, for each balance sheet presented:
a. Aggregate fair value?
b. Gross unrealized holding gains or losses?
c. Amortized cost basis?
♦ 6. For investments in debt securities classified as available-for-sale or
held-to-maturity is:
a. Disclosure made about their contractual maturities, as of the date 
of the latest balance-sheet date presented (maturity information 
may be combined in appropriate groupings)?
[SFAS 115, par. 20 (AC I80.119)]
♦ 7. Is consideration given to separate disclosure for securities not due
at a single date and the basis for allocation if such securities are 
allocated?
[SFAS 115, par. 20 (AC I80.119)]
♦ 8. If an option (to purchase securities that will be accounted for under SFAS
115) is classified as held-to-maturity or available-for-sale, is the account­
ing policy for the premium paid to acquire the option disclosed?
[EITF 96-11]
♦ 9. For each period for which an earnings statement is presented, are the
following disclosures made:
a. The proceeds from sales of available-for-sale securities and gross 
realized gains and losses on those sales?
b. The basis on which cost was determined in computing realized 
gain or loss (i.e., specific identification, average cost, or other 
method used)?
c. The gross gains and losses included in earnings from transfers 
of securities from the available-for-sale category to the trading 
category?
d. The change in net unrealized holding gain or loss on available-for- 
sale securities that is included in other comprehensive income 
during the period?
10
No N/A
Yes
e. The change in net unrealized holding gain or loss on trading
securities that is included in earnings during the period? ____
[SFAS 115, par. 21 (AC I80.120)]
♦ 10. For any sales of or transfers from securities classified as held-to- 
maturity, are the following disclosed for each period for which an 
earnings statement is presented:
a. Amortized cost amount of the sold or transferred security? ____
b. Related realized or unrealized gain or loss? ____
c. The circumstances leading to the decision to sell or transfer the
security? ____
[SFAS 115, par. 22 (AC I80.121)]
★♦11. Are significant concentrations of credit risk arising from concentra­
tions of securities of a particular issuer disclosed? ____
[SFAS 105, par. 20 (AC F25.115)]
Note: SFAS 133, Accounting for Derivative Instruments and Hedging Activi­
ties, supersedes SFAS 105. SFAS 133, as amended by SFAS 137, Accounting 
for Derivative Instruments and Hedging Activities—Deferral of the Effective 
Date of FASB Statement No. 133, is effective for all fiscal quarters of fiscal 
years beginning after June 15, 2000. If SFAS 133 has been adopted, refer 
to the disclosure requirements listed in the Other Financial Statement 
Disclosures section G1 of this checklist.
On March 3, 2000 the FASB issued an exposure draft, Accounting for Certain 
Derivative Instruments and Certain Hedging Activities, that would amend 
SFAS 133. Readers should be alert to the issuance of a final standard.
★ 12. Are realized gains and losses; unrealized gains and losses; dividend,
interest, and other similar investment income; and other than tempo­
rary impairment losses reported in the statement of activities as 
increases or decreases in unrestricted net assets or in temporarily 
restricted net assets or in permanently restricted net assets, depending 
on the existence of or lack of donor restrictions or law?
[SFAS 124, pars. 8 and 9 (AC No5.154 and .155); AAG, pars. 4.07 and 
4.08]
★ 13. Are realized gains and losses; dividend, interest and other similar invest­
ment income; and other than temporary impairment losses included in 
the performance indicator within the statement of activities?
[SFAS 124, par. 49; AAG, par. 4.07]
★ 14. Are unrealized gains and losses on trading securities (as defined in
SFAS 115) included in the performance indicator within the statement 
of activities?
[SFAS 124, par. 49; AAG, par. 4.07]
★ 15. Are unrealized gains and losses on available-for-sale and held-to-
maturity securities excluded from the performance indicator within 
the statement of activities?
[SFAS 124, par. 49; AAG, par. 4.07]
★ 16. If a provider reports gains and investment income that are limited to
specific uses by donor-imposed restrictions as increases in unre­
stricted net assets because the restrictions are met in the same report­
ing period as the gains and income are recognized, does the provider:
11
No N/A
Yes No N/A
a. Have a similar policy for reporting contributions received?
b. Report consistently from period to period?
c. Disclose its accounting policy?
[SFAS 124, par. 10 (AC No5.156); AAG, par. 4.09]
★ 17. For each period that a statement of activities is presented, are the
following disclosures made on the face of the financial statements or 
in the notes thereto:
a. The composition of investment return including, at a minimum, 
investment income, net realized gains or losses on investments 
reported at other than fair value, and net gains or losses on 
investments reported at fair value?
b. A reconciliation of investment return to amounts reported in the 
statement of activities, if investment return is separated into oper­
ating and nonoperating amounts?
c. A description of the policy used to determine the amount of invest­
ment return included in the measure of operations, if investment 
return is separated into operating and nonoperating amounts?
d. A discussion of circumstances leading to a change, if any, in the 
policy referred to in Step 17c above?
[SFAS 124, par. 14 (AC No5.161); AAG, par. 4.11]
★ 18. For each period for which a statement of financial position is pre­
sented, are the following disclosures made on the face of the financial 
statements or in the notes thereto:
a. The aggregate carrying amount of investments by major types 
(e.g., equity securities, corporate debt securities, etc.)?
b. The basis for determining the carrying amount for investments 
other than equity securities with readily determinable fair values 
and all debt securities?
c. The methods and assumptions used to estimate the fair values of 
investments other than financial instruments, if those other invest­
ments are reported at fair value?
d. The aggregate amount of the deficiencies for all donor-restricted 
endowment funds, for which the fair value of the assets at the 
reporting date is less than the level required by donor stipulations 
or law?
[SFAS 124, par. 15 (AC No5.162); AAG, par. 4.11]
★ 19. For the most recent period for which a statement of financial position
is presented, does the provider disclose the nature of and carrying 
amount for every individual investment or group of investments that 
represents a significant concentration of market risk (market risk may 
result from the nature of the investments, a lack of diversity of 
industry, currency, or geographic location)?
[SFAS 124, pars. 16 and 86 (AC No5.163); AAG, par. 4.11]
20. Are significant net realized and net unrealized gains and losses that 
arose after the latest statement of financial position date, but before 
issuance of the financial statements, disclosed?
[SAS 1, sec. 560, pars. 5 and 7 (AU 560.05 and .07)]
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Yes No N/A
D. Receivables
1. Are charity care revenue and receivables excluded from the financial
statements? ____
[AAG, par. 5.03]
2. Are differences between the estimates originally reported and sub­
sequent revisions, including final settlements:
a. Included in the statement of activities/income statement in the
period the revisions are made and disclosed, if material? ____
b. Reported in the current period unless they meet the criteria for
prior-period adjustments? ____
[AAG, par. 5.07; SFAS 16 (AC A35)]
★♦3. Are advances from third-party payors reported as a liability (unless
the right of setoff against a related receivable applies)? ____
[AAG, par. 7.01]
★♦4. Are deposits received from individuals reported as a liability (to the
extent that a right of setoff does not exist)? ____
[AAG, par. 7.01]
★♦5. Are receivables (less an allowance for uncollectibles, discounts, and
contractual adjustments) reported as current assets? ____
a. If the terms of payment are extended beyond one year from the
balance-sheet date, is that portion classified as noncurrent? ____
b. Are amounts due from third-party payors for retroactive adjust­
ments of items (such as final settlements or appeals) reported
separately in the financial statements? ____
[AAG, pars. 5.17 and 5.18]
★ 6. When displaying total assets and total liabilities, are interfund assets
and liabilities eliminated?1 ____
1 The display of interfund items in a statement of financial position is not prohibited by SFAS 117. However, since interfund items are 
not organizational assets or liabilities, those interfund items must be clearly labeled and arranged in the statement of financial position 
to eliminate their amounts when total assets and liabilities are displayed.
★ 7. Do entities that receive unconditional promises to give disclose the
following:
a. The amounts of promises receivable in less than one year, in one
to five years, and in more than five years? ____
b. The amount of any allowance for uncollectible promises receivable? ____
[SFAS 116, par. 24 (AC C67.121)]
★ 8. Do entities that receive conditional promises to give disclose the
following:
a. The total of the amounts promised? ____
b. A description and amount for each group of promises having 
similar characteristics (such as amount of promises conditioned 
on establishing new programs, completing a new building, and
raising matching gifts by a specified date)? ____
[SFAS 116, par. 25 (AC C67.122)]
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Yes
9. Are all receivables reported net of any related allowance for uncol­
lectible amounts, with appropriate disclosure? ____
[AAG, par. 5.17; APB 12, par. 3 (AC V18.102)]
10. Are accounts and notes receivable from officers, employees, and affili­
ated organizations shown separately with appropriate disclosures? ____
[ARB 43, Ch. 1A, par. 5 (AC R36.105)]
11. Are significant concentrations of credit risk arising from receivables
disclosed? ____
[SFAS 105, par. 20 (AC F25.115)]
Note: SFAS 133, Accounting for Derivative Instruments and Hedging Activi­
ties, supersedes SFAS 105. SFAS 133, as amended by SFAS 137, Accounting 
for Derivative Instruments and Hedging Activities—Deferral of the Effective 
Date of FASB Statement No. 133, is effective for all fiscal quarters of fiscal 
years beginning after June 15, 2000. If SFAS 133 has been adopted, refer 
to the disclosure requirements listed in the Other Financial Statement 
Disclosures section G1 of this checklist.
On March 3, 2000 the FASB issued an exposure draft, Accounting for Certain 
Derivative Instruments and Certain Hedging Activities, that would amend 
SFAS 133. Readers should be alert to the issuance of a final standard.
E. Beneficial Interests in Assets Held by Others
Note: This section has been included to reflect the requirements of SFAS 
136, Transfers of Assets to a Not-for-Profit Organization or Charitable Trust That 
Raises of Holds Contributions for Others. That Statement is effective for fiscal 
periods beginning after December 15, 1999, although the FASB encour­
ages earlier application.
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No N/A
★ 1. If the organization transferred assets to another entity and specified
itself or its affiliate as the beneficiary, has it:
a. Reported the transfer as an equity transaction if the criteria in 
paragraph 18 of SFAS 136 are met?
b. Reported the transfer as an exchange of an asset for another asset 
if the criteria in Paragraph 18 of SFAS 136 are not met?
[SFAS 136, pars. 17 and 18]
★ 2. If the organization transferred assets to another entity and specified
itself or its affiliate as the beneficiary, has it disclosed the following 
for each period in which a statement of financial position is presented:
a. The identity of the recipient organization to which the transfer was 
made?
b. Whether variance power was granted to the recipient organization 
and, if so, a description of the terms of the variance power?
c. The terms under which amounts will be distributed to the organi­
zation or its affiliate?
d. The aggregate amount recognized in the statement of financial 
position for those transfers and whether that amount is recorded 
as an interest in the net assets of the recipient organization or as 
another asset (such as a beneficial interest in assets held by others 
or as a refundable advance)?
[SFAS 136, par. 19]
Yes
F. Property and Equipment, Supplies, and Other Assets
♦ 1. Is property and equipment that is donor-restricted reported as tem­
porarily or permanently restricted assets? ____
[SFAS 116, par. 14]
2. Are donor or legal restrictions on the proceeds from the disposition
of property and equipment disclosed? ____
[AAG, par. 6.07]
3. For depreciable assets, do the financial statements or notes disclose:
a. Depreciation expense for each period? ____
b. Balances of major classes of depreciable assets by nature or function? ____
c. Accumulated depreciation, either by major classes of assets or in
total? ____
d. The method or methods used in computing depreciation with
respect to major classes of depreciable assets? ____
[APB 12, par. 5 (AC D40.105)]
★♦4. Do disclosures include the method and period of amortization of
intangible assets? ____
[APB 22, par. 13 (AC A10.106)]
♦ 5. In a classified balance sheet:
a. Are deferred tax assets and deferred tax liabilities classified as 
current or noncurrent based on the classification of the related
asset or liability for financial reporting? ____
[SFAS 109, par. 41 (AC I27.140)]
b. Are deferred tax assets or liabilities not related to an asset or 
liability for financial reporting (including those related to carry­
forwards) classified according to the expected reversal date of the
temporary difference pursuant to SFAS 37? ____
[SFAS 109, par. 41 (AC I27.140)]
c. Is the valuation allowance for a particular tax jurisdiction allocated 
between current and noncurrent deferred tax assets for that tax
jurisdiction on a pro rata basis? ____
[SFAS 109, par. 41 (AC I27.140)]
d. Are the following items offset and presented as a single amount 
for a particular taxpaying component and within a particular 
taxpaying jurisdiction:
(1) All current deferred tax liabilities and assets? ____
(2) All noncurrent deferred tax liabilities and assets? ____
[SFAS 109, par. 42 (AC I27.141)]
♦ 6. Are the totals of (a) all deferred tax liabilities, (b) all deferred tax assets,
and (c) the related valuation allowance recognized in the balance sheet
disclosed? ____
[SFAS 109, par. 43 (AC I27.142)]
♦ 7. Is the net change during the year in the total valuation allowance
disclosed? ____
[SFAS 109, par. 43 (AC I27.142)]
8. Is the amount of interest cost incurred and charged to expense during 
the period disclosed for an accounting period in which no interest cost
is capitalized? ____
[SFAS 34, par. 21a (AC I67.118)]
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No N/A
Yes
★♦9. Is the amount of interest cost incurred during the period and the 
amount that has been capitalized disclosed for an accounting period
in which some interest cost is capitalized? ____
[SFAS 34, par. 21b (AC I67.118)]
10. Are material commitments for property expenditures disclosed? ____
[SFAS 5, pars. 18 and 19 (AC C59.120)]
★♦11. For an existing property with an asbestos problem, are the costs 
incurred to treat the problem, if charged to expense, not classified as
an extraordinary item? ____
[EITF 89-13]
★♦ 12. If an impairment loss is recognized for assets to be held and used, are 
the following disclosures made in financial statements that include 
the period of the impairment write-down:
a. A description of the impaired assets and the facts and circum­
stances leading to the impairment? ____
b. The amount of the impairment loss and how fair value was
determined? ____
c. The caption in the income statement or statement of activities in 
which the impairment loss is aggregated if that loss has not been 
presented as a separate caption or reported parenthetically on the
face of the statement? ____
[SFAS 121, par. 14 (AC I08.133)]
★♦ 13. If assets to be disposed of are accounted for in accordance with para­
graphs 15-17 of SFAS 121, are all of the following disclosed in financial 
statements that include a period during which those assets are held:
a. A description of assets to be disposed of, the facts and circum­
stances leading to the expected disposal, the expected disposal
date, and the carrying amount of those assets? ____
b. The loss resulting from the application of paragraph 15 of SFAS 121? ____
c. The gain or loss, resulting from changes in the carrying amounts
of assets to be disposed of that arises from application of para­
graph 17 of SFAS 121? ____
d. The caption in the statement of activities/income statement in
which the gains or losses in b. and c. are aggregated if those gains 
or losses have not been presented as a separate caption or reported 
parenthetically on the face of the statement? ____
e. The results of operations for assets to be disposed of to the extent 
that those results are included in the entity's results of operations
for the period and can be identified? ____
[SFAS 121, par. 19 (AC I08.138)]
★♦ 14. If an impairment loss is recognized, is it reported as a component of 
income from continuing operations before income taxes, or similar
caption, in the statement of activities or income statement? ____
[SFAS 121, pars. 13 and 18]
G. Current Liabilities, Notes Payable, and Other Debt
1. Current liabilities:
★♦ a. For classified balance sheets and classified statements of financial 
position, do current liabilities include:
(1) Obligations for items that entered the operating cycle? ____
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No N/A
Yes
(2) Collections received in advance of the performance of services? ____
(3) Debts that arise from operations directly related to the oper­
ating cycle? ____
(4) Other liabilities whose regular and ordinary liquidation is
likely to occur within a relatively short time period? ____
(5) Obligations that, by their terms, are due on demand or will
be due within one year (or operating cycle, if longer) from the 
balance-sheet date, even though liquidation may not be ex­
pected within that period? ____
[ARB 43, Ch. 3A, pars. 7 and 8 (AC B05.108 and .109); SFAS
78, par. 5 (AC B05.109A)]
b. Do current liabilities exclude short-term obligations that the
provider intends to refinance on a long-term basis, provided the 
provider has demonstrated the ability to consummate the long­
term financing? ____
[SFAS 6, pars. 8-14 (AC B05.113-.116); FASBI 8, pars. 2-4 (AC 
B05.117, .138, and .139)]
c. In classified statements of financial position and in classified bal­
ance sheets, are current portions of debt obligations presented as
current liabilities? ____
[ARB 43, Ch. 3A, pars. 7 and 8 (AC B05.108 and .109)]
2. Notes payable and other debt:
a. Is there adequate disclosure of interest rates, maturities, and other 
terms and conditions provided in loan agreements and bond 
indentures (such as assets pledged as collateral, and covenants to
reduce debt, and maintain working capital)? ____
[SFAS 5, par. 18 (AC C59.120)]
b. Are the combined aggregate amounts of maturities and sinking 
fund requirements for all long-term borrowings disclosed for each 
of the five years following the date of the latest balance sheet
presented? ____
[SFAS 47, par. 10b (AC C32.105b)]
c. For unconditional purchase obligations that have been recorded
in accordance with SFAS 47, paragraph 6, is the amount of pay­
ments due in the aggregate and for every year during the five years 
following the date of the latest statement of financial position/bal­
ance sheet presented disclosed? ____
[SFAS 47, par. 10a (AC C32.105a)]
d. If a note is non-interest-bearing or has an inappropriate stated 
interest rate:
(1) Is the discount or premium presented as a deduction from or
addition to the face amount of the note? ____
(2) Does the disclosure include the effective interest rate and face
amount of the note? ____
(3) Is amortization of the discount or premium reported as interest? ____
(4) Are issue costs reported in the balance sheet/statement of
financial position as deferred charges? ____
[APB 21, par. 16 (AC I69.109)]
e. Are debt conversion features (such as rates and pertinent dates)
disclosed? ____
[APB 14 (AC D10)]
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No N/A
Yes
 ♦ f. If a short-term obligation is to be excluded from current liabilities 
in a classified balance sheet/statement of financial position, do 
disclosures include:
(1) General description of the financing agreement?
(2) Terms of any new obligation incurred or expected to be 
incurred, or equity securities issued or expected to be issued 
as a result of the refinancing?
[SFAS 6, par. 15 (AC B05.118)]
For troubled debt restructuring occurring during the current pe­
riod, do disclosures include:
(1) Description of the principal changes in terms and/or the 
major features of settlement?
(2) Aggregate gain on restructuring of payables and the related 
income tax effect?
(3) Aggregate net gain or loss on transfers of assets recognized 
during the period?
(4) Per-share amount, if applicable, of the aggregate gain on 
restructuring of payables, net of related income tax effect? 
[SFAS 15, par. 25 (AC D22.121)]
h. For periods after a troubled debt restructuring, do disclosures include:
(1) Extent to which amounts contingently payable are included 
in the carrying amount of restructured payables?
(2) Total amounts contingently payable, if applicable, and con­
ditions under which those amounts would become payable 
or forgiven?
[SFAS 15, par. 26 (AC D22.122)]
i. Are the gains and losses from extinguishment(s) of debt aggre­
gated and, if material, shown as an extraordinary item, net of 
related income tax effect? (Note: Does not apply to gains and 
losses from extinguishments of debt made to satisfy sinking fund 
requirements that the reporting entity must meet within one year 
of the date of the extinguishment.)
[SFAS 4, par. 8, as amended by SFAS 64, par. 4 (AC L35.107)]
j. Are gains or losses from extinguishment(s) made to satisfy sinking 
fund requirements that the reporting entity must meet within one 
year of the date of the extinguishment aggregated and identified 
as a separate item?
[SFAS 4, par. 8, as amended by SFAS 64, par. 4 (AC L35.107)]
k. Do disclosures related to gains and losses classified as extraordi­
nary include the following:
(1) A description of the extinguishment transactions, including 
the sources of any funds used to extinguish debt if it is 
practicable to identify the sources?
(2) The income tax effect in the period of extinguishment?
(3) The per-share amount of the aggregate gain or loss net of 
related income tax effect?
[SFAS 4, par. 9 (AC L35.109)]
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No N/A
Yes No N/A
l. If debt was considered to be extinguished under the provisions of 
SFAS 76 prior to the effective date of SFAS 125, do disclosures 
include:
(1) A general description of the transaction?
(2) The amount of debt that is considered extinguished at the end 
of the period as long as the debt remains outstanding?
[SFAS 125, par. 17b (AC L35.109)]
m. If assets are set aside after the effective date of SFAS 125 solely for 
satisfying scheduled payments of a specific obligation, is disclo­
sure made describing the nature of restrictions placed on those 
assets?
[SFAS 125, par. 17c (AC L35.109)]
n. Are long-term obligations that are or will be callable by the credi­
tor, either because the debtor's violation of the debt agreement at 
the balance-sheet/statement-of-financial-position date makes the 
obligation callable, or because the violation (if not cured within a 
specified grace period) will make the obligation callable, classified 
as current unless one of the following conditions is met:
(1) The creditor waives or subsequently loses the right to de­
mand repayment for more than one year (or operating cycle, 
if longer) from the balance-sheet date?
(2) The obligation contains a grace period within which the 
debtor may cure the violation and it is probable that the 
violation will be cured within that period, thus preventing 
the violation from becoming callable?
[SFAS 78, par. 5 (AC B05.109A)]
o. If an obligation under Question n(2) above is included in long­
term liabilities (or in the case of an unclassified balance sheet is 
included as a long-term liability in the disclosure of debt maturi­
ties), are the circumstances disclosed?
[SFAS 78, par. 5 (AC B05.118); see also EITF 86-30]
★ p. Does the not-for-profit provider report tax-exempt obligations 
that were issued for its benefit as liabilities if the provider is 
responsible for repayment?
[AAG, par. 7.15]
q. Is consideration given to the effects, if any, of current and prior tax 
examinations on the financial statements and disclosures related 
to the existence of contingent liabilities for unrelated business 
income tax, additional payroll tax liabilities, or penalties and 
interest on delinquent taxes?
[AAG, par. 7.11]
r. Is disclosure considered for any changes in the provider's activi­
ties that could affect its tax-exempt status?
[AAG, par. 7.11]
s. Are disclosures appropriate regarding the provider's tax-exempt 
status and any other significant tax matters?
[AAG, par. 7.11]
t. Is appropriate disclosure made if unrelated business income tax 
has not been accrued on income from:
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Yes
(1) Debt-financed investments that are not functionally related 
to the exempt purpose?
(2) Certain related entities not engaged in an exempt activity?
(3) Pharmacy operations in a medical building for the conven­
ience of physicians' private patients?
(4) A gift shop, cafeteria or food shop that the provider encour­
ages the general public (except patients, visitors and employ­
ees) to use?
(5) A parking lot available to the general public (except patients, 
visitors, and employees)?
[AAG, pars. 7.10 and 7.11]
H. Other Liabilities and Deferred Credits
1. If the reporting entity has not accrued compensated absences (SFAS
43) because the amount cannot be reasonably estimated, is that fact
disclosed? ____
[SFAS 43, par. 6 (AC C44.104)]
2. If an obligation for postemployment benefits is not accrued in accord­
ance with SFAS 5 or SFAS 43 only because the amount cannot be 
reasonably estimated, is the fact that the benefits have not been
accrued disclosed in the financial statements? ____
[SFAS 112, par. 7 (AC P32.105)]
I. Lessor Leases
1. For sales-type and direct financing leases, do disclosures include:
a. Appropriate components of the net investment in the leases as of 
the date of each balance sheet/statement of financial position
presented? ____
[SFAS 91, par. 25d (AC L10.119a)]
b. Future minimum lease payments to be received for each of the five 
succeeding fiscal years as of the latest balance-sheet/statement-of-
financial-position date presented? ____
[SFAS 13, par. 23a (AC L10.119a)]
c. Total contingent rentals included in income for each period for
which an income statement/statement of activities is presented? ____
[SFAS 13, par. 23a (AC L10.119a)]
d. For direct financing leases, the amount of initial direct costs as part
of the investment? ____
[SFAS 91, par. 25d (AC L10.119a(1))]
2. For operating leases, do disclosures include:
a. Cost and carrying amount of property on lease or held for leasing
by major classes and the amount of accumulated depreciation as 
of the date of the latest balance sheet/statement of financial posi­
tion presented? ____
b. Minimum future rentals on noncancelable leases as of the date of 
the latest balance sheet presented in the aggregate and for each of
the five succeeding fiscal years? ____
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No N/A
Yes
c. Total contingent rentals included in income for each period for
which an income statement/statement of operations is presented? ____
[SFAS 13, par. 23b (AC L10.119b)]
★♦3. Do disclosures include a general description of the lessor's leasing
arrangements? ____
[SFAS 13, par. 23 (AC L10.119c)]
4. For investments in leveraged leases, do disclosures include:
a. In the balance sheet, the amount of deferred taxes presented
separately from the remainder of the net investment? ____
b. In the income statement or the notes thereto, separate presentation 
(from each other) of pretax income from the leveraged lease, the 
tax effect of pretax income, and the amount of investment tax
credit recognized as income during the period? ____
c. When leveraged leasing is a significant part of the lessor's business 
activities in terms of revenue, net income, or assets, the compo­
nents of the net investment balance in leveraged leases in the notes
to the financial statements? ____
[SFAS 13, par. 47 (AC L10.149)]
5. For leasing transactions with related parties, are the nature and extent
of the transaction disclosed? ____
[SFAS 13, par. 29 (AC L10.125)]
J. Lessee Leases
1. For capital leases do disclosures include:
a. Gross amounts of assets recorded by major classes, as of the date
of each balance sheet/statement of financial position presented? ____
[SFAS 13, par. 16a.i. (AC L10.112a(1))]
b. Future minimum lease payments, as of the date of the latest 
balance sheet/statement of financial position presented, in total 
and for each of the next five years, with separate deductions for 
executory costs and imputed interest to reduce net minimum lease
payments to present value? ____
[SFAS 13, pars. 10 and 16a.ii. (AC L10.106 and .112a(2))]
c. Total future minimum sublease rentals under noncancelable sub­
leases as of the date of the latest balance sheet/statement of
financial position presented? ____
[SFAS 13, par. 16a.iii (AC L10.112a(3))]
d. Total contingent rentals actually incurred for each period presented? ____
[SFAS 13, par. 16a.iv (AC L10.112a(4))]
e. Assets recorded under capital leases and the related accumulated 
amortization, and obligations under those leases identified sepa­
rately in the balance sheet/statement of financial position or a
note? ____
[SFAS 13, pars. 13 and 16 (AC L10.112a)]
2. For operating leases that have initial or remaining noncancelable lease 
terms in excess of one year, do disclosures include:
21
No N/A
Yes
a. Future minimum rental payments required as of the latest balance 
sheet/statement of financial position presented in total and for
each of the next five years? ____
b. Total future minimum rentals under noncancelable subleases as
of the date of the latest balance sheet/statement of financial posi­
tion presented? ____
[SFAS 13, par. 16b (AC L10.112b)]
3. For all operating leases, do disclosures include rental expense for each 
period presented, with separate amounts for minimum rentals, con­
tingent rentals, and sublease rentals? ____
[SFAS 13, par. 16c (AC L10.112c)]
★♦4. Do disclosures include a general description of the lessee's leasing 
arrangements including, but not limited to:
a. Bases for determination of contingent rentals? ____
b. Terms of any renewal or purchase options or escalation clauses? ____
c. Restrictive covenants? ____
[SFAS 13, par. 16d (AC L10.112d)]
5. Is the nature and extent of leasing transactions with related parties
disclosed? ____
[SFAS 13, par. 29 (AC L10.125)]
★♦6. If material, is the accounting policy used in recognizing amounts 
related to a modification of an operating lease (that does not change
the lease classification) disclosed? ____
[EITF 95-17]
K. Net Assets
♦ 1. Are the equity accounts of investor-owned providers presented in a
similar fashion as other investor-owned businesses? ____
[AAG, par. 9.01]
2. Is the nature of restrictions on donor-restricted resources disclosed? ____
[AAG, par. 9.07]
♦ 3. Are limits on the use of unrestricted net assets (such as loan covenants
and board-designated endowments) and information about the na­
ture and amounts of different types of permanent and temporary
restrictions disclosed? ____
[SFAS 117, par. 16 (AC No5.114); AAG, pars. 9.03 and 9.04]
★4. Are net assets released from restriction, such as those related to the 
fufillment of time or purpose restrictions, reported separately in the
financial statements or disclosed in the notes? ____
[AAG, par. 10.07]
♦ 5. Shareholders' equity (corporations):
a. For each class of stock, do disclosures include the number of shares 
authorized, issued and outstanding, and par or stated value per
share and changes therein? ____
[Generally Accepted]
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No N/A
Yes No N/A
♦ b. Are classes of capital stock presented in order of priority in liqui­
dation?
[Generally accepted]
c. Do the financial statements include a description, in summary 
form, sufficient to explain the pertinent rights and privileges of the 
various securities outstanding, (e.g., dividend and liquidation 
preferences, participation rights, call prices and dates, conversion 
or exercise prices or rates and pertinent dates, sinking fund re­
quirements, unusual voting rights, significant terms of contracts 
to issue additional shares)?
[SFAS 129, par. 4 (AC C24.102)]
d. Do disclosures include the number of shares issued upon conver­
sion, exercise, or satisfaction of required conditions during at least 
the most recent annual fiscal period and any subsequent interim 
period presented?
[SFAS 129, par. 5 (AC C24.103)]
e. Are the following disclosed on the face of the statement of financial 
position or in the notes:
(1) The aggregate or per-share amounts at which preferred stock 
may be called or is subject to redemption through sinking- 
fund operations or otherwise?
(2) The aggregate and per-share amounts of arrearages in cumu­
lative preferred dividends?
[SFAS 129, par. 7 (AC C24.105)]
f. For preferred stock that has a preference in involuntary liquida­
tion considerably in excess of par or stated value of the shares, is 
the liquidation preference disclosed? [Note: Disclosure shall be 
made in the equity section of the statement of financial position 
in the aggregate, either parenthetically or "in short," rather than 
on a per-share basis or through disclosure in the notes.]
[SFAS 129, par. 6 (AC C24.104)]
g. For redeemable stock, do disclosures include the amount of re­
demption requirements, separately by issue or combined, for all 
issues of capital stock that are redeemable at fixed or determinable 
prices on fixed or determinable dates in each of the five years 
following the date of the latest statement of financial position 
presented?
[SFAS 129, par. 8 (AC C24.106)]
h. Are any appropriations of retained earnings for loss contingencies 
clearly identified and included in stockholders' equity?
[SFAS 5, par. 15 (AC R70.103)]
i. Are restrictions on payment of dividends disclosed?
[SFAS 5, pars. 18 and 19 (AC C59.120)]
j. Are receivables for stock issued or subscribed appropriately iden­
tified and presented as a deduction from capital or, if presented as 
an asset, stated separately, clearly labeled, and their status clearly 
described to distinguish them from any other type of assets?
♦ k. Are the carrying basis, the cost and the number of shares disclosed
for treasury stock?
[Generally Accepted]
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Yes
l. Are preferred stock dividends in arrears and dividend restrictions
disclosed? ____
[SFAS 5, par. 18 (AC C59.120)]
♦ m. After completion of a quasi-reorganization, is a new retained
earnings account established and dated with the date being dis­
closed in subsequent financial statements until it is no longer
deemed significant? ____
[ARB 43, Ch. 7A, par. 10; ARB 46, par. 2 (AC Q15.111)]
♦ n. Are the nature and extent to which retained earnings is restricted
indicated? ____
[APB 6, par. 13 (AC C23.104)]
6. Changes in net assets:
a. When both financial position and results of operations are 
presented:
(1) Are changes in the separate component accounts of equity
disclosed? ____
[APB 12, par. 10 (AC C08.102)]
(2) Are changes in the number of shares of capital stock disclosed 
for at least the latest year and any subsequent interim periods
presented (for-profit only)? ____
[APB 12, par. 10 (AC C08.102)]
b. If prior-period adjustments have been recorded during the current 
year, are their resulting effects (both gross and net of applicable 
income taxes and including the amounts of income tax applicable
to the prior period adjustments) appropriately disclosed? ____
[APB 9, par. 26 (AC A35.107)]
c. For a correction of an error, is the nature of the error disclosed in
the period in which the error was discovered and corrected? ____
(1) Nature of the error in previously issued financial statements? ____
(2) Effect of its correction on income before extraordinary items,
net income, and related per-share amounts, if applicable? ____
[APB 20, par. 37 (AC C35.105)]
L. Restricted Resources
★ 1. Are cash or other assets received with a donor-imposed restriction
that limits their use to long-term purposes reported separately from
assets that are unrestricted and available for current use? ____
[SFAS 117, par. 11 (AC No5.109)]
★ 2. Does the entity provide information about the nature and amounts of
different types of permanent restrictions and temporary restrictions by 
reporting their amounts on the face of the statement of financial position
or by including relevant details in notes to financial statements? ____
[SFAS 117, par. 14 (AC No5.112)]
M. Agency Transactions
Note: This section has been updated to reflect the requirements of SFAS 
136, Transfers of Assets to a Not-for-Profit Organization or Charitable Trust That 
Raises of Holds Contributions for Others. That Statement is effective for fiscal 
periods beginning after December 15, 1999, although the FASB encour­
ages earlier application.
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Yes
★ 1. If the organization acts as an agent or intermediary, has it recorded a
liability to the resource provider if the transfer is revocable or repay­
able? ____
[SFAS 136, par. 17]
★ 2. If the organization acts as an agent or intermediary in a transfer in
which the resource provider specified itself or its affiliate as benefici­
ary, has it reported the transfer as:
a. An equity transaction if the criteria in Paragraph 18 of SFAS 136
are met? ____
b. A liability if the criteria in Paragraph 18 of SFAS 136 are not met? ____
[SFAS 136, pars. 17 and 18]
★3. If the organization acts as an agent or intermediary in a transfer in 
which the donor granted variance power and named an unaffiliated 
entity as the beneficiary, has it reported the transfer as a contribu­
tion? ____
[SFAS 136, par. 12. Note: This requirement has an effective date of 
fiscal years ending after September 15, 1996.]
★4. If the organization acts as an agent or intermediary in a transfer in 
which it is financially interrelated to the specified beneficiary (as 
defined in paragraph 13 of SFAS 136), has it reported the transfer as
a contribution? ____
[SFAS 136, par. 14]
★5. If the organization acts as an agent or intermediary in a transfer 
that is not revocable or repayable, does not involve financially 
interrelated parties, and in which the donor did not grant variance 
power, has it reported the resources received as increases in assets 
and liabilities and has it reported the distribution of those resources 
to the beneficiaries as decreases in those accounts, except as noted
in Step 6 below? ____
[SFAS 136, pars. 8 and 11]
★ 6. If the organization received nonfinancial assets in a transfer of the type
described in Step 5, did it report the receipt of those nonfinancial 
assets as assets and liabilities only if that is its accounting policy, it 
reports consistently from period to period, and it discloses that policy
in the financial statements? ____
[SFAS 136, pars. 8 and 11]
Statement of Activities/Income Statement/Statement of 
Operations/Statement of Changes in Net Assets
A. General
★ 1. Does the statement of activities/operations or statement of changes 
in net assets report the amount of change in net assets for the period 
for the provider as a whole (using a descriptive term such as 
"change in net assets" or "change in equity"), and does that amount 
articulate to the net assets reported in the statement of financial 
position?
[SFAS 117, par. 18 (AC No5.116)]
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No N/A
Yes
★ 2. Does the statement of activities/operations or the statement of
changes in net assets report the amount of change in permanently 
restricted net assets, temporarily restricted net assets, and unre­
stricted net assets for the period? ____
[SFAS 117, par. 19 (AC No5.117)]
★ 3. Does the statement of activities/operations report the following:
a. Revenues as increases in unrestricted net assets unless the use of
the assets received is limited by donor-imposed restrictions? ____
b. Expenses as decreases in unrestricted net assets? ____
c. Events that simultaneously increase one class of net assets and 
decrease another (reclassifications), including expiration of donor- 
imposed restrictions, separately from revenues, expenses, gains,
and losses? ____
[SFAS 117, pars. 19 and 20 (AC No5.117 and .118); SFAS 116, par.
17 (AC No5.147)]
★ 4. Are revenues and expenses (arising from ongoing activities associated
with health care services) classified as operating and displayed as
gross amounts? ____
[SFAS 117, par. 24 (AC No5.121)]
★ 5. If the provider elects to report investment revenues net of related
expenses, does the provider disclose the amount of expenses, either 
on the face of the statement of activities or in the notes to the financial
statements? ____
[SFAS 117, par. 24 (AC No5.121)]
★ 6. If the entity reports an intermediate measure of operations (for exam­
ple, excess or deficit of operating revenues over expenses), is this 
intermediate measure reported only in a financial statement that, at a
minimum, reports the change in unrestricted net assets for the period? ____
[SFAS 117, par. 23 (AC No5.120)]
★ 7. If the entity's use of the term operations is not apparent from the details
provided on the face of the statement of activities, does a note to 
financial statements describe the nature of the reported measure of
operations or the items excluded from operations? ____
[SFAS 117, par. 23 (AC No5.120)]
★ 8. If the entity reports net gains and losses or revenue and expense on
its statement of activities/operations, do these net amounts result 
from peripheral or incidental transactions or from events largely
beyond the control of the entity and its management? ____
[SFAS 117, pars. 25 and 138 (AC No5.122)]
★ 9. Does the not-for-profit provider report total income or loss in a
statement that, at a minimum, also presents the total changes in
unrestricted net assets? ____
[AAG, par. 10.17]
10. Is management's policy for providing charity care, as well as the level
of charity care provided, disclosed? ____
[AAG, par. 10.21]
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Yes
★ 11. Does the statement of activities/operations include a performance
indicator that reports results of operations and that is clearly labeled 
with a descriptive term such as revenues over expenses, revenues and 
gains over expenses and losses, earned income, or performance earnings? 
[AAG, par. 10.17]
★ 12. Do the notes to the financial statements include a description of the
nature and composition of the performance indicator?
[AAG, par. 10.17]
★♦ 13. Does the organization report the following items separately from the 
performance indicator:
a. Transactions with owners acting in that capacity?
b. Equity transfers involving other entities that control the reporting 
entity, are controlled by the reporting entity, or are under common 
control with the reporting entity?
c. Receipt of restricted contributions, including temporary restric­
tions (such as time or purpose) or permanent restrictions?
d. Contributions of (and assets released from donor restrictions re­
lated to) long-lived assets?
e. Unrealized gains and losses on investments not restricted by 
donors or by law, except for those investments classified as trading 
securities?
f. Investment returns restricted by donors or by law?
g. Other items that are required by GAAP to be reported separately 
(such as extraordinary items, the effect of discontinued operations, 
or the cumulative effect of accounting changes)?
[AAG, par. 10.18]
★♦14. For investments in common stock accounted for by the equity 
method, is the investor's share of earnings shown as a single amount 
except for investee extraordinary items and prior-period adjustments 
that are material to the investor?
[APB 18, pars. 19c and d (AC 182.109c and d)]
★♦ 15. Are total research and development costs charged to expenses dis­
closed for each period for which a statement of activities/income 
statement is presented?
[SFAS 2, pars. 12 and 13 (AC R50.108 and .109); FASBI 4, par. 5 (AC 
B50.152); FASBI 6, par. 8 (AC R50.117); SFAS 86, par. 3 (AC Co2.102)]
★♦ 16. If the provider accounts for its obligation under a research and devel­
opment arrangement as a contract to perform research and develop­
ment for others, is there disclosure of:
a. The terms of significant agreements under the research and develop­
ment arrangement as of the date of each balance sheet presented?
b. The amount of compensation earned or costs incurred under such 
contracts for each period for which a statement of revenues and 
expenses (statement of operations) is presented?
[SFAS 68, par. 14 (AC R55.112)]
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No N/A
Yes
♦ 17. Are the following excluded from the determination of net income or
results of operations under all circumstances:
a. Adjustments or charges or credits resulting from transactions in 
the provider's own capital stock?
b. Transfers to and from accounts properly designated as appropri­
ated retained earnings?
c. Adjustments made pursuant to a quasi-reorganization?
[APB 9, par. 28 (AC C08.101)]
★ 18. Are net assets released from restriction, such as those related to the
fulfillment of time or purpose restrictions, reported separately in the 
financial statements or disclosed in the notes?
[AAG, par. 10.07]
B. Revenue
★♦ 1. Is revenue classified based on the type of service (such as patient or
resident) rendered or contracted to be rendered? ____
[AAG, par. 10.04]
★♦ 2. Are gains, losses, and interest earned properly classified and reported? ____
[AAG, par. 10.07]
★♦ 3. Is patient service revenue reported net of provisions for contractual
charity care and other adjustments? ____
[AAG, par. 10.20]
★♦ 4. Do disclosures include methods of revenue recognition? ____
[AAG, par. 10.20]
★♦ 5. With regard to contractual adjustments and third-party settlements, 
does the provider identify and explain the estimated amounts payable
or receivable? ____
[AAG, par. 10.20]
★ 6. Is significant revenue earned under capitation arrangements reported
separately? ____
[AAG, par. 10.20]
C. Income Taxes
♦ 1. Are the types of significant temporary differences and carryforwards
disclosed?
[SFAS 109, par. 43 (AC I27.142)]
♦ 2. Are the following significant components of income tax expense
attributable to continuing operations for each year presented dis­
closed in the financial statements or notes thereto:
a. Current tax expense or benefit?
b. Deferred tax expense or benefit (exclusive of the effects of other 
components listed below)?
c. Investment tax credits?
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No N/A
Yes
d. Government grants (to the extent recognized as a reduction of 
income tax expense)?
e. The benefits of operating loss carryforwards?
f Tax expense that results from allocating certain benefits, either 
directly to contributed capital or to reduce goodwill or other 
noncurrent intangible assets of an acquired entity?
g. Adjustments of a deferred tax liability or asset for enacted changes 
in tax laws or rates or a change in the tax status of the provider?
h. Adjustments of the beginning-of-the-year balance of a valuation 
allowance because of a change in circumstances that causes a 
change in judgment about the realizability of the related deferred 
tax asset in future years?
i. Any portion of the valuation allowance for deferred tax assets for 
which subsequently recognized tax benefits will be allocated to 
reduce goodwill or other noncurrent intangible assets of an ac­
quired entity or directly to contributed capital?
[SFAS109, pars. 45 and 48 (AC I27.144 and .147)]
♦ 3. Is the amount of income tax expense or benefit allocated to continuing
operations and the amounts separately allocated to other items dis­
closed for each year for which those items are presented?
[SFAS 109, pars. 35-39 and 46 (AC I27.134-.138 and .145)]
♦ 4. If the reporting entity is a public enterprise, is a reconciliation in both
percentages and dollars of the reported amount of income tax expense 
attributable to continuing operations for the year to date to the amount 
of income tax expense that would result from applying domestic federal 
statutory rates to pretax income from operations?
[SFAS 109, par. 47 (AC I27.146)]
♦ 5. If the reporting entity is a nonpublic enterprise, is there disclosure of
the nature of significant items required to reconcile the reported 
amount of income tax expense attributable to continuing operations 
for the year to the amount of income tax expense that would result 
from applying domestic federal statutory tax rates to pretax income 
from continuing operations?
[SFAS 109, par. 47 (AC I27.146)]
♦ 6. Are the amounts and expiration dates of operating loss and tax credit
carryforwards for tax purposes disclosed?
[SFAS 109, par. 48 (AC I27.147)]
♦ 7. If the provider is a member of a group that files a consolidated tax
return, are the following items disclosed in its separately-issued finan­
cial statements:
a. The aggregate amount of current and deferred tax expense for 
each period presented, and the amount of any tax-related balances 
due to or from affiliates as of the date of each balance sheet 
presented?
b. The method by which the consolidated amount of current and de­
ferred tax expense is allocated to members of the group and the 
nature and effect of any changes in that method (and in determining 
related balances to or from affiliates) for each period presented? 
[SFAS 109, par. 49 (AC I27.148)]
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♦ 8. Are the amounts of income taxes applicable to the results of discontinued
operations disclosed on the income statement or in related notes? ____
[APB 30, par. 8 (AC I13.105)]
♦ 9. Are the income taxes applicable to extraordinary events disclosed on
the face of the income statement or in related notes? ____
[APB 30, par. 11 (AC I17.102)]
D. Discontinued Operations
1. Are operations of a segment that are discontinued or are the subject 
of a formal plan for disposition:
a. Reported separately from continuing operations and as a component 
(including applicable income taxes) of income before extraordinary
items and the cumulative effect of accounting changes (if any)? ____
b. Accompanied by disclosure in the notes of revenue applicable to
the discontinued operations? ____
[APB 30, par. 8 (AC I13.105)]
2. Is gain or loss from disposal of a discontinued segment reported sepa­
rately (including applicable income taxes) in conjunction with results of 
discontinued operations as a component of income before extraordinary
items and the cumulative effect of accounting changes (if any)? ____
[APB 30, pars. 8,13, and 15-18 (AC I13.101-.103, .105, .106, .108, and .109)]
3. If a provider has accounted for the discontinuance of a segment in
accordance with APB 30 and subsequently decides to retain the seg­
ment, is any impairment write-down of the individual assets classi­
fied in continuing operations? ____
[EITF 90-16]
4. If the entity plans to dispose of two segments of a business, and a net 
gain is expected (one has a net gain and the other a net loss), is that
gain shown net? ____
[EITF 85-36]
5. Are the revenues applicable to the discontinued operations disclosed
in the notes to the financial statements? ____
[APB 30, par. 8 (AC I13.105)]
★♦6. For the period encompassing the measurement date, do notes to 
financial statement disclose:
a. Identity of the segment discontinued? ____
b. Expected disposal date, if known? ____
c. Expected manner of disposal? ____
d. Description of the remaining assets and liabilities of the discontin­
ued segment at the balance-sheet date? ____
e. Results of operations and any proceeds from disposal of the 
discontinued segment during the period from the measurement
date to the balance-sheet date? ____
[APB 30, par. 18 (AC I13.108)]
7. If the loss on disposal cannot be estimated within reasonable limits,
is that fact disclosed? ____
[APB 30, par. 18, fn. 7 (AC I13.109)]
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No N/A
★♦8. For periods subsequent to the measurement date and including the 
period of disposal, do notes to the financial statements disclose the 
information listed in Questions 6a, b, c, and d above as well as the 
information in 6e compared with prior estimates?
[APB 30, par. 18 (AC I13.108)]
9. If the entity decides to dispose of a segment of a business and the 
measurement date occurs after the balance-sheet/statement-of- 
financial-position date but before the financial statements for the 
prior period have been issued:
a. Are the segment's operating results presented as discontinued 
operations in the income statement/statement of operations of the 
not-yet-released financial statements?
b. Is the estimated loss on disposal recognized in the period that 
includes the measurement date, if the decision to dispose of the 
segment results from a discrete and identifiable event that occurs 
unexpectedly after the balance-sheet date?
c. Is the estimated loss on disposal recognized in the period prior to 
the measurement date, if the decision to dispose of the segment 
does not result from a discrete and identifiable event that occurs 
unexpectedly after the balance-sheet date?
[EITF 95-18]
E. Extraordinary Items
1. Are extraordinary items segregated and shown (including applicable 
income taxes) following income before extraordinary items and be­
fore net income?
[APB 30, par. 11 (AC I17.102 and .103)]
2. Are descriptive captions and amounts (including applicable income 
taxes) presented for individual extraordinary events or transactions, 
preferably on the face of the statement of operations/income state­
ment, if practicable?
[APB 30, par. 11 (AC I17.102)]
3. Do disclosures include descriptions of extraordinary events or trans­
actions and the principal items entering into determination of extraor­
dinary gains or losses?
[APB 30, par. 11 (AC I17.102)]
4. For an adjustment of an extraordinary item reported in a prior period 
(except for correction of an error):
a. Is the adjustment classified separately as an extraordinary item in 
the current period?
b. Are the nature, origin, and amount of the item disclosed?
[SFAS 16, par. 16(c) (AC I17.119)]
F. Unusual or Infrequent Items
1. Are material events or transactions that are either unusual in nature 
or of infrequent occurrence, but not both (and therefore not meeting 
criteria for extraordinary items):
a. Reported as a separate component of income from continuing 
operations?
b. Accompanied by disclosure of the nature and financial effects of 
each event?
[APB 30, par. 26 (AC I22.101)]
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G. Advertising Costs
1. Do disclosures for advertising costs include:
a. The accounting policy selected from the two alternatives in the 
beginning of paragraph 26 of SOP 93-7 for reporting advertising, 
indicating whether such costs are expensed as incurred or the first
time the advertising takes place? ____
b. A description of the direct-response advertising reported as assets
(if any), the accounting policy for it, and the amortization period? ____
c. The total amount charged to advertising expense for each state­
ment of activities/income statement presented, with separate dis­
closure of amounts, if any, representing a write-down of the 
capitalized advertising costs to net realizable value? ____
d. The total amount of advertising reported as assets in each balance
sheet/statement of financial position presented? ____
[SOP 93-7, par. 49]
H. Donated or Contributed Services
★ 1. If the provider receives contributed services, does it disclose the
following:
a. A description of the programs or activities for which those services 
were used, including the nature and extent of contributed services 
received for the period and the amount recognized as revenues for 
the period?
b. The fair value of contributed services received but not recognized, 
if practicable (optional)?
c. Nonmonetary information such as the number and trends of 
donated hours received or service outputs provided by volunteer 
efforts (optional)?
d. Dollar amount of contributions raised by volunteers (optional)? 
[SFAS 116, pars. 10 and 123 (AC C67.110)]
I. Donated Materials and Facilities
★ 1. If donated materials merely pass through the organization to its
charitable beneficiaries, and the organization is only an agent or 
intermediary for the donors, has that donation been excluded from 
contribution revenues? (Refer to Agency Transaction section)
[SFAS 116, pars. 52 and 53; SFAS 136, pars. 8 and 11]
J. Fund Raising
★ 1. Do financial statement disclosures include:
a. The types of activities for which joint costs have been incurred?
b. A statement that such costs have been allocated?
c. The total amount allocated during the period and the portion 
allocated to each functional expense category?
[SOP 98-2, par. 18]
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Note: SOP 98-2 encourages, but does not require, that the amount of joint 
costs for each kind of joint activity be disclosed, if practical.
★ 2. If the organization includes within its financial statements a ratio of
fundraising expenses to amounts raised, has it disclosed how that
ratio was computed? ____
[SFAS 136, par. 20]
K. Contributions/Pledges
★ 1. Does the provider distinguish between contributions received with per­
manent restrictions, those received with temporary restrictions, and 
those received without donor-imposed restrictions, so that they are 
reported as support increasing permanently restricted net assets, tempo­
rarily restricted net assets, or unrestricted net assets, respectively? ____
[SFAS 116, par. 14 (AC No5.143)]
★ 2. If donor-restricted contributions whose restrictions are met in the
same reporting period are reported as unrestricted support, is such
treatment consistent from period to period and is the policy disclosed? ____
[SFAS 117, par. 21; SFAS 116, par. 14 (AC No5.143)]
★ 3. Does the provider report receipt of unconditional promises to give
with payments due in future periods as restricted support, unless 
explicit donor stipulations or circumstances surrounding the receipt 
of the promise make clear that the donor intended the contribution to
be used to support activities of the current period? ____
[SFAS 116, par. 15 (AC No5.144)]
★ 4. Does an entity that receives gifts of long-lived assets without donor
stipulation about how long the donated asset must be used:
a. Disclose its accounting policy of implying or not implying a time
restriction that expires over the useful life of the asset? ____
b. Report such support as restricted if it is the provider's policy to
imply a time restriction that expires over the useful life of the 
donated asset? ____
c. Report such support as unrestricted in the absence of such a policy? ____
[SFAS 116, par. 16 (AC No5.145)]
★ 5. Does a provider that receives unconditional promises to give, in which
cash promised will be received in future periods, measure the fair value 
of the contribution as the present value of estimated future cash flows, 
using a discount rate commensurate with the risks involved, and report 
subsequent accruals of the interest element as contribution income in­
creasing either the temporarily or permanently restricted class of net
assets if the underlying promise to give is donor restricted? ____
[SFAS 116, par. 20 (AC C67.116)]
★ 6. In discounting unconditional promises to give (as described in Step
5), are the provisions of APB 21 applied? ____
[SOP 94-2, par. 20]
7. Are unrestricted pledges/contributions reported in the statement of
operations? ____
[AAG, par. 10.08]
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L. Expenses
★ 1. Does the provider provide information about expenses reported by
their functional classification (such as major classes of program serv­
ices and supporting services) either in the statement of activities or in
notes to financial statements? ____
[SFAS 117, par. 26 (AC No5.123)]
★ 2. For deferred compensation agreements, are estimated amounts to be
paid properly accrued? ____
[APB 12, pars. 6 and 7 (AC C38.101 and .102)]
M. Wills
★♦1. If the entity receives a promise to give conditioned on a future 
uncertain event that is contained in a will and the will has been 
declared valid by the probate court, has the provider disclosed the
conditional promise to give? ____
[SFAS 116, par. 208 (AC C67.160)]
N. Endowments
★ 1. Does the provider report gains and losses on endowments in the
following manner:
a. As an increase or decrease in permanently restricted net assets if the 
governing board has determined that the relevant law requires the
entity to retain permanently some portion of gains on investments? ____
[SFAS 117, pars. 22 and 129 (AC No5.119)]
b. As an increase or decrease in unrestricted or temporarily restricted
net assets, whichever is consistent with the reporting of the en­
dowment's income in the absence of such a law noted in Step a.? ____
[SFAS 117, par. 129 (AC No5.119, fn. 8)]
O. Earnings Per Share
Note: SFAS 128, Earnings per Share, applies only to entities with publicly 
held common stock or potential common stock.
♦ 1. Are earnings per share (EPS) data presented for all periods for which
an income statement or summary of earnings is presented? ____
[SFAS 128, par. 38 (AC E11.133)]
♦ 2. If diluted EPS data are reported for at least one period, are they reported
for all periods presented, even if they are the same amounts as basic EPS? ____
[SFAS 128, par. 38 (AC E11.133)]
♦ 3. For entities with only common stock outstanding, are basic EPS
amounts for income from continuing operations and for net income
presented on the face of the income statement? ____
[SFAS 128, par. 36 (AC E11.131)]
♦ 4. For entities with potential common stock, are basic and diluted EPS
amounts for income from continuing operations and for net income
presented on the face of the income statement with equal prominence? ____
[SFAS 128, par. 36 (AC E11.131)]
♦ 5. If discontinued operations, extraordinary items, or the cumulative
effect of accounting changes are reported in a period, are the basic and
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diluted per share amounts for those line items presented on the face
of the income statement or in the notes? ____ ____ ____
[SFAS 128, par. 37 (AC E11.132)]
♦ 6. If per share amounts not required to be presented by SFAS 128 are
disclosed, are they disclosed only in the notes and do the disclosures
indicate whether the per share amounts are pretax or net of tax? ____ ____  ____
[SFAS 128, par. 37 (AC E11.132)]
♦ 7. Are the following disclosed for each period for which an income
statement is presented:
a. A reconciliation of the numerators and denominators of the basic 
and diluted per share computations for income from continuing
operations? ____ ____  ____
b. The effect that has been given to preferred dividends in arriving at
income available to common stockholders in computing basic EPS? ____ ____  ____
c. Securities (including those issuable pursuant to contingent stock 
agreements) that could potentially dilute basic EPS in the future 
that were not included in the computation of diluted EPS because
to do so would have been antidilutive for the period(s) presented? ____ ____  ____
[SFAS 128, par. 40 (AC E11.135)]
♦ 8. For the latest period for which an income statement is presented, do
disclosures include a description of any transaction that occurs after 
the end of the most recent period but before issuance of the financial 
statements that would have changed materially the number of com­
mon shares or potential common shares outstanding at the end of the
period if the transaction had occurred before the end of the period? ____ ____  ____
[SFAS 128, par. 41 (AC E11.136)]
P. Comprehensive Income
Practice Tip
A listing of items of other comprehensive income under current accounting standards can be found in section 
C49.106 of the FASB Current Text.
♦ 1. Are all components of comprehensive income reported in the finan­
cial statements in the period in which they are recognized?
[SFAS 130, par. 14 (AC C49.108)]
♦ 2. Is a total for comprehensive income displayed in the financial statement
where the components of other comprehensive income are reported? 
[SFAS 130, par. 14 (AC C49.108)]
♦ 3. Is an amount for net income displayed and included as a component
of comprehensive income?
[SFAS 130, pars. 15 and 22 (AC C49.109 and .116)]
♦ 4. Are items included in other comprehensive income classified sepa­
rately into foreign currency items, minimum pension liability adjust­
ments, and unrealized gains and losses on certain investments in debt 
and equity securities?
[SFAS 130, par. 17 (AC C49.111)]
♦ 5. Are reclassification adjustments presented on the face of the financial
statement in which comprehensive income is reported or disclosed in 
the notes?
[SFAS 130, par. 20 (AC C49.114)]
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♦ 6. (Not required, but encouraged) Are the components of other compre­
hensive income and total comprehensive income displayed below the
total for net income? ____
[SFAS 130, par. 23 (AC C49.117)]
♦ 7. Are the components of other comprehensive income displayed either
net of related tax effects, or before related tax effects with one amount 
shown for the aggregate tax effect related to the total of other compre­
hensive income items? ____
[SFAS 130, par. 24 (AC C49.118)]
♦ 8. Is the amount of income tax expense or benefit allocated to each
component of other comprehensive income (including reclassifica­
tion adjustments) disclosed in the notes? ____
[SFAS 130, par. 25 (AC C49.119)]
♦ 9. Is the total of other comprehensive income for a period transferred to a
component of equity that is displayed separately from retained earnings 
and additional paid-in-capital in a statement of financial position with a
descriptive title such as accumulated other comprehensive income? ____
[SFAS 130, par. 26 (AC C49.120)]
♦ 10. Are accumulated balances for each classification within accumulated
other comprehensive income disclosed on the face of the statement of
financial position, in a statement of changes in equity, or in the notes? ____
[SFAS 130, par. 26 (AC C49.120)]
♦ 11. If condensed interim financial statements are issued, is total compre­
hensive income reported? ____
[SFAS 130, par. 27 (AC C49.121)]
♦ 12. Are unrealized holding gains and losses for available-for-sale securi­
ties, including those classified as current assets, reported in other
comprehensive income? ____
[SFAS 115, par. 13, as amended by SFAS 130 (AC I80.110)]
13. If an additional pension liability is required to be recognized and 
exceeds unrecognized prior service cost, is the excess (which would 
represent a net loss not yet recognized as net periodic pension cost) 
reported in other comprehensive income net of any tax benefits that
result from considering such losses as temporary differences? ____
[SFAS 87, par. 37, as amended by SFAS 130 (AC P16.131)]
Note: Questions 14 and 15 apply only if SFAS 133, Accounting for Deriva­
tive Instruments and Hedging Activities, has been adopted. SFAS 133, as 
amended by SFAS 137, Accounting for Derivative Instruments and Hedging 
Activities—Deferral of the Effective Date of FASB Statement No. 133, is effec­
tive for all fiscal quarters of fiscal years beginning after June 15, 2000.
On March 3, 2000 the FASB issued an exposure draft, Accounting for Certain 
Derivative Instruments and Certain Hedging Activities, that would amend 
SFAS 133. Readers should be alert to the issuance of a final standard.
♦ 14. Has the entity displayed as a separate classification within other 
comprehensive income the net gain or loss on derivative instruments 
designated and qualifying as cash flow hedging instruments that are 
reported in comprehensive income pursuant to paragraphs 30 and 41 
of SFAS 133?
[SFAS 133, par. 46 (AC D50.143)]
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No N/A
Yes No N/A
♦ 15. As part of the disclosures of accumulated other comprehensive in­
come, pursuant to paragraph 26 of SFAS 130, Reporting Comprehensive 
Income, has the entity separately disclosed the beginning and ending 
accumulated derivative gain or loss, the related net change associated 
with current period hedging transactions, and the net amount of any
reclassification into earnings? ____ ____  ____
[SFAS 133, par. 47 (AC D50.144)]
Statement of Cash Flows2
2 SFAS 95, Statement of Cash Flows, and GASB Statement 9, Reporting Cash Flows of Proprietary and Nonexpendable Trust Funds and 
Governmental Entities That Use Proprietary Fund Accounting, established standards for cash flow reporting for investor-owned 
organizations and governmental entities, respectively. SFAS 95 excludes not-for-profit organizations from its scope; however, not-for- 
profit health care entities should apply the provisions of SFAS 95 to ensure that their financial statements are comparable with those of 
investor-owned entities. The statement of cash flows may be prepared using the direct or indirect method of reporting cash flows. 
(SFAS 117 amends SFAS 95 to extend its provisions to not-for-profit organizations and to extend its description of cash flows from 
financing activities to include certain donor-restricted cash that must be used for long-term purposes.)
1. Is a statement of cash flows presented as a basic financial statement 
for each period for which both a statement of financial position/bal­
ance sheet and a statement of activities/income statement is pre­
sented?
[SFAS 95, par. 3, as amended by SFAS 117, par. 30a (AC C25.101); 
AAG, par. 1.07]
2. Does the statement of cash flows show the change in cash and cash 
equivalents?
[SFAS 95, par. 7 (AC C25.105)]
3. Is the policy for defining cash equivalents disclosed?
[SFAS 95, par. 10 (AC C25.108)]
Note: Any change in policy for determining which items are treated as 
cash equivalents is a change in accounting principle.
★♦4. If the direct method is used, is a separate schedule provided to 
reconcile net income of an investor-owned provider or change in net 
assets of a not-for-profit provider to net cash flow from operating 
activities?
[SFAS 95, par. 30, as amended by SFAS 117, par. 30f (AC C25.128)]
5. If the indirect method is used:
a. Is the same amount for net cash flow from operating activities 
reported indirectly by adjusting net income of an investor-owned 
provider or change in net assets of a not-for-profit provider to 
reconcile it to net cash flow from operating activities?
[SFAS 95, par. 28, as amended by SFAS 117, par. 30f (AC C25.126)]
b. Is the reconciliation of net income of an investor-owned provider 
or change in net assets of a not-for-profit provider to net cash 
flows from operating activities reported, either within the state­
ment of cash flows or provided in a separate schedule, with the 
statement of cash flows reporting only the net cash flow from 
operating activities?
[SFAS 95, par. 30, as amended by SFAS 117, par. 30f (AC C25.128)]
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N/AYes No
★♦ 6. Are cash receipts and cash payments from operating activities shown
separately on the statement of cash flows? ____ ___
[SFAS 95, par. 27 (AC C25.125)]
7. Are cash receipts and cash payments for the following transactions 
classified as cash flows from operating activities:
a. Interest received on loans? ____ ___
b. Insurance proceeds except those directly related to investing or
financing activities? ____ ___
c. Interest paid to creditors? ____ ___
A. Payments to suppliers and employees? ____ ___
e. Payments to governments for taxes, duties, fines, and other fees
or penalties? ____  ___
f. Payments to settle lawsuits? ____ ___
g. Contributions to charities? ____ ___
[SFAS 95, pars. 22 and 23 (AC C25.120 and .121)]
h. Cash flows from purchases, sales, and maturities of trading secu­
rities? ____  ___
[SFAS 115, par. 18 (AC I80.117); AAG, par. 4.15]
8. Are cash receipts and cash payments from investing activities shown
separately on statement of cash flows? ____  ___
[SFAS 95, par. 31 (AC C25.129)]
9. Are cash receipts and cash payments for the following transactions 
classified as cash flows from investing activities:
a. Receipts from collections or sales of loans? ____  ___
b. Receipts from sales of property? ____ ___
c. Loans to others? ____ ___
d. Payments to acquire property? ____ ___
e. Purchases of and proceeds from sales of available-for-sale securi­
ties? ____ ___
f. Proceeds from maturities of available for sale and held-to-matur­
ity securities? ____  ___
g. Purchases of held-to-maturity securities? ____ ___
[SFAS 95, pars. 16 and 17 (AC C25.114 and .115); SFAS 115, par. 18
(AC I80.117)]
10. Are cash receipts and cash payments from financing activities shown
separately on the statement of cash flows? ____ ___
[SFAS 95, par. 31 (AC C25.129)]
★♦11. Are cash receipts and cash payments for the following transactions 
classified as cash flows from financing activities:
a. Proceeds from issuing debt? ____  ___
b. Repayments for amounts borrowed? ____ ___
[SFAS 95, pars. 19 and 20 (AC C25.117 and .118)]
c. Cash payments for debt issue costs? ____ ___
[EITF 95-13]
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Yes
★♦ 12. Are investing and financing activities that affect recognized assets or 
liabilities but that do not result in cash receipts or cash payments
disclosed? ____
[SFAS 95, par. 32, as amended by SFAS 117, par. 30g (AC C25.134)]
13. In its statement of cash flows, does the organization include in cash 
flows from financing activities any amounts received with donor-
imposed stipulations that they must be used for long-term purposes? ____
[SFAS 117, par. 30c (AC C25.116)]
14. Are the following classes of operating cash receipts and payments for 
providers using the direct method, at a minimum, separately disclosed:
a. Cash received from service recipients? ____
b. Cash received from contributors? ____
c. Interest and dividends received? ____
d. Cash collected on contributions receivables? ____
e. Other operating cash receipts, if any? ____
f. Cash paid to employees and suppliers? ____
g. Interest paid? ____
h. Income taxes paid? ____
i. Grants paid? ____
j. Other operating cash payments, if any? ____
[SFAS 95, par. 27, as amended by SFAS 117, par. 30e (AC C25.125)]
Note: SFAS 95 encourages enterprises to provide further breakdowns of 
operating cash receipts and payments that they consider meaningful and 
feasible.
15. Is the reconciliation of net income to net cash flow from operating 
activities, including separate reporting of all major classes of reconcil­
ing items, presented?
[SFAS 95, par. 29 (AC C25.127)]
★♦16. If the indirect method of reporting net cash flow from operating 
activities is used, are amounts of interest paid (net of amounts capi­
talized) and income taxes paid during the period provided in related 
disclosures?
[SFAS 95, par. 29 (AC C25.127)]
Other Financial Statement Disclosures
A. Accounting Changes
★♦ 1. For changes in accounting principle, does disclosure in the period of 
the change include:
a. Nature of the change?
b. Justification for the change, including a clear explanation of why 
the newly adopted principle is preferable?
c. Effect on income?
[APB 20, par. 17 (AC A06.113)]
★♦ 2. For other changes in accounting principle (excluding specific excep­
tions related to an initial public offering, change in the reporting entity,
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No N/A
Yes
or adoption of certain authoritative pronouncements), is the presen­
tation and disclosure guidance in APB 20 properly applied?
[APB 20, pars. 17-22 and 24-26 (AC A06.113-.118, .121, and .122); 
FASBI20, par. 5, as amended by SFAS 111 (A06.127)]
★♦3. Is the correction of an error shown as a prior-period adjustment 
with disclosure of the following in the period of its discovery and 
correction:
a. Nature of the error in previously issued financial statements?
b. Effect of its correction on revenue and gains in excess of expenses 
and losses (income) before extraordinary items and net revenue 
and gains in excess of expenses and losses (net income) (and 
related per share amounts if applicable)?
[APB 20, par. 37 (AC A35.105); SFAS 109, par. 288n (AC A35.103)]
B. Accounting Policies
1. Is a description of all pertinent accounting policies of the provider 
presented as an integral part of the financial statements?
[APB 22, pars. 8 and 9 (AC A10.102 and .103)]
2. Does disclosure of significant accounting policies encompass impor­
tant judgments as to the appropriateness of principles concerning 
recognition of revenue and allocation of asset costs to current and 
future periods?
[APB 22, par. 12 (AC A10.105)]
3. Does disclosure of significant accounting policies include appropriate 
reference to details presented elsewhere (in the statements and notes 
thereto) so duplication of details is avoided?
[APB 22, par. 14 (AC A10.107)]
C. Business Combinations
Note: EITF 97-2, Application of FASB Statement No. 94 and APB Opinion No. 
16 to Physician Practice Management Entities and Certain Other Entities with 
Contractual Management Arrangements, provides guidance to assist physi­
cian practice management companies (PPMs) in applying APB 16 when 
PPMs acquire a physician practice.
★♦1. If a business combination occurred during the period and met the 
specified conditions for a pooling-of-interests, do the statements and 
notes include the required disclosures?
[APB 16, pars. 63-65 (AC B50.122-.124)]
Note: Not-for-profit organizations are, under certain circumstances, per­
mitted to use the pooling-of-interests method, even though they generally 
do not issue common stock. [AAG, pars. 1.33 and 1.34]
2. If a business combination occurred during the period and is to be 
accounted for under the purchase method, do the statements and 
notes include the required disclosures?
[APB 16, pars. 95 and 96 (AC B50.164 and .165); SFAS 79, par. 6 (AC 
B50.165); SFAS 38, par. 10 (AC B50.166)]
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No N/A
Yes
★♦3. If, as part of a business combination accounted for as a purchase, a 
material liability is recognized by the combined company for costs 
incurred to (a) exit an activity, (b) involuntarily terminate employees 
of an acquired company, or (c) relocate employees of an acquired 
company:
a. Are the following disclosures made for the period in which a 
purchase business combination occurs:
(1) If the plans to exit an activity or involuntarily terminate 
(relocate) employees of the acquired company are not final as 
of the balance sheet date, a description of any unresolved 
issues, the types of additional liabilities that may result in an 
adjustment to the purchase price allocation, and how any 
adjustment will be reported?
(2) A description of the type and amount of liabilities assumed 
in the purchase price allocation for costs to exit an activity or 
involuntary terminate (relocate) employees?
(3) A description of the major actions comprising the plan to exit 
an activity or involuntarily terminate (relocate) employees of 
an acquired company?
(4) A description of activities of the acquired company that will 
not be continued, including the method of disposition, and 
the anticipated date of completion and description of em­
ployee group(s) to be terminated (relocated)?
b. Are the following disclosures made for all periods presented 
subsequent to the acquisition date in which a purchase business 
combination occurred, until a plan to exit an activity or involun­
tarily terminate or relocate employees of an acquired company is 
fully executed:
(1) A description of the type and amount of exit costs, involun­
tary employee termination costs, and relocation costs paid 
and charged against the liability?
(2) The amount of any adjustment to the liability account and 
whether the corresponding entry was an adjustment of the 
costs of the acquired company or included in the determina­
tion of net income for the period?
[EITF 95-3]
D. Commitments and Contingencies
1. Uninsured medical malpractice claims:
a. If a minimum amount of a probable loss (usually associated with 
litigating or settling malpractice claims) is accrued, is there disclo­
sure as to a reasonable possibility of an additional potential loss 
in excess of the amount accrued?
[AAG, par. 8.07; SFAS 5 (AC C59)]
b. If a range of loss cannot be reasonably estimated, is a contingency 
disclosed?
[AAG, par. 8.11; SFAS 5 (AC C59)]
c. Is the program of medical malpractice coverage and basis for loss 
accruals disclosed?
[AAG, par. 8.11]
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No N/A
Yes No N/A
  d. If the provider discounts accrued malpractice claims, are the fol­
lowing disclosed:
(1) The carrying amount of the claims? ____
(2) The interest rates or other rates used to discount the claims? ____
[AAG, par. 8.12]
2. Retrospectively rated premiums:
a. If the provider cannot estimate losses from asserted or unasserted
malpractice claims, is the existing contingency disclosed? ____
[AAG, par. 8.14; SFAS 5 (AC C59)]
b. Does the provider disclose that it is insured under a retrospec­
tively rated policy? ____
[AAG, par. 8.15]
c. Does the provider disclose that premiums are accrued based on
the ultimate cost of the experience to date of a group of entities? ____
[AAG, par. 8.15]
3. Medical malpractice claims insured with captive insurance compa­
nies (controlled by a parent entity for the main purpose of providing 
insurance for the parent):
a. Does the provider disclose that it is insured under a retrospec­
tively rated policy of a multiprovider captive? ____
[AAG, par. 8.18]
b. Does the provider disclose that premiums are accrued based on
the captive's experience to date? ____
[AAG, par. 8.18]
c. Is the provider's ownership percentage in the captive disclosed? ____
[AAG, par. 8.19]
d. Is the method of accounting for its investment in and the opera­
tions of the captive disclosed? ____
[AAG, par. 8.19]
e. If the provider cannot make the necessary estimates of losses 
from asserted or unasserted claims, does it disclose the existing
contingency? ____
[AAG, par. 8.19; SFAS 5 (AC C59)]
4. Trust funds:
a. If trust funds (revocable or irrevocable) are included in the 
provider's financial statements:
(1) Is a portion of the funds (the amount of assets expected to be 
liquidated to pay malpractice claims classified as current 
liabilities) classified as a current asset in a classified balance
sheet/statement of financial position? ____
[AAG, par. 8.20]
(2) Is the balance of the funds, if any, classified as a noncurrent 
asset in a classified balance sheet/statement of financial
position? ____
[AAG, par. 8.20]
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Yes
(3) Are trust fund revenue and administrative expenses included 
in the statement of activities (statement of operations)? 
[AAG, par. 8.20]
(4) Are estimated losses from asserted and unasserted claims 
reported?
[AAG, par. 8.21]
(5) Is the existence of trust funds and whether they are irrevoca­
ble disclosed?
[AAG, par. 8.22]
5. Prepaid health care services:
a. Health care costs:
(1) Is the basis for accruing health care costs disclosed?
(2) Are significant business and contractual arrangements 
with hospitals, physicians, and other associated entities 
disclosed?
[AAG, par. 13.04]
b. Stop-loss insurance:
(1) Are receivables representing amounts recoverable from in­
surers reported as assets net of any valuation allowance?
(2) Are the nature, amounts, and effects of significant stop-loss 
insurance contracts disclosed?
[AAG, par. 13.08]
c. Loss contracts:
(1) Are losses recognized, in accordance with SFAS 5, when it is 
probable that expected future health care costs and mainte­
nance costs under a group of existing contracts will exceed 
anticipated future premiums and stop-loss insurance on 
those contracts?
[AAG, par. 13.06]
d. Contract acquisition costs:
(1) Are acquisition costs of providers of prepaid health care serv­
ices, other than costs of advertising, expensed as incurred? 
[AAG, par. 13.10]
6. Other disclosures:
a. Are the nature and, if applicable, amount (or a statement that no 
loss estimate can be made) disclosed for loss contingencies (includ­
ing guarantees)?
[SFAS 5, pars. 9-12 and FASBI 34, pars. 2 and 3 (AC C59.108-.114)]
b. If exposure to loss exists in excess of the amount accrued for a loss 
contingency, do disclosures include the excess amount or state that 
no estimate is possible?
[SFAS 5, par. 10 (AC C59.109)]
c. Are gain contingencies adequately disclosed with care to avoid 
misleading implications as to the likelihood of realization?
[SFAS 5, par. 17 (AC C59.118)]
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No N/A
Yes No N/A
d. Are the nature, term, amount and other required information 
disclosed for long-term unconditional purchase obligations? 
[SFAS 47, pars. 7 and 10a (AC C32.102 and .105a)]
e. Are the nature and amount of guarantees disclosed (for example, 
of indebtedness of others)?
[SFAS 5, par. 12 (AC C59.113); FASBI 34, pars. 2 and 3 (AC 
C59.114)]
Is there adequate disclosure of commitments such as those for 
plant acquisition or an obligation to reduce debts, maintain work­
ing capital, or restrict dividends?
[SFAS 5, pars. 18 and 19 (AC C59.120)]
If an obligation for postemployment benefits (other than pensions) 
is not accrued in accordance with SFAS 5 (AC C59) or SFAS 43 (AC 
C44) only because the amount cannot reasonably be estimated, is 
the fact of nonaccrual disclosed in the financial statements?
[SFAS 112, par. 7 (AC P32.105)]
h. Are environmental remediation obligations reported and dis­
closed in accordance with SOP 96-1?
[SOP 96-1]
E. Costs to Exit an Activity
1. If a material liability is recognized for certain employee termination 
benefits in accordance with Section A of EITF 94-3, Liability Recognition 
for Certain Employee Termination Benefits and Other Costs to Exit an 
Activity (including Certain Costs Incurred in a Restructuring), are the 
following disclosures made in all periods until the plan of termination 
is completed:
a. The amount of termination benefits accrued and charged to ex­
pense and the classification of those costs in the income state­
ment/statement of activities?
b. The number of employees to be terminated?
c. A description of the employee group(s) to be terminated?
d. The amount of actual termination benefits paid and charged 
against the liability and the number of employees actually termi­
nated as a result of the plan to terminate employees?
e. The amount of any adjustment(s) to the liability?
★♦2. If management commits to an exit plan that meets the criteria in
Section B of EITF 94-3, are the following reporting requirements 
followed:
a. Reporting the income statement effect of recognizing a liability at 
the commitment date in income from continuing operations and 
not on the face of the income statement net of taxes?
b. No disclosure made on the face of the income statement for 
earnings per share effect?
c. Revenue and related costs and expenses of activities that will not 
be continued should not be combined and reported as a separate 
component of income?
[EITF 94-3, Section B]
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★♦3. If the activities that will not be continued are significant to the enter­
prise's revenue or operating results, or if the exit costs recognized at 
the commitment date are material, are the following disclosures made 
in all periods until the exit plan is completed:
a. A description of the major actions comprising the exit plan, activi­
ties that will not be continued, including the method of disposi­
tion, and the anticipated date of completion?
b. A description of the type and amount of exit costs recognized as 
liabilities and the classification of those costs in the income state­
ment/statement of activities?
c. A description of the type and amount of exit costs paid and 
charged against the liability?
d. The amount of any adjustment(s) to the liability?
e. For all periods presented, the revenue and net operating income 
or losses from activities that will not be continued if those activities 
have separately identifiable operations?
[EITF 94-3, Section B]
F. Derivatives
Note: If SFAS 133, Accounting for Derivative Instruments and Hedging Ac­
tivities, has been adopted, the following Questions do not apply. See 
Section G1 for the required disclosures. SFAS 133, as amended by SFAS 
137, Accounting for Derivative Instruments and Hedging Activities—Deferral 
of the Effective Date of FASB Statement No. 133, is effective for all fiscal 
quarters of fiscal years beginning after June 15, 2000.
On March 3, 2000 the FASB issued an exposure draft, Accounting for Certain 
Derivative Instruments and Certain Hedging Activities, that would amend 
SFAS 133. Readers should be alert to the issuance of a final standard.
1. For options held and other derivative financial instruments not within 
the scope of SFAS 105 that do not have off-balance-sheet risk, are the 
following disclosures made by category of financial instrument:
a. The face or contract amount (or notional principal amount if there 
is no face or contract amount)?
b. The nature and terms, including a discussion of:
(1) Credit and market risk?
(2) Cash requirements?
(3) Related accounting policy as required by APB 22?
c. Do disclosures in Steps a. and b. above distinguish between finan­
cial instruments held or issued for:
(1) Trading purposes, including dealing and other trading activi­
ties measured at fair value with gains and losses recognized 
in earnings?
(2) Purposes other than trading?
[SFAS 119, pars. 8 and 9 (AC Appendix E, F25.115L-.115M)]
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Yes
★♦2. Does the provider that holds or issues derivative financial instru­
ments for trading purposes disclose:
a. The average fair value during the reporting period and the related
end-of-period fair value, distinguishing between assets and li­
abilities? ____
b. The net gains or losses (net trading revenue) arising from trading
activities during the reporting period disaggregated by class, busi­
ness activity, risk or other category consistent with management 
of those activities and where those net trading gains or losses are 
reported in the income statement? ____
(1) If the disaggregation is other than by class, did the provider 
also disclose for each category the classes of derivative finan­
cial instruments, other financial instruments, and nonfinan­
cial assets and liabilities from which the net trading gains and 
losses arose? ____
c. The average fair value for assets and liabilities from the trading of 
other types of financial instruments or non financial assets? (This
disclosure is encouraged but not required.) ____
[SFAS 119, par. 10 (AC Appendix E, F25.115N)]
3. Does a provider that holds or issues derivative financial instruments 
for purposes other than trading disclose:
a. A description of:
(1) The objectives for holding or issuing? ____
(2) The context needed to understand those objectives? ____
(3) The strategies for achieving those objectives? ____
(4) The classes of derivative financial instruments used? ____
b. A description of how each class of derivative financial instrument 
is reported in the financial statements, including:
(1) The policies for recognition and measurement or nonrecog­
nition of the derivative financial instruments? ____
(2) When recognized, where the instruments and related gains
and losses are reported? ____
c. For derivative financial instruments that are held or issued and 
accounted for as hedges of anticipated transactions, both firm and 
forecasted transactions for which there is no firm commitment, 
including:
(1) A description of the anticipated transactions whose risks are
hedged, including the expected time period of occurrence? ____
(2) A description of the classes of derivative financial instru­
ments used to hedge? ____
(3) The amount of explicitly deferred hedging gains and losses? ____
(4) A description of the transaction or events that result in recog­
nition in earnings of the deferred gains or losses? ____  
[SFAS 119, par. 11 (AC Appendix E, F25.115O)]
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★♦4. Are the following encouraged, but not required, quantitative disclo­
sures made:
a. Interest rate? ____
b. Foreign exchange? ____
c. Commodity price? ____
d. Other market risks consistent with management's strategies? ____
e. Information of the risk of other financial instruments or nonfinan­
cial assets and liabilities related by risk management strategy 
pertaining to the objectives for holding or issuing derivative finan­
cial instruments? ____
[SFAS 119, pars. 12 and 13 (AC Appendix E, F25.115P-.115Q)]
G. Financial Instruments
Note: If SFAS 133, Accounting for Derivative Instruments and Hedging Ac­
tivities, has been adopted, the following Questions do not apply. See 
Section G1 for the required disclosures. SFAS 133, as amended by SFAS 
137, Accounting for Derivative Instruments and Hedging Activities—Deferral 
of the Effective Date of FASB Statement No. 133, is effective for all fiscal 
quarters of fiscal years beginning after June 15, 2000.
On March 3, 2000 the FASB issued an exposure draft, Accounting for Certain 
Derivative Instruments and Certain Hedging Activities, that would amend 
SFAS 133. Readers should be alert to the issuance of a final standard.
★♦1. Except for certain excluded items (SFAS 105, pars. 14 and 15 (AC
F25.104 and .105)), are the following disclosed in the financial state­
ments or notes for each category of financial instruments with 
off-balance-sheet risk (health care organizations that enter into certain 
types of receivable financing arrangements should disclose their off- 
balance-sheet risk):
a. The face or contract amount, or notional principal amount if there
is no face or contract amount? ____
b. The nature and terms, including, at a minimum, a discussion of:
(1) Credit and market risk of those instruments? ____
(2) Cash requirements of those instruments? ____
(3) Related accounting policy, as required by APB 22, Disclosure
of Accounting Policies (AC A10)? ____
[SFAS 105, par. 17, as amended by SFAS 119, par. 14 (AC 
Appendix E, F25.112-.112A); AAG, par. 5.20]
c. For the disclosures in a. and b. above, distinguish between financial 
instruments with off-balance-sheet risk held or issued for trading 
purposes, and financial instruments with off-balance-sheet risk
held or issued for purposes other than trading? ____
2. For financial instruments with off-balance-sheet credit risk (except for
the items excluded in SFAS 105 (AC Appendix E, F25)), are the following 
disclosed, either in the financial statements or in the notes, by category 
of financial instrument:
a. The amount of accounting loss the entity would incur if any party 
to the financial instrument failed completely to perform according 
to the terms of the contract and if the collateral or other security, 
if any, for the amount due proved to be of no value to the entity? ____
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No N/A
Yes No N/A
b. Regarding collateral or other security to support financial instru­
ments subject to credit risk:
(1) The entity's policy of requiring such collateral or other security? ____
(2) Information about the entity's access to that collateral or other
security? ____
(3) The nature and a brief description of the collateral or other
security supporting those financial instruments? ____
[SFAS 105, par. 18, as amended by SFAS 119, par. 14 (AC 
Appendix E, F25.113)]
★♦3. Do disclosures of all significant concentrations of credit risk arising 
from all financial instruments, whether from an individual counter­
party or groups of counterparties (except for certain excluded items 
[SFAS 105, par. 14 (AC Appendix E, F25.104)]), include:
Note: Health care providers that enter into certain types of receivable 
financing arrangements should disclose their off-balance-sheet risk.
a. Information about the (shared) activity, region, or economic char­
acteristic that identifies the concentration? ____
b. The amount of the accounting loss due to credit risk the entity 
would incur if any party to the financial instruments that make up 
the concentration failed completely to perform according to the 
terms of the contracts and if the collateral or other security, if any,
for the amount due proved to be of no value to the entity? ____
c. Regarding collateral or other security to support financial instru­
ments subject to credit risk:
(1) The entity's policy of requiring such collateral or other security? ____
(2) Information about the entity's access to that collateral or other
security? ____
(3) The nature and a brief description of the collateral or other
security supporting those financial instruments? ____
[SFAS 105, pars. 14 and 20 (AC Appendix E, F25.104 and .115)]
4. Is disclosure made of the primary geographic sources of patients? ____
[AAG, par. 5.19]
Note: SFAS 126, Exemption from Certain Required Disclosures about Financial 
Instruments for Certain Nonpublic Entities, states that disclosures about the 
fair value of financial instruments prescribed in SFAS 107 shall be optional 
for an entity that meets all of the following criteria:
a. The entity is a nonpublic company.
b. The entity's total assets are less than $100 million on the date of the 
financial statements.
c. The entity has not held or issued any derivative financial instru­
ments as defined in SFAS 119 other than loan commitments, during 
the reporting period.
[For organizations that have adopted SFAS 133, criterion c. is, "the or­
ganization has no instrument that, in whole or in part, is accounted for 
as a derivative instrument under SFAS 133 during the reporting period."]
Consider this exemption when reviewing Steps 5 through 10 below.
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Yes
5. Is the fair value of financial instruments for which it is practicable to 
estimate that value (except for those excluded in paragraphs 8 and 13 
of SFAS 107) disclosed, together with the related carrying amount in 
a form that makes it clear whether the fair value and carrying amount 
represent assets or liabilities and how the carrying amounts relate to 
what is reported in the statement of financial position? [Note: If 
disclosed in more than a single note, one of the notes should include 
a summary table containing the fair value and related carrying 
amounts and cross-references to the location(s) of the remaining 
disclosures required by SFAS 107, as amended.]
[SFAS 107, par. 10, as amended by SFAS 119, par. 15 (AC Appendix 
E, F25.115C)]
6. Do the disclosures in Step 5 distinguish between financial instruments 
held or issued for trading purposes, including dealing and other 
trading activities measured at fair value with gains and losses recog­
nized in earnings, and financial instruments held or issued for pur­
poses other than trading?
[SFAS 107, par. 10, as amended by SFAS 119, par. 15 (AC Appendix 
E, F25.115C)]
7. Are the methods and significant assumptions used to estimate the fair 
value of financial instruments disclosed?
[SFAS 107, par. 10 (AC Appendix E, F25.115C)]
8. If it is not practicable to estimate the fair market value of a financial 
instrument, do disclosures include:
a. Information pertinent to estimating the fair value of the financial 
instrument or class of financial instruments, such as the carrying 
amount, effective interest rate, and maturity?
b. The reasons why it is not practicable to estimate fair value?
[SFAS 107, par. 14 (AC F25.115J)]
9. If the offsetting of derivative financial instruments against nonderi­
vative financial instruments is not permitted under FASBI39, Offset­
ting of Amounts Related to Certain Contracts, as amended by FASBI 41, 
Offsetting of Amounts Related to Certain Repurchase and Reverse Repur­
chase Agreements, does the organization, in disclosing the fair value of 
a derivative financial instrument, not:
a. Combine, aggregate, or net the fair value with the fair value of a 
nonderivative financial instrument?
b. Net the fair value with the fair value of other derivative financial 
instruments?
[SFAS 107, par. 13, as amended by SFAS 119, par. 15 (AC Appendix 
E, F25.115I)]
10. For all fiscal years subsequent to the year of transition, are SFAS 107 
disclosures included for each year for which a statement of financial 
position is presented for comparative purposes?
[SFAS 107, par. 17]
11. For a written put option involving a reporting entity's own stock that 
gives the reporting entity a choice of settlement methods, is the 
classification within equity based on the settlement method that 
required the written put option to be initially classified as equity 
under the EITF 94-7 framework?
[EITF 96-13]
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12. Are the classification guidelines under EITF 96-13 followed for writ­
ten put options involving a reporting entity's own stock that give the 
reporting entity a choice of settlement methods?
[EITF 96-13]
Gl. Financial Instruments
Note: The following disclosures apply only if SFAS 133, Accounting for 
Derivative Instruments and Hedging Activities, has been adopted. SFAS 133, 
as amended by SFAS 137, Accountingfor Derivative Instruments and Hedging 
Activities—Deferral of the Effective Date of FASB Statement No. 133, is effec­
tive for all fiscal quarters of fiscal years beginning after June 15, 2000.
On March 3, 2000 the FASB issued an exposure draft, Accounting for Certain 
Derivative Instruments and Certain Hedging Activities, that would amend 
SFAS 133. Readers should be alert to the issuance of a final standard.
Derivative Instruments and Hedging Activities
1. If an entity holds or issues derivative instruments (or nonderivative instru­
ments that are designated and qualify as hedging instruments pursuant to 
paragraphs 37 and 42 of SFAS 133) has disclosure been made of its objectives 
for holding or issuing those instruments, the context needed to under­
stand those objectives, and its strategies for achieving those objectives? ____
[SFAS 133, par. 44 (AC D50.141)]
2. Does the description distinguish between derivative instruments (and 
nonderivative instruments) designated as fair value hedging instruments, 
derivative instruments designated as cash flow hedging instruments, 
derivative instruments (and nonderivative instruments) designated as 
hedging instruments for hedges of the foreign currency exposure of a net
investment in a foreign operation, and all other derivatives? ____
[SFAS 133, par. 44 (AC D50.141)]
3. Does the description also indicate the entity's risk management policy 
for each of those types of hedges, including a description of the items
or transactions for which risks are hedged? ____
[SFAS 133, par. 44 (AC D50.141)]
4. For derivative instruments not designated as hedging instruments,
does the description indicate the purpose of the derivative activity? ____
[SFAS 133, par. 44 (AC D50.141)]
5. Qualitative disclosures about an entity's objectives and strategies for 
using derivative instruments may be more meaningful if such objec­
tives and strategies are described in the context of an entity's overall 
risk management profile. If appropriate, an entity is encouraged, but 
not required, to provide such additional qualitative disclosures. Have
such disclosures been made? ____
[SFAS 133, par. 44 (AC D50.141)]
6. Do the entity's disclosures for every reporting period for which a com­
plete set of financial statements is presented also include the following:
Fair Value Hedges
a. For derivative instruments, as well as nonderivative instruments 
that may give rise to foreign currency transaction gains or losses
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under SFAS 52, that have been designated and have qualified as 
fair value hedging instruments and for the related hedged items:
(1) The net gain or loss recognized in earnings during the report­
ing period representing (a) the amount of the hedges' ineffec­
tiveness and (b) the component of the derivative instruments' 
gain or loss, if any, excluded from the assessment of hedge 
effectiveness, and a description of where the net gain or loss 
is reported in the statement of income or other statement of 
financial performance? ____
(2) The amount of net gain or loss recognized in earnings when 
a hedged firm commitment no longer qualifies as a fair value
hedge? ____
[SFAS 133, par. 45a (AC D50.142)]
Cash Flow Hedges
b. For derivative instruments that have been designated and have 
qualified as cash flow hedging instruments and for the related 
hedged transactions:
(1) The net gain or loss recognized in earnings during the report­
ing period representing (a) the amount of the hedges' ineffec­
tiveness and (b) the component of the derivative instruments' 
gain or loss, if any, excluded from the assessment of hedge 
effectiveness, and a description of where the net gain or loss 
is reported in the statement of income or other statement of 
financial performance? ____
(2) A description of the transactions or other events that will 
result in the reclassification into earnings of gains and losses 
that are reported in accumulated other comprehensive in­
come, and the estimated net amount of the existing gains or 
losses at the reporting date that is expected to be reclassified
into earnings within the next 12 months? ____
(3) The maximum length of time over which the entity is hedging
its exposure to the variability in future cash flows for fore­
casted transactions excluding those forecasted transactions 
related to the payment of variable interest on existing finan­
cial instruments? ____
(4) The amount of gains and losses reclassified into earnings as a 
result of the discontinuance of cash flow hedges because it is
probable that the original forecasted transactions will not occur? ____
[SFAS 133, par. 45b (AC D50)]
Note: SFAS 133, paragraph 43, states that an entity that does not report 
earnings as a separate caption in a statement of financial performance (for 
example, a not-for-profit organization) shall recognize the gain or loss on 
a hedging instrument and a nonhedging derivative instrument as a 
change in net assets in the period of change unless the hedging instrument 
is designated as a hedge of the foreign currency exposure of a net invest­
ment in a foreign operation. Entities that do not report earnings shall 
recognize the changes in the carrying amount of the hedged item pursuant 
to paragraph 22 of SFAS 133 in a fair value hedge as a change in net assets 
in the period of change. Those entities are not permitted to use cash flow 
hedge accounting because they do not report earnings separately.
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Hedges of the Net Investment in a Foreign Operation
c. For derivative instruments, as well as nonderivative instruments 
that may give rise to foreign currency transaction gains or losses 
under SFAS 52, that have been designated and have qualified as 
hedging instruments for hedges of the foreign currency exposure 
of a net investment in a foreign operation, the net amount of gains 
or losses included in the cumulative translation adjustment during
the reporting period? ____ ___
[SFAS 133, par. 45c (AC D50.142)]
7. The quantitative disclosures about derivative instruments may be 
more useful, and less likely to be perceived to be out of context or 
otherwise misunderstood, if similar information is disclosed about 
other financial instruments or nonfinancial assets and liabilities to 
which the derivative instruments are related by activity. Accordingly, 
in such situations, has the entity presented a more complete picture 
of its activities by disclosing that information? (Encouraged, but not
required.) ____ ___
[SFAS 133, par. 45 (AC D50)]
Disclosures About Fair Value of Financial Instruments
8. Has the entity disclosed, either in the body of the financial statements 
or in the accompanying notes, the fair value of financial instruments 
(except for those excluded in paragraphs 8 and 13 of SFAS 107) for
which it is practicable to estimate fair value? ____ ___
[SFAS 107, par. 10 (AC F25)]
Note: If disclosed in more than a single note, one of the notes shall include 
a summary table. The summary table shall contain the fair value and 
related carrying amounts and cross-references to the location(s) of the 
remaining disclosures required by SFAS 107 as amended.
9. Has the fair value disclosed in the notes been presented together with 
the related carrying amount in a form that makes it clear whether the 
fair value and carrying amount represent assets or liabilities and how 
the carrying amounts relate to what is reported in the statement of 
financial position?
[SFAS 107, par. 10 (AC F25)]
10. In disclosing the fair value of a financial instrument, has the entity 
taken care not to net that fair value with the fair value of other financial 
instruments—even if those financial instruments are of the same class 
or are otherwise considered to be related, for example, by a risk 
management strategy—except to the extent that the offsetting of 
carrying amounts in the statement of financial position is permitted 
under the general principle in paragraphs 5 and 6 of FASBI 39, 
Offsetting of Amounts Related to Certain Contracts, or the exceptions for 
master netting arrangements in paragraph 10 of 39 and for amounts 
related to certain repurchase and reverse repurchase agreements in 
paragraphs 3 and 4 of FASBI 41, Offsetting of Amounts Related to Certain 
Repurchase and Reverse Repurchase Agreements?
[SFAS 107, par. 14 (AC F25)]
11. If it is not practicable to estimate the fair value of a financial instru­
ment or a class of financial instruments, are the following disclosed:
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a. Information pertinent to estimating the fair value of that financial 
instrument or class of financial instruments, such as the carrying 
amount, effective interest rate, and maturity?
b. The reasons why it is not practicable to estimate fair value?
[SFAS 107, par. 14 (AC F25)]
Note: SFAS 126, Exemption from Certain Required Disclosures about Financial 
Instruments for Certain Nonpublic Entities, makes the disclosures about fair 
values of financial instruments prescribed in SFAS 107 optional for report­
ing entities that:
• Are nonpublic entities,
• Have total assets of less than $100 million on the date of the financial 
statements, and
• Have no instrument that, in whole or in part, is accounted for as a 
derivative instrument under SFAS 133, Accounting for Derivative In­
struments and Hedging Activities, during the reporting period.
Disclosure About Concentrations of Credit Risk of All Financial Instruments
12. Except as indicated in paragraph 15B of SFAS 107, has the entity 
disclosed all significant concentrations of credit risk arising from all 
financial instruments, whether from an individual counterparty or 
groups of counterparties (Group concentrations of credit risk exist if a 
number of counterparties are engaged in similar economic charac­
teristics that would cause their ability to meet contractual obligations
to be similarly affected by changes in economic or other conditions)? ____
[SFAS 107, par. 15A (AC F25)]
Note: SFAS 107, paragraph 15B provides that these disclosure require­
ments do not apply to the following financial instruments, whether writ­
ten or held:
a. Financial instruments of a pension plan, including plan assets, when 
subject to the accounting and reporting requirements of SFAS 87 
(Financial instruments of a pension plan, other than the obligations 
for pension benefits, when subject to the accounting and reporting 
requirements of SFAS 35, Accounting and Reporting by Defined Benefit 
Pension Plans, are subject to the reporting of paragraph 15A).
b. The financial instruments described in paragraphs 8(a), 8(c), 8(e), 
and 8(f) of SFAS 107, as amended by SFAS 112, Employers' Accounting 
for Postemployment Benefits, SFAS 123, Accounting for Stock Based 
Compensation, and SFAS 125, Accounting for Transfers and Servicing 
of Financial Assets and Extinguishments of Liabilities, except for rein­
surance receivables and prepaid reinsurance premiums.
13. Has the entity made the following disclosures about each significant 
concentration:
a. Information about the (shared) activity, region, or economic char­
acteristic that identifies the concentration?
b. The maximum amount of loss due to credit risk that, based on the 
gross fair value of the financial instrument, the entity would incur 
if parties to the financial instruments that make up the concentra­
tion failed completely to perform according to the terms of the 
contracts and the collateral or other security, if any, for the amount 
due proved to be of no value to the entity?
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c. The entity's policy of requiring collateral or other security to 
support financial instruments subject to credit risk, information 
about the entity's access to that collateral or other security, and the 
nature and a brief description of the collateral or other security 
supporting those financial instruments?
d. The entity's policy of entering into master netting arrangements 
to mitigate the credit risk of financial instruments, information 
about the arrangements for which the entity is a party, and a brief 
description of the terms of those arrangements, including the 
extent to which they would reduce the entity's maximum amount 
of loss due to credit risk?
[SFAS 107, par. 15A (AC F25)J
14. Has the entity disclosed quantitative information about the market 
risks of financial instruments that is consistent with the way it man­
ages or adjusts those risks? (Encouraged, but not required.)
[SFAS 107, par. 15C (AC F25)]
Note: Appropriate ways of reporting the quantitative information en­
couraged will differ for different entities and will likely evolve over time 
as management approaches and measurement techniques evolve. Possi­
bilities include disclosing (a) more details about current positions and 
perhaps activity during the period, (b) the hypothetical effects on compre­
hensive income (or net assets), or annual income, of several possible 
changes in market prices, (c) a gap analysis of interest rate repricing or 
maturity dates, (d) the duration of the financial instruments, or (e) the 
entity's value at risk from derivatives and from other positions at the end 
of the reporting period and the average value at risk during the year. This 
list is not exhaustive, and an entity is encouraged to develop other ways 
of reporting quantitative information.
15. For a written put option involving a reporting entity's own stock that 
gives the reporting entity a choice of settlement methods, is the 
classification within equity based on the settlement method that 
required the written put option to be initially classified as equity 
under the EITF 94-7 framework?
[EITF 96-13]
16. Are the classification guidelines under EITF 96-13 followed for writ­
ten put options involving a reporting entity's own stock that give the 
reporting entity a choice of settlement methods?
[EITF 96-13]
Note: If SFAS 133 has been adopted, replace questions 5, 6, 7, 9, and 10 in 
Section C of the Balance Sheet section with the following Questions:
♦ 5. For securities classified as available-for-sale, has the reporting entity 
made the following disclosures by major-security type as of each date 
for which a statement of financial position is presented:
a. Aggregate fair value?
b. Total gains for securities with net gains in accumulated other 
comprehensive income?
c. Total losses for securities with net losses in accumulated other 
comprehensive income?
[SFAS 115, par. 19 (AC I80.118)]
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♦ 6. For securities classified as held-to-maturity, has the reporting entity
made the following disclosures by major-security type as of each date 
for which a statement of financial position is presented:
a. Aggregate fair value? ____
b. Gross unrecognized holding gains or losses? ____
c. Net carrying amount? ____
d. Gross gains and losses in accumulated other comprehensive in­
come for any derivatives that hedged the forecasted acquisition of
the held-to-maturity securities? ____
[SFAS 115, par. 19 (AC I80.118)]
♦ 7. For investments in debt securities classified as available-for-sale or
held-to-maturity:
a. Is disclosure made about their contractual maturities as of the date
of the latest balance sheet presented (maturity information may be 
combined in appropriate groupings)? ____
b. If securities not due at a single date (such as mortgage-backed 
securities) are allocated over several maturity groupings, is the
basis for allocation disclosed? ____
[SFAS 115, par. 20 (AC I80.119)]
♦ 8. For each period for which an income statement is presented, are the
following disclosed:
a. The proceeds from sales of available-for-sale securities and gross 
realized gains and losses that have been included in earnings as a
result of those sales? ____
b. The basis on which the cost of a security sold or the amount 
reclassified out of accumulated other comprehensive income into 
earnings was determined (i.e., specified identification, average
cost, or other method used)? ____
c. The gross gains and losses included in earnings from transfers of
securities from the available-for-sale category to the trading category? ____
d. The amount of the net unrealized holding gain or loss on avail­
able-for-sale securities for the period that has been included in 
accumulated other comprehensive income and the amount of 
gains and losses reclassified out of accumulated other comprehen­
sive income into earnings for the period? ____
e. The portion of trading gains and losses for the period that relates
to trading securities still held at the reporting date? ____
[SFAS 115, par. 21 (AC I80.120)]
♦ 9. For any sales of or transfers from securities classified as held-to-
maturity, are the following disclosed for each period for which an 
earnings statement is presented:
a. Net carrying amount of the sold or transferred security? ____
b. The net gain or loss in accumulated other comprehensive income
for any derivative that hedged the forecasted acquisition of the 
held-to-maturity security? ____
c. Related realized or unrealized gain or loss? ____
d. The circumstances leading to the decision to sell or transfer the
security? ____
[SFAS 115, par. 22 (AC I80.121)]
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H. Nonmonetary Transactions
1. Do disclosures include:
a. Nature of the transactions? ____
b. Basis of accounting for the assets transferred? ____
c. Gains or losses recognized on the transfers? ____
[APB 29, par. 28 (AC 01.102 and N35.120)]
I. Pension and Other Postretirement Benefit Plans
Note: The disclosures required by SFAS 132 may be aggregated for all of 
an employer's defined benefit pension plans and may be aggregated for 
all of an employer's defined benefit postretirement plans or may be 
disaggregated in groups if that is considered to provide the most useful 
information or is otherwise required by paragraph 7 of the Statement. 
Disclosures about pension plans with assets in excess of the accumulated 
benefit obligation generally may be aggregated with disclosures about 
pension plans with accumulated benefit obligations in excess of assets. 
The same aggregation is permitted for postretirement plans. An employer 
may combine disclosures about pension or postretirement benefit plans 
outside the United States with those for U.S. plans unless the benefit 
obligations of the plans outside the United States are significant relative 
to the total benefit obligation and those plans use significantly different 
assumptions. A nonpublic entity, as defined by SFAS 132, may elect the 
reduced disclosure requirements permitted by the Statement.
1. If an employee sponsors one or more defined benefit pension plans 
or one or more defined benefit postretirement plan, do disclosures 
include:
a. A reconciliation of beginning and ending balances of the benefit 
obligation showing separately, if applicable, the effects during the 
period attributable to each of the following: service cost, interest 
cost, contributions by plan participants, actuarial gains and losses, 
foreign currency exchange rate changes, benefits paid, plan 
amendments, business combinations, divestitures, curtailments, 
settlements, and special termination benefits?
b. A reconciliation of beginning and ending balances of the fair value 
of plan assets showing separately, if applicable, the effects during 
the period attributable to each of the following: actual return on 
plan assets, foreign currency exchange rate changes, contributions 
by the employer, contributions by plan participants, benefits paid, 
business combinations, divestitures, and settlements?
c. The funded status of the plans, the amounts not recognized in the 
statement of financial position, and the amounts recognized in the 
statement of financial position, including:
(1) The amount of any unamortized prior service cost?
(2) The amount of any unrecognized net gain or loss (including 
asset gains and losses not yet reflected in market-related 
value)?
(3) The amount of any remaining unamortized, unrecognized 
net obligation or net asset existing at the initial date of appli­
cation of SFAS 87 or SFAS 106?
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(4) The net pension or other postretirement benefit prepaid as­
sets or accrued liabilities?
(5) Any intangible asset and the amount of accumulated other 
comprehensive income recognized pursuant to paragraph 37 
of SFAS 87, as amended?
d. The amount of net periodic benefit cost recognized, showing 
separately the service cost component, the interest cost compo­
nent, the expected return on plan assets for the period, the amor­
tization of the unrecognized transition obligation or transition 
asset, the amount of recognized gains and losses, the amount of 
prior service cost recognized, and the amount of gain or loss 
recognized due to a settlement or curtailment?
e. The amount included within other comprehensive income for the 
period arising from a change in the additional minimum pension 
liability recognized pursuant to paragraph 37 of SFAS 87, as 
amended?
f. On a weighted-average basis, the following assumptions used in 
the accounting for the plans: assumed discount rate, rate of com­
pensation increase (for pay-related plans), and expected long-term 
rate of return on plan assets?
g. The assumed health care cost trend rate(s) for the next year used 
to measure the expected cost of benefits covered by the plan (gross 
eligible charges) and a general description of the direction and 
pattern of change in the assumed trend rates thereafter, together 
with the ultimate trend rate(s) and when that rate is expected to 
be achieved?
h. The effect of a one-percentage-point increase and the effect of a 
one-percentage-point decrease in the assumed health care cost trend 
rates on (1) the aggregate of the service and interest cost components 
of net periodic postretirement health care benefit cost and (2) the 
accumulated postretirement benefit obligation for health care bene­
fits (For purposes of this disclosure, all other assumptions shall be 
held constant, and the effects shall be measured based on the sub­
stantive plan that is the basis for the accounting.)?
i. If applicable, the amounts and types of securities of the employer 
and related parties included in plan assets, the approximate 
amount of future annual benefits of plan participants covered by 
insurance contracts issued by the employer or related parties, and 
any significant transactions between the employer or related par­
ties and the plan during the period?
j. If applicable, any alternative amortization method used to amor­
tize prior service amounts or unrecognized net gains and losses 
pursuant to paragraphs 26 and 33 of SFAS 87 or paragraphs 53 and 
60 of SFAS 106?
k. If applicable, any substantive commitment, such as past practice 
or a history of regular benefit increases, used as the basis for 
accounting for the benefit obligation?
l. If applicable, the cost of providing special or contractual termina­
tion benefits recognized during the period and a description of the 
nature of the event?
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m. An explanation of any significant change in the benefit obligation 
or plan assets not otherwise apparent in the other disclosures 
required by SFAS 132?
[SFAS 132, par. 5 (AC P16.150)]
2. For employers that sponsor more than one defined benefit pension 
plan or more than one defined benefit postretirement plan, are the 
disclosures required by Step I.2 above aggregated for all of the em­
ployer's defined benefit pension plans and for all of the employer's 
defined benefit postretirement plans or disaggregated in groups if 
that is considered to provide the most useful information or is other­
wise required by paragraph 7 of SFAS 132?
[SFAS 132, par. 6 (AC P16.153)]
3. For employers that have aggregated disclosures about postretirement 
plans with assets in excess of the accumulated benefit obligations with 
disclosures about postretirement plans with accumulated benefit ob­
ligations in excess of assets, do disclosures include:
a. The aggregate benefit obligation and aggregate fair value of plan 
assets for plans with benefit obligations in excess of plan assets?
b. The aggregate pension accumulated benefit obligation and aggre­
gate fair value of plan assets for pension plans with accumulated 
benefit obligations in excess of plan assets?
c. Amounts recognized separately in the statement of financial posi­
tion as prepaid benefit costs and accrued benefit liabilities?
[SFAS 132, par. 6 (AC P16.153)]
4. Are disclosures about pension or postretirement benefit plans outside 
the United States separate from those for U.S. plans when the plans 
outside the United States have benefit obligations that are significant 
relevant to the total benefit obligation and use significantly different 
assumptions?
[SFAS 132, par. 7 (AC P16.153A)]
Reduced Disclosure Requirements for Nonpublic Entities
5. For a nonpublic entity that has elected the reduced disclosure require­
ments for its pension and other postretirement benefit plans in lieu of 
the disclosures required by paragraph 5 of SFAS 132 (Step I.2.), do 
disclosures include:
a. The benefit obligation, fair value of plan assets, and funded status 
of the plan?
b. Employer contributions, participant contributions, and benefits 
paid?
c. The amounts recognized in the statement of financial position, 
including the net pension and other postretirement benefit pre­
paid assets or accrued liabilities and any intangible asset and the 
amount of accumulated other comprehensive income recognized 
pursuant to paragraph 37 of SFAS 87, as amended?
d. The amount of net periodic benefit cost recognized and the 
amount included within other comprehensive income arising 
from a change in the minimum pension liability recognized pur­
suant to paragraph 37 of SFAS 87, as amended?
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e. On a weighted-average basis, the following assumptions used in 
the accounting for the plans: assumed discount rate, rate of com­
pensation increase (for pay-related plans), and expected long-term
rate of return on plan assets? ____
f. The assumed health care cost trend rate(s) for the next year used 
to measure the expected cost of benefits covered by the plan (gross 
eligible charges) and a general description of the direction and 
pattern of change in the assumed trend rates thereafter, together 
with the ultimate trend rate(s) and when that rate is expected to
be achieved? ____
g. If applicable, the amounts and types of securities of the employer
and related parties included in plan assets, the approximate 
amount of future annual benefits of plan participants covered by 
insurance contracts issued by the employer or related parties, and 
any significant transactions between the employer or related par­
ties and the plan during the period? ____
h. The nature and effect of significant nonroutine events, such as 
amendments, combinations, divestitures, curtailments, and
settlements? ____
[SFAS 132, par. 8 (AC P16.150A)]
Defined Contribution Plans
  6. If there are one or more defined contribution plans:
a. Is the amount of cost recognized for the defined contribution
pension or other postretirement benefit plans during the period 
disclosed separately from the amount of cost recognized for de­
fined benefit plans? ____
b. Do disclosures include a description of the nature and effect of any 
significant changes during the period affecting comparability, 
such as a change in the rate of employer contributions, a business
combination, or a divestiture? ____
[SFAS 132, par. 9 (AC P16.162)]
Multiemployer Plans
7. If there are one or more multiemployer plans:
a. Do disclosures include the amount of contributions to the mul­
tiemployer plan(s) during the period? ____
b. If the employer discloses total contributions to multiemployer
plans without disaggregating the amounts attributable to pen­
sions and other postretirement benefits, do the disclosures include 
a description of the nature and effect of any changes affecting 
comparability, such as a change in the rate of employee contribu­
tions, a business combination, or a divestiture? ____
[SFAS 132, par. 10 (AC P16.166)]
c. If the situation arises where the withdrawal from a multiemployer 
plan may result in the employer having an obligation to the plan for 
a portion of its unfunded benefit obligations that is either probable or
reasonably possible, are the provisions of SFAS 5 (AC C59) applied? ____
rSFAS 87, par. 70 (AC P16.167)]
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  8. Are the provisions of SFAS 5 (AC C59) applied if the situation arises 
where withdrawal from a multiemployer plan may result in an em­
ployer's having an obligation to the plan for a portion of the plan's 
unfunded accumulated postretirement benefit obligation and it is 
probable or reasonably possible that:
a. An employer would withdraw from the plan under circumstances 
that would give rise to an obligation?
or
b. An employer's contribution to the fund would be increased during 
the remainder of the shortfall in the funds necessary to maintain 
the negotiated level of benefit coverage?
[SFAS 106, par. 83 (AC P40.179)]
J. Related Organizations and Economic Dependency
1. Consolidation and combination:
a. If the provider and another entity are related and they meet the 
criteria for consolidation or combination ("consolidation"), are 
consolidated or combined ("consolidated") financial statements 
presented?
[AAG, pars. 11.10 and 11.11; ARB 51 (AC C51); SFAS 94 (AC C51)]
b. If consolidated statements are presented:
(1) Is the consolidation policy disclosed?
[ARB 51, par. 5 (AC C51.108); APB 22, par. 13 (AC A10.106)]
(2) When the financial reporting periods of consolidated entities 
differ, is recognition given, by disclosure or otherwise, to the 
effect of intervening events that materially affect financial 
position or results of operations?
[ARB 51, par. 4 (AC C51.107)]
c. Do disclosures about formerly unconsolidated subsidiaries that 
are now consolidated include summarized information about the 
assets, liabilities, and results of operations (or separate statements) 
in the consolidated financial statements or notes?
[SFAS 94, par. 14 (AC C51.120A)]
2. Related parties and economic dependency:
a. If the reporting entity controls a separate not-for-profit entity 
through a form other than majority ownership or voting interest, 
has an economic interest in that other entity, and consolidated 
financial statements are not presented, is identification of the other 
entity and the nature of its relationship with the reporting entity 
disclosed; and is summarized financial data of the related organi­
zation disclosed?
[AAG, par. 11.12]
b. If the reporting entity has control over a related party, or has an 
economic interest in a related party, but the related party is not 
consolidated, are the following disclosures made:
(1) The nature of the relationship between the entity and the 
related party?
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(2) If there are material transactions between the entity and the 
related party:
(i) A description of the transactions, including transactions
to which nominal or no amounts were ascribed? ____  ___
(ii) The amount of such transactions? ____ ___
(iii) Amounts due from or to the related party and, if not
apparent, the terms and manner of settlement? ____  ___
(iv) The information required by paragraph 49 of SFAS 109? ____  ___
[AAG, par. 11.13; SFAS 13, par. 29 (AC L10.125); SFAS
57, pars. 2-4, as amended by SFAS 109, paragraph 288(s)
(AC R36.102-.104)]
c. If consolidated financial statements are presented and they in­
clude a controlled not-for-profit organization, are the following 
disclosed:
(1) Restrictions made by entities outside of the reporting entity
on distributions from the controlled not-for-profit organiza­
tion to the reporting entity? ____  ___
and
(2) Any resulting unavailability of the net assets of the controlled
not-for-profit organization for use by the reporting entity? ____ ___
[AAG, par. 11.14]
d. Are significant relationships and transactions not in the ordinary 
course of business with directors, management, medical staff, etc.
disclosed in the financial statements? ____  ___
[AAG, par. 11.25]
e. If representations about transactions with related parties are 
made, do they avoid the implication that the related party trans­
actions were consummated at arm's length, or if such implications
are made, can they be substantiated? ____  ___
[SFAS 57, par. 3 (AC R36.103)]
f. If (a) the reporting entity and one or more other enterprises are
under common ownership or management control and (b) the 
existence of the control could result in operating results or finan­
cial position of the reporting entity being significantly different 
from that if the enterprise were autonomous, is the nature of the 
controlled relationships disclosed (even if there are no transac­
tions between the enterprises)? ____ ___
[SFAS 57, pars. 2 and 4 (AC R36.102 and .104)]
K. Risks and Uncertainties
1. Are the following disclosed:
a. A description of the principal services performed by the health
care provider and the revenue sources for the entity's services? ____ ___
b. The fact that financial statements prepared in accordance with
GAAP require the use of management's estimates? ____  ___
[SOP 94-6, pars. 10 and 11]
★♦2. If (1) it is at least reasonably possible that the estimate(s) used in 
preparing the financial statements will change in the near term, and 
(2) the effect(s) of the change will be material, are the following 
disclosed:
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Yes No N/A
a. The nature of uncertainties inherent in estimates used to deter­
mine the carrying amounts of assets and liabilities, or used to
disclose gain or loss contingencies? ____ ____ ____
b. That a material change in the estimate could occur in the near
term? ____ ____ ____
[SOP 94-6, pars. 12-14]
3. If the estimate in Step 2 above involves a loss contingency covered by
SFAS 5, Accounting for Contingencies, do disclosures include an esti­
mate of the possible loss or range of loss, or state that such an estimate
cannot be made?3 ____ ____  ____
3 If risk reduction techniques are used to mitigate losses or the uncertainty that may result from certain events, these disclosures are 
encouraged but not required.
[SOP 94-6, par. 14]
★♦4. If (1) concentrations exist at the financial statement date, and (2) the 
concentrations could cause the provider a near-term severe impact, 
are the following disclosed:
a. Concentrations in the volume of the business transacted with a
particular customer (patient), supplier, lender, grantor, or con­
tributor? ____ ____ ____
b. Concentrations in revenue from particular services provided or
fund-raising events? ____ ____  ____
c. Concentrations in the available sources of supply of labor, serv­
ices, or of applicable licenses necessary to provide services? ____ ____  ____
d. Concentrations in the market or geographical area in which an 
entity conducts its operations, including the carrying amounts of
net assets and their locations? ____ ____  ____
e. Concentrations of labor subject to collective bargaining agree­
ments, including the percentage of the labor force covered by a 
collective bargaining agreement and the percentage of the labor 
force covered by a collective bargaining agreement that will expire
within one year? ____  ____  ____
f Information adequate to inform users of the general nature of the
risk associated with the concentration? ____ ____ ____
[SOP 94-6, pars. 21-24]
L. Segment Information
Note: Public business enterprises are required to provide the disclosures 
described in SFAS 131, Disclosures about Segments of an Enterprise and 
Related Information, and nonpublic business enterprises are encouraged 
to do so.
1. Are the following items disclosed for each reportable segment for each 
period for which an income statement is presented:
a. General information as described in SFAS 131, paragraph 26?
b. Information about profit or loss (including certain revenues and 
expenses included in profit or loss), segment assets, and the 
basis of measurement, as described in SFAS 131, paragraphs 
27-31?
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Yes
c. Reconciliations of the totals of segment revenues, reported profit 
or loss, assets, and other significant items to corresponding enter­
prise amounts as described in SFAS 131, paragraph 32?
d. Interim period information as described in SFAS 131, paragraph 
33?
[SFAS 131, pars. 25-33, as amended by SFAS 135, par. 4 (AC 
S30.124-.132)]
Note: Reconciliations of balance sheet amounts for reportable segments 
to consolidated balance sheet amounts are required only for each year for 
which a balance sheet is presented.
2. If an enterprise changes the structure of its internal organization in a 
manner that changes the composition of its reportable segments, has 
it disclosed whether it has restated the corresponding items of seg­
ment information for earlier periods?
[SFAS 131, par. 34 (AC S30.133)]
3. If segment information is not restated to reflect a change in the 
composition of reportable segments, is current year segment informa­
tion under both the old basis and the new basis of segmentation 
disclosed, unless it is impracticable to do so?
[SFAS 131, par. 35 (AC S30.134)]
4. For all enterprises subject to SFAS 131, including those that have a 
single reportable segment, are the following enterprise-wide items 
disclosed:
a. Revenues from external customers for each product and service or 
each group of similar products and services unless it is impracti­
cable to do so?
b. Geographic information as described in paragraph 38 unless it is 
impracticable to do so?
c. Information about the extent of the enterprise's reliance on its 
major customers as described in paragraph 39?
[SFAS 131, pars. 36-39 (AC S30.135-.138)]
5. If the information described in items 4.c. and 4.b. above has not been 
disclosed because it is impracticable, is that fact disclosed?
[SFAS 131, pars. 37 and 38 (AC S30.136-.137)]
M. Subsequent Events
1. Are subsequent events that provide evidence about conditions that 
did not exist at the date of the balance sheet, but arose subsequent to 
that date, adequately disclosed to keep the financial statements from 
being misleading?
[SFAS 5, par. 11 (AC C59.112); APB 16 (AC B50.120); SAS 1, secs. 
560.05-.07, .09, and 561.01-.09 (AU 560.05-.07, .09, and 561.01-.09)]
Note: Consider the appropriateness of dual dating the auditor's report if 
a subsequent event is disclosed in the financial statements.
[SAS 1, sec. 530.05 (AU 530.05)
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No N/A
Yes
N. Managed Care Organizations—Adoption of NAIC's Codification of SAP
Note: The National Association of Insurance Commissioners (NAIC) 
finalized the Codification of Statutory Accounting Principles (SAP) guid­
ance which will replace the current Accounting Practices and Procedures 
manual as the NAIC's primary guidance on statutory accounting. The 
NAIC adopted a recommendation to state insurance departments that 
they adopt the Codification guidance as soon as possible, with an effective 
date of January 1, 2001. States may however elect effective dates before or 
after that date. Companies will not be required to follow the Codification 
guidance until it is adopted by the state of domicile.
[AAG, pars. 2.58 and 2.59]
1. If the state of domicile has not yet adopted the NAIC's codification of 
SAP, has consideration been given to disclosure in the financial state­
ments if the effect of the adoption is expected to be material or in 
situations in which the client has not determined the effect of the 
codification?
[AAG, pars. 2.60 and 2.61]
Continuing Care Retirement Communities (CCRCs)
A. Refundable Advance Fees
1. Is the estimated amount of advance fees expected to be refunded to 
current residents reported as a liability?
[AAG, par. 14.22]
2. Is the remaining amount of advance fees reported in the balance sheet 
as deferred revenue?
[AAG, par. 14.22]
★♦3. Are the following disclosed:
a. The gross amount of contractual refund obligations under existing 
contracts?
b. The CCRC's refund policy?
[AAG, par. 14.22]
4. Are amounts refunded disclosed in the statement of cash flows as a 
financing transaction?
[AAG, par. 14.22]
5. Is the method of accounting, including the amortization method, for 
deferred revenue disclosed?
[AAG, par. 14.23]
B. Fees Refundable to Residents Only From Reoccupancy Proceeds of a 
Contract Holder's Unit
1. Are the following reported as deferred revenue:
a. The portion of fees to be paid to current residents or their desig­
nees, only to the extent of a contract holder's unit reoccupancy 
proceeds, if law and management policy and practice support the 
withholding of refunds under this condition?
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No NLA
Yes
b. Similar amounts received from new residents in excess of the 
amount to be paid to previous residents or their designees? 
[AAG, par. 14.25]
C. Nonrefundable Advance Fees
1. Are nonrefundable advance fees reported as deferred revenue? 
[AAG, par. 14.26]
★♦2. Is unamortized deferred revenue reported as revenue upon a resi­
dent's death or contract termination?
[AAG, par. 14.23]
D. Obligation to Provide Future Services and Use of Facilities to Current 
Residents
1. If the obligation to provide future services and use of facilities to 
current residents under continuing-care contracts results in a liability, 
are the following disclosed:
a. The carrying amount of the liability that is presented at present 
value in the financial statements (if not separately disclosed in the 
balance sheet/statement of financial position)?
b. The interest rate used to discount that liability?
[AAG, par. 14.31]
E. Costs of Acquiring Initial Continuing-Care Contracts
1. Are costs of acquiring initial continuing-care contracts capitalized if 
they are expected to be recovered from future contract revenues? 
[AAG, par. 14.33]
★♦2. Are continuing-care contract acquisition costs expensed if incurred 
after (a) the CCRC is substantially occupied or (b) one year following 
completion?
[AAG, par. 14.33]
F. Other
★♦1. Do the notes to the financial statements of the CCRC include a 
description of the CCRC and the nature of the related continuing-care 
contracts entered into by the CCRC?
[AAG, par. 14.35]
★♦2. Do the notes to the financial statements of the CCRC include the 
statutory escrow or similar requirements?
[AAG, par. 14.35]
OMB Circular A-133 Presentation Requirements
1. Does the schedule of expenditures of federal awards disclose the basis 
of accounting and the significant accounting policies used in prepar­
ing the schedule?
[SOP 98-3, par. 5.5]
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No N/A
Yes
2. Did the auditee prepare a schedule of expenditures of federal awards 
for the period covered by the auditee's financial statements that, at a 
minimum:
a. Lists individual federal programs by federal agency? ____
b. Include, for federal awards received as a subrecipient, the name 
of the pass-through entity and the identifying number assigned by
the pass-through entity? ____
c. Provide the total federal awards expended for each individual
federal program and the CFDA number or other identifying num­
ber when the CFDA information is not available? ____
d. Include notes that describe the significant accounting policies used
in preparing the schedule? ____
e. Identify, to the extent practical, the total amount provided to
subrecipients by pass-through entities from each federal program? ____
f. Include, in either the schedule or a note to the schedule, the value 
of federal awards expended in the form of noncash assistance, the 
amount of insurance in effect during the year, and loans or loan
guarantees outstanding at year end? ____
[SOP 98-3, par. 5.6]
3. If nonfederal data are presented in the schedule of expenditures of 
federal awards:
a. Are the nonfederal data segregated and clearly designated as
nonfederal? ____
b. Is the title of the schedule modified to indicate that nonfederal
awards are included? ____
[SOP 98-3, par. 5.9]
4. If the auditee is unable to obtain the CFDA number, does the schedule 
include:
a. A statement that the CFDA number is not available? ____
b. The program's name and, if available, other identifying numbers? ____
[SOP 98-3, par. 5.10]
Exhibit A
Stock-Based Compensation
♦ 1. If an entity continues to apply APB 25 in accounting for its stock-based 
compensation arrangements, is the pro forma net income and, if pre­
sented, earnings per share (determined as if the fair value based
method had been applied in measuring compensation cost) disclosed? ____
[SFAS 123, pars. 11 and 45 (AC C36.110 and .144)]
♦2. If an entity has one or more stock-based compensation plans, is a 
description of the plan(s), including the general terms of awards
under the plan(s), disclosed? ____
[SFAS 123, par. 46 (AC C36.145)]
♦3. Is the information in paragraph 47 of SFAS 123 disclosed for each year
for which an income statement is presented? ____
[SFAS 123, par. 47a-f (AC C36.146)]
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No N/A
Yes
♦4. If an entity grants options under multiple stock-based employee 
compensation plans, are the items in paragraph 47 disclosed sepa­
rately for different types of awards to the extent that the differences 
in the characteristics of the awards make separate disclosure important
to an understanding of the entity's use of stock-based compensation? ____
[SFAS 123, par. 47 (AC C36.146)]
♦5. Are the following disclosed for options outstanding at the date of the 
latest statement of financial position presented:
a. The range of exercise prices? ____
b. The weighted-average exercise price? ____
c. The weighted-average remaining contractual life? ____
[SFAS 123, par. 48 (AC C36.147)]
♦6. If the range of exercise prices is wide, are they segregated into ranges? ____
[SFAS 123, par. 48 (AC C36.147)]
♦7. Are the following disclosed for each range identified in Step 6:
a. The number, weighted-average exercise price, and weighted-av­
erage remaining contractual life of options outstanding? ____
b. The number and weighted-average exercise price of options cur­
rently exercisable? ____
[SFAS 123, par. 48 (AC C36.147)]
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No N/A
FSP Section 11,300
Auditors’ Reports Checklist
.01 This checklist has been developed by the staff of the Accounting and Auditing Publications Team of 
the AICPA as a nonauthoritative practice aid. This checklist contains the basic requirements for reporting on 
an audit of the financial statements in accordance with GAAS. It does not contain all requirements for reports 
required to be issued in audits in accordance with government auditing standards ("Yellow Book") or with 
the audit requirements of OMB Circular A-133 ("Single Audits").
.02 Explanation of References:
SAS = AICPA Statement on Auditing Standards
AU = Reference to section number in AICPA Professional Standards (vol. 1)
SSARS = AICPA Statements on Standards for Accounting and Review Services
AR = Reference to section number in AICPA Professional Standards (vol. 2)
.03 Checklist Questionnaire:
Yes No N/A
1. Is each financial statement audited specifically identified in the intro­
ductory paragraph of the auditor's report? ____  ____  ____
[SAS 58, as amended, par. 6 (AU 508.06)]
2. Do the titles of the financial statements referred to in the introductory 
paragraph of the auditor's report match the titles of the financial
statement presented? ____  ____  ____
[Generally Accepted]
3. Do the dates of the financial statements referred to in the introductory 
paragraph of the auditor's report match the dates of the financial
statements presented? ____ ____  ____
[Generally Accepted]
4. Is the report appropriately addressed? ____  ____  ____
[SAS 58, par. 9 (AU 508.09)]
5. Does the auditor's report include appropriate:
a. A title that includes the word "independent"? ____  ____  ____
[SAS 58, par. 8a (AU 508.08a)]
b. A statement that the financial statements identified in the report
were audited? ____ ____  ____
[SAS 58, par. 8b (AU 508.08b)]
c. A statement that the financial statements are the responsibility of 
management and that the auditor's responsibility is to express an
opinion on the financial statements based on his or her audit? ____  ____  ____
[SAS 58, par. 8c (AU 508.08c)]
d. A statement that the audit was conducted in accordance with
generally accepted auditing standards? ____  ____  ____
[SAS 58, par. 8d (AU 508.08d)]
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Yes
e. A statement that generally accepted auditing standards require 
that the auditor plan and perform the audit to obtain reasonable 
assurance about whether the financial statements are free of ma­
terial misstatement?
[SAS 58, par. 8e (AU 508.08e)]
f. A statement that an audit includes examining, on a test basis, 
evidence supporting the amounts and disclosures in the financial 
statements; assessing the accounting principles used and signifi­
cant estimates made by management; and evaluating the overall 
financial statement presentation?
[SAS 58, par. 8f (AU 508.08f)]
g. A statement that the auditor believes that his or her audit provides 
a reasonable basis for his or her opinion?
[SAS 58, par. 8g (AU 508.08g)]
h. An opinion as to whether the financial statements present fairly, 
in all material respects, the financial position of the reporting 
entity as of the balance sheet date and the results of its operations 
and its cash flows for the period then ended in conformity with 
generally accepted accounting principles?
[SAS 58, par. 8h (AU 508.08h]
i. The manual or printed signature of the auditor's firm?
[SAS 58, par. 8i (AU 508.080]
j. The date of the audit report?
[SAS 58, par. 8j (AU 508.08j)]
6. If a subsequent event disclosed in the financial statements occurs after 
completion of fieldwork but before the issuance of the auditor's 
report, has the need for dual-dating of the report been considered? 
[SAS 1, sec. 530, pars. 3-5 (AU 530.03-.05)]
7. If the auditor is not independent, is a compilation report indicating 
the lack of independence issued (non-public companies only)?
[SAS 26, par. 10 (AU 504.10); SSARS 1, pars. 22 and 38 (AR 100.22 and .38)]
8. If the opinion is based in part on the report of another auditor:
a. Does the introductory paragraph of the standard report disclose 
the fact that the opinion is based, in part, on the report of other 
auditors?
b. Does the opinion paragraph include a reference to the report of 
the other auditor?
[SAS 58, pars. 11a, 12, and 13 (AU 508.11a, .12, and .13)]
9. If, to prevent the financial statements from being misleading because 
of unusual circumstances, the financial statements contain a depar­
ture from an accounting principle promulgated by a body designated 
by the AICPA Council to establish such principles, does the report 
include, in a separate paragraph or paragraphs, the information re­
quired by the rule?
[SAS 58, pars, lib and 15 (AU 508.11b and .15)]
10. If there is substantial doubt about the entity's ability to continue as a 
going concern:
a. Does the report include an explanatory paragraph, following the 
opinion paragraph, to reflect that conclusion?
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No N/A
Yes No N/A
b. Is that conclusion expressed through the use of the phrase "sub­
stantial doubt about its (the entity's) ability to continue as a going 
concern" or similar wording that includes the terms substantial
doubt and going concern? ____ ____  ____
[SAS 58, par. 11c (AU 508.11c); SAS 59, as amended by SAS 64, par.
12 (AU 341.12)]
Practice Tip
In a going concern paragraph, the auditor should not use conditional language in expressing a conclusion 
concerning the existence of substantial doubt about the entity's ability to continue as a going concern. See 
SAS 77 for an example.
11. If there has been a material change between periods in accounting 
principles or in the method of their application that has a material effect 
on the comparability of the reporting entity's financial statements:
a. Does the report include an explanatory paragraph, following the 
opinion paragraph, that refers to the change?
b. Does the explanatory paragraph identify the nature of the change 
and refer the reader to the note to the financial statements that 
discusses the change in detail?
[SAS 58, as amended by SAS 79, pars. 11d and 16 (AU 508.11d and .16)]
Note: SAS 88 clarifies that the auditor need not add a consistency para­
graph to the auditor's report when a change in the reporting entity results 
from a transaction or event. However, the auditor would still be required 
to express a qualified or adverse opinion because of the departure from 
GAAP.
[SAS 88, par. 4 (AU 420.08)]
12. In an updated report, the opinion is different from the opinion pre­
viously expressed on the financial statements of a prior period:
a. Does the report include an explanatory paragraph, preceding the 
opinion paragraph, that discloses all of the substantive reasons for 
the different opinion?
b. Does the explanatory paragraph disclose:
(1) The date of the auditor's previous report?
(2) The type of opinion previously expressed?
(3) The circumstances or events that caused the auditor to ex­
press a different opinion?
(4) That the auditor's updated opinion on the financial state­
ments of the prior period is different from his or her previous 
opinion on those statements?
[SAS 58, as amended by SAS 79, pars, 11e and 69 (AU 508.11e 
and .69)]
13. If financial statements of a prior period (presented for comparative 
purposes) have been audited by a predecessor auditor whose report 
is not presented:
a. Does the introductory paragraph of the report indicate:
(1) That the financial statements of the prior period were audited 
by another auditor?
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Yes No N/A
(2) The date of the predecessor auditor's report?
(3) The type of report issued by the predecessor auditor?
(4) If the report was other than a standard report, the substantive 
reasons therefor, including a description of the nature of and 
reasons for the explanatory paragraph added to the predeces­
sor's report or his or her opinion qualification?
b. If the financial statements have been restated, does the introduc­
tory paragraph indicate that the predecessor auditor reported on 
the financial statements of the prior period before restatement? 
[SAS 58, as amended by SAS 79, pars. 11e and 74 (AU 508.11e and 
.74)]
14. If selected quarterly financial data required by SEC Regulation S-K 
has been omitted or has not been reviewed, does the report include 
an additional paragraph stating that fact?
[SAS 58, par. 11f (AU 508.11f); SAS 71, par. 41 (AU 722.41)]
15. If supplementary information required by the FASB has been omitted, 
the presentation of such information departs materially from FASB 
guidelines, the auditor is unable to complete prescribed procedures 
with respect to such information, or the auditor is unable to remove 
substantial doubt about whether the supplementary information con­
forms to FASB guidelines, does the report include an additional 
paragraph stating that fact?
[SAS 58, par. 11g (AU 508.11g); SAS 52, par. 8 (AU 558.08)]
16. If other information in a document containing audited financial state­
ments is materially inconsistent with information appearing in the 
financial statements, has it been determined whether the financial 
statements, the auditor's report, or both require revision?
[SAS 58, par. 11h (AU 508.11h); SAS 8, par. 4 (AU 550.04)]
17. If the auditor decides to emphasize a matter regarding the financial 
statements in the report, is the explanatory information presented in 
a separate paragraph that avoids use of phrases such as "with the 
foregoing (following) explanation"?
[SAS 58, pars. 11 and 19, as amended by SAS 79 (AU 508.11 and .19); 
Interpretation 3 of SAS 1, sec. 410 (AU 9410.18); Interpretation 1 of 
SAS 57 (AU 9342.03)]
Practice Tip
In December 1995, SAS 79, Amendment to Statement on Auditing Standards No. 58, Reports on Audited Financial 
Statements, was issued. This Statement amends SAS 58 to eliminate the requirement that, when certain 
criteria are met, the auditor add an uncertainties explanatory paragraph to the auditor's report. This 
Statement is effective for reports issued after February 29, 1996.
18. If it has not been possible to conduct the audit in accordance with 
GAAS or to apply all of the procedures considered necessary in the 
circumstances, has consideration been given to the need to issue a 
qualified opinion or to disclaim an opinion?
[SAS 58, as amended by SAS 79, par. 22 (AU 508.22)]
19. If a qualified opinion is to be expressed because of a scope limitation:
a. Are all of the substantive reasons for the qualification disclosed in one 
or more explanatory paragraphs preceding the opinion paragraph?
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Yes No N/A
b. Does the qualified opinion include the word except or exception in
a phrase such as except for or with the exception of? ____ ____  ____
c. Is the situation described and referred to in both the scope and
opinion paragraphs? ____ ____  ____
d. Does the wording in the opinion paragraph indicate that the
qualification pertains to the possible effects on the financial state­
ments and not the scope limitation itself? ____ ____  ____
[SAS 58, as amended by SAS 79, pars. 22-27 (AU 508.22-.27)]
Practice Tip
Scope limitations include situations in which the auditor is unable to obtain sufficient evidential matter to 
support management's assertions about the nature of a matter involving an uncertainty and its presentation 
or disclosure in the financial statements. [SAS 58, as amended by SAS 79, par. 31]
SOP 00-1, Auditing Health Care Third-Party Revenues and Related Receivables, discusses auditing matters to 
consider in testing third-party revenues and related receivables, and provides guidance regarding the 
sufficiency of evidential matter (SOP 00-1, pars. 16-21). SOP 00-1 was issued on March 10, 2000 and is effective 
for audits of periods ending on or after June 30, 2000 with early application permitted.
Note: Consult the Topical Index to the AICPA Professional Standards 
under "Scope of Audit—Limitations" for additional references to specific 
types of scope limitations that could result in either a qualified or dis­
claimer of opinion.
20. If an opinion is disclaimed because of a scope limitation:
a. Are all of the substantive reasons for the disclaimer stated in a 
separate paragraph or paragraphs?
b. Does the report state that the scope of the audit was not sufficient 
to warrant the expression of an opinion?
c. Does the report avoid identifying procedures that were per­
formed?
d. Is the scope paragraph omitted?
e. If there are reservations about fair presentation of the financial 
statements in conformity with GAAP, are they described in the 
report?
[SAS 58, as amended by SAS 79, par. 63 (AU 508.63)]
21. If the financial statements are materially affected by a departure from
GAAP (including inadequate disclosure, inappropriate accounting 
principles, and unreasonable accounting estimates), has considera­
tion been given to the need to issue a qualified opinion or an adverse 
opinion?
[SAS 58, as amended by SAS 79, par. 35 (AU 508.35)]
Note: SOP 00-1, Auditing Health Care Third-Party Revenues and Related 
Receivables, discusses auditing matters to consider in testing third-party 
revenues and related receivables, and provides guidance regarding the 
sufficiency of evidential matter and reporting on financial statements of 
health care entities exposed to material uncertainties. Paragraphs 22-37 
specifically address potential departures from GAAP related to estimates 
and uncertainties that fall into three categories: unreasonable accounting 
estimates; inappropriate accounting principles; and inadequate disclo­
sure. SOP 00-1 was issued on March 10, 2000 and is effective for audits of 
periods ending on or after June 30, 2000 with early application permitted.
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Yes No N/A
22. If a qualified opinion is to be expressed because of a GAAP departure:
a. Are all of the substantive reasons that have led to the conclusion that 
there is a departure from GAAP disclosed in one or more separate 
explanatory paragraphs preceding the opinion paragraph?
b. Does the qualified opinion include the word except or exception in 
a phrase such as except for or with the exception of and a reference to 
the explanatory paragraph?
c. Does the explanatory paragraph disclose the principle effects of 
the departure on financial position, results of operations, and cash 
flows, if practicable, or state that the effects are not reasonably 
determinable, if not practicable to do so?
[SAS 58, as amended by SAS 79, pars. 37 and 38 (AU 508.37 and 
.38)]
23. If an adverse opinion is to be expressed because of a GAAP departure:
a. Are all of the substantive reasons for the adverse opinion disclosed 
in one or more separate explanatory paragraphs preceding the 
opinion paragraph?
b. Does the explanatory paragraph disclose the principle effects of 
the departure on financial position, results of operations, and cash 
flows, if practicable, or state that the effects are not reasonably 
determinable, if not practicable to do so?
c. State that the financial statements do not present fairly the finan­
cial position, or results of operations or cash flows in conformity 
with GAAP?
[SAS 58, as amended by SAS 79, pars. 58 and 59 (AU 508.58 and 
.59)]
Note: Consult the Topical Index to the AICPA Professional Standards under 
"Departures From Established Principles," "Adverse Opinions," and "Quali­
fied Opinions" for additional references to specific types of GAAP departures 
that could result in either a qualified or adverse opinion.
24. If information accompanies the basic financial statements and audi­
tor's report in an auditor-submitted document, is it accompanied by 
a report that:
a. States that the audit was performed for the purpose of forming an 
opinion on the basic financial statements taken as a whole?
b. Specifically identifies the accompanying information?
c. States that the accompanying information is presented for pur­
poses of additional analysis and is not a required part of the basic 
financial statements?
d. Includes either an opinion on whether the accompanying informa­
tion is fairly stated in all material respects in relation to the basic 
financial statements taken as a whole or a disclaimer of opinion 
(depending on whether the information was subjected to the 
auditing procedures applied in the audit of the basic financial 
statements)?
[SAS 29, par. 6 (AU 551.06)]
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Practice Tip
SAS 87, Restricting the Use of an Auditor's Report, provides guidance to auditors in determining whether an 
engagement requires a restricted-use report and, if so, what elements to include in that report. SAS 87 is 
effective for reports issued after December 31, 1998.
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FSP Section 11,400
Auditors’ Reports on Audits Performed 
Under Government Auditing Standards 
and Under OMB Circular A-133 Checklist
.01 This checklist has been developed by the staff of the Accounting and Auditing Publications Team of 
the AICPA as a nonauthoritative practice aid.
.02 This checklist has two parts: Part I is for auditors' reports on financial audits performed under 
Government Auditing Standards (GAS, which is also known as the Yellow Book). (This checklist does not address 
the performance auditing standards of GAS.) Part II contains the additional requirements for auditors' 
reports on audits performed under the Single Audit Act Amendments of 1996 in accordance with OMB 
Circular A-133. For audits performed under Circular A-133, both Parts I and II of this checklist must be 
completed.
.03 Explanation of References:
A-133 = Office of Management and Budget (OMB) Circular A-133, Audits of States, Local
Governments, and Non-Profit Organizations (June 1997 Revision)
GAS = General Accounting Office 1994 revision to Government Auditing Standards, as
amended
SAS = AICPA Statement on Auditing Standards
AU = Reference to section number in AICPA Professional Standards (vol. 1)
SOP = AICPA Statement of Position
.04 Checklist Questionnaire:
Yes No N/A
Part I—Reports on Audits Performed in Accordance with 
Government Auditing Standards
1. In a financial audit performed in accordance with GAS, are the fol­
lowing reports issued:
a. A report on the entity's financial statements?1
b. A report on compliance and on internal control over financial 
reporting based on an audit of financial statements performed in 
accordance with GAS?
1 See the checklist for auditor's reports on the financial statements at section 11,300.
[GAS, Ch. 5, pars. 2 and 15; SOP 98-3, par. 10.15]
Report on the Financial Statements
2. Does the auditor's report on the financial statements: 1
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Yes No N/A
a. Contain a statement that the audit was conducted in accordance 
with GAAS and with the standards applicable to financial audits 
contained in Government Auditing Standards, issued by the Comp­
troller General of the United States?2
[GAS, Ch. 5, par. 11; SOP 98-3, pars. 10.16a and 10.35]
b. Either describe the scope of the auditors' testing of compliance 
with laws and regulations and internal controls and present the 
results of these tests or refer to separate reports containing that 
information?
[GAS, Ch. 5, par. 15; SOP 98-3, pars. 10.16b and 10.35]
3. If parent-only financial statements are presented because of federal 
regulations and if consolidated financial statements are not also prepared 
as required by generally accepted accounting principles, has the auditor 
considered whether to express other than an unqualified opinion due to 
departure from GAAP on the parent-only financial statements?
[SOP 98-3, par. 10.34]
Report on Compliance and on Internal Control Over Financial Report­
ing Based on an Audit of Financial Statements Performed in Accordance 
With GAS
4. Does the report on compliance and on internal control conform to the 
standard reports illustrated in examples 2 and 2a in SOP 98-3?
[SOP 98-3, App. D]
5. Does the report contain the following elements:
a. A statement that the auditor has audited the financial statements 
of the auditee and a reference to the auditor's report on the 
financial statements, including a description of any departure 
from the standard report (for example, a qualified opinion, a 
modification as to consistency because of a change in accounting 
principle, or a reference to the report of other auditors)?
[SOP 98-3, par. 10.39 and App. D, Ex. 2, fn. 14]
b. A statement that the audit was conducted in accordance with 
GAAS and with the standards applicable to financial audits con­
tained in Government Auditing Standards, issued by the Comp­
troller General of the United States?
c. A statement that as part of obtaining reasonable assurance about 
whether the auditee's financial statements are free of material 
misstatement, the auditor performed tests of the auditee's compli­
ance with certain provisions of laws, regulations, contracts and 
grants, noncompliance with which could have a direct and mate­
rial effect on the determination of financial statement amounts?
d. A statement that providing an opinion on compliance with those 
provisions was not an objective of the audit and that, accordingly, 
the auditor does not express such an opinion?
e. A statement that notes whether the results of tests disclosed in­
stances of noncompliance that are required to be reported under
2 GAS must be referenced when the report on the financial statements is submitted to comply with a legal, regulatory, or contractual 
requirement for an audit in accordance with GAS.
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Yes No N/A
GAS and, if they are, describes the instances of noncompliance or 
refers to the schedule of findings and questioned costs in which 
they are described?3 ____
3 For an audit that is not subject to Circular A-133 (that is, in accordance with GAS only), any reportable instances of noncompliance, 
reportable conditions, and material weaknesses can either be described in the body of the report or the report can refer to a separate 
schedule that summarizes the findings noted. For an audit in accordance with Circular A-133, all findings, including those required to 
be reported under GAS, must be included in the schedule of findings and questioned costs. [SOP 98-3, Ch. 10, fn. 14]
4 See footnote 3.
5 See footnote 3.
6 This paragraph conforms to SAS 87, Restricting the Use of an Auditor’s Report (AU 532). See SAS 87 for additional guidance on 
restricted use reports.
7 For an audit that is not subject to Circular A-133 (that is, in accordance with GAS only), the reference to federal awarding agencies 
and pass-through entities should be deleted. [SOP 98-3, Ch. 10, fn. 19]
f. If applicable, a statement that certain immaterial instances of 
noncompliance were communicated to management in a separate
letter? ____
g. A statement that in planning and performing the audit, the auditor
considered the auditee's internal control over financial reporting 
in order to determine the auditing procedures for the purpose of 
expressing an opinion on the financial statements and not to 
provide assurance on the internal control over financial reporting? ____
h. If applicable, a statement that reportable conditions were noted
and the definition of a reportable condition? ____
i. If no reportable conditions are noted, a statement that the auditor's
consideration of the internal control over financial reporting 
would not necessarily disclose all matters in the internal control 
that might be material weaknesses; if reportable conditions are 
noted, a statement that the auditor's consideration of the internal 
control over financial reporting would not necessarily disclose all 
matters in the internal control that might be reportable conditions 
and, accordingly, would not necessarily disclose all reportable 
conditions that are also considered to be material weaknesses? ____
j. If applicable, a description of reportable conditions noted or a 
reference to the schedule of findings and questioned costs in which
the reportable conditions are described?4 ____
k. The definition of a material weakness? ____
l. If applicable, a statement about whether the auditor believes any 
of the reportable conditions noted are material weaknesses, and, 
if they are, describes the material weaknesses noted or refers to the 
schedule of findings and questioned costs in which they are de­
scribed?5 67(If there are no reportable conditions, a statement should
be made that no material weaknesses were noted.) ____
m. If applicable, a statement that other matters involving the internal
control over financial reporting were communicated to manage­
ment in a separate letter? ____
n. A separate paragraph at the end of the report stating that the report 
is intended solely for the information and use of the audit commit­
tee, management, specified legislative or regulatory bodies, fed­
eral awarding agencies, and (if applicable) pass-through entities 
and is not intended to be and should not be used by anyone other
than these specified parties?6,7 ____
o. The manual or printed signature of the auditor's firm? ____
79
Yes
p. The date of the auditor's report? ____
[SOP 98-3, par. 10.39]
6. If parent-only financial statements are presented because of federal
regulations and if consolidated financial statements are not also pre­
pared as required by generally accepted accounting principles, has 
the auditor considered whether to express other than an unqualified 
opinion due to the departure from GAAP on the parent-only financial 
statements? ____
7. Do the reported instances of noncompliance include all instances of 
fraud and illegal acts (unless clearly inconsequential) and other non-
compliance that is material to the financial statements? ____
[GAS, Ch. 5, par. 18; SOP 98-3, par. 10.21]
8. If the report contains material instances of noncompliance or fraud and 
illegal acts that are not clearly inconsequential, is the effect of such
instances on the auditor's report on the financial statements considered? ____
[SAS 74, par. 20 (AU 801.20)]
9. Do the findings presented in or referred to from the report include all 
essential elements, including information to place the finding in 
proper perspective, condition, cause, criteria, effect, and the views of
responsible officials? ____
[GAS, Ch. 5, par. 19 and fn. 5; SOP 98-3, pars. 10.58-10.61]
10. Does the report disclose the status of known but uncorrected material 
findings and recommendations from prior audits that could have
affected the current financial statement audit? ____
[GAS, Ch. 4, par. 10; SOP 98-3, par. 10.62]
11. Does the report carry the same date as the report on the financial
statements? ____
[SOP 98-3, par. 10.50]
Other Matters
12. Are instances of fraud and illegal acts communicated directly to 
outside parties if such reporting is required by law or regulation or 
involves financial assistance received directly or indirectly from a
government agency? ____
[GAS, Ch. 5, pars. 21-25; SOP 98-3, pars. 10.23-10.25]
13. If the audit disclosed immaterial instances of noncompliance or 
deficiencies in internal control were not considered reportable 
conditions (referred to as "nonreportable conditions"), are those 
matters communicated to the entity in writing (or orally, with
working paper documentation)? ____
[GAS, Ch. 5, pars. 20 and 28; SOP 98-3, pars. 10.22 and 10.29]
14. Has the auditor communicated the following information—in writing 
(orally with work paper documentation)—to the organization or 
entity being audited, the individuals contracting for or requesting 
audit services, and the audit committee during the planning stages of 
the audit:
a. The auditor's responsibilities in a financial statement audit, in­
cluding his or her responsibilities for testing and reporting on 
compliance with laws and regulations and internal control over 
financial reporting? ____
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No N/A
Yes
b. The nature of any additional testing of compliance and internal 
control required by laws and regulations or otherwise requested, 
and whether the auditor is planning or providing an opinion with
laws and regulations and internal control over financial reporting? ____
c. A contrasting of the information in Steps a. and b. above with other
financial related audits of compliance and controls? ____
[GAS, Ch. 4, pars. 4.63-4.6.7; SOP 98-3, pars. 3.14 and 3.15]
Part II—Reports on Audits Performed Under OMB Circular A-133
1. If the entity is subject to the requirements of Circular A-133, are the 
following reports (in addition to those in Part I of this checklist) 
issued:
a. A report on the supplementary schedule of expenditures of federal
awards? ____
b. A report on compliance with requirements applicable to each
major program and on internal control over compliance in accord­
ance with Circular A-133? ____
c. A schedule of findings and questioned costs? ____
[SOP 98-3, par. 10.8]
Report on the Supplementary Schedule of Expenditures of Federal 
Awards
2. Is the report on the supplementary schedule of expenditures of federal 
awards (a) included in the auditors' report on the financial statements,
(b) included in the report on compliance with requirements applicable 
to each major program and on internal control over compliance in
accordance with Circular A-133, or (c) issued as a stand-alone report? ____
[SOP 98-3, pars. 10.36, 10.47, and 10.52]
3. Does the report conform to the standard reports illustrated in Exam­
ple 1a, Example 3 (footnote 34), or Example 3a (footnote 40) of SOP
98-3? ____
[SOP 98-3, pars. 10.36 and 10.37 and App. D]
4. Does the report contain the following elements:
a. A statement that the supplementary schedule of expenditures of 
federal awards is presented for purposes of additional analysis
and is not a required part of the financial statements? ____
b. An opinion on whether the schedule is fairly stated in all material
respects in relation to the financial statements taken as a whole? ____
[SOP 98-3, par. 10.35]
5. If the report on the financial statements refers to the work of other 
auditors, has the auditor considered the need to refer to the programs 
audited by other auditors in the report on the supplementary schedule
of expenditures of federal awards? ____
[SOP 98-3, par. 3.46]
6. Does the report carry the same date as the report on the financial 
statements, even if that requires a dual date on the report on compli­
ance with requirements applicable to each major program and on
internal control over compliance in accordance with Circular A-133? ____
[SOP 98-3, pars. 10.50 and 10.52]
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No N/A
Yes
7. If the report on the schedule of expenditures of federal awards is 
issued as a stand-alone report (instead of being included in the report 
on the financial statements), has the guidance in SAS No. 58 been
followed in issuing that report? ____
[SOP 98-3, par. 10.52]
Report on Compliance With Requirements Applicable to Each Major 
Program and on Internal Control Over Compliance in Accordance With 
Circular A-133
8. Does the report conform to the standard reports illustrated in Exam­
ples 3-5 of SOP 98-3? ____
[SOP 98-3, App.D]
9. Does the report contain the following elements:
a. A statement that the auditor has audited the compliance of the 
auditee with the types of compliance requirements described in 
the OMB Circular A-133 Compliance Supplement that are applicable
to each of its major programs? ____
b. A statement that the auditee's major programs are identified in the
summary of auditor's results section of the accompanying sched­
ule of findings and questioned costs? ____
c. A statement that compliance with the requirements of laws, regu­
lations, contracts, and grants applicable to each of the auditee's 
major federal programs is the responsibility of the auditee's man­
agement, and that the auditor's responsibility is to express an 
opinion on the auditee's compliance based on the audit? ____
d. A statement that the audit of compliance was conducted in accord­
ance with GAAS, the standards applicable to financial audits 
contained in Government Auditing Standards issued by the Comp­
troller General of the United States, and A-133? ____
e. A statement that those standards and A-133 require that the audi­
tor plan and perform the audit to obtain reasonable assurance 
about whether noncompliance with the types of compliance re­
quirements that could have a direct and material effect on a major
federal program occurred? ____
f. A statement that an audit includes the examining, on a test basis,
evidence about the auditee's compliance with those requirements 
and performing such other procedures as the auditor considered 
necessary in the circumstances? ____
g. A statement that the auditor believes that the audit provides a
reasonable basis for the auditor's opinion? ____
h. A statement that the audit does not provide a legal determination
on the auditee's compliance with those requirements? ____
i. If instances of noncompliance are noted that result in an opinion 
modification, a reference to a description in the accompanying 
schedule of findings and questioned costs, including:
(1) The reference number(s) of the finding(s)? ____
(2) An identification of the type(s) of compliance requirements
and related major program(s)? ____
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No N/A
Yes No N/A
(3) A statement that compliance with such requirements is nec­
essary, in the auditor's opinion, for the auditee to comply 
with requirements applicable to the program(s)?
An opinion on whether the auditee complied, in all material 
respects, with the types of compliance requirements that are ap­
plicable to each of its major federal programs?
k. If applicable, a statement that the results of the auditing procedures 
disclosed instances of noncompliance that are required to be reported 
in accordance with A-133 and a reference to the schedule of findings 
and questioned costs in which they are described?
l. A statement that the auditee's management is responsible for 
establishing and maintaining effective internal control over com­
pliance with requirements of laws, regulations, contracts, and 
grants applicable to federal programs?
m. A statement that in planning and performing the audit, the auditor 
considered the auditee's internal control over compliance with re­
quirements that could have a direct and material effect on a major 
federal program, to determine the auditing procedures for the pur­
pose of expressing an opinion on compliance and to test and report 
on the internal control over compliance in accordance with A-133?
n. If applicable, a statement that reportable conditions were noted 
and the definition of a reportable condition?
o. If applicable, a reference to a description of reportable conditions 
noted in the accompanying schedule of findings and questioned 
costs, including the reference number of the finding(s)?
p. If no reportable conditions are noted, a statement that the auditor's 
consideration of the internal control over compliance would not 
necessarily disclose all matters in internal control that might be 
material weaknesses; if reportable conditions are noted, a state­
ment that the auditor's consideration of the internal control over 
compliance would not necessarily disclose all matters in the inter­
nal control that might be reportable conditions and, accordingly, 
would not necessarily disclose all reportable conditions that are 
also considered to be material weaknesses?
q. The definition of a material weakness?
r. If applicable, a statement about whether the auditor believes any of 
the reportable conditions noted are material weaknesses and, if they 
are, a reference to a description of the material weaknesses in the 
schedule of findings and questioned costs, including the reference 
number of the finding(s). If there are no reportable conditions, a 
statement is made that no material weaknesses were noted?
s. A separate paragraph at the end of the report stating that the report 
is intended solely for the information and use of the audit commit­
tee, management, specified legislative or regulatory bodies, fed­
eral awarding agencies, and (if applicable) pass-through entities 
and is not intended to be and should not be used by anyone other 
than these specified parties?8
8 This paragraph conforms to SAS 87, Restricting the Use of an Auditor's Report (AU 532). See SAS 87 for additional guidance on 
restricted use reports.
83
Yes
t. The manual or printed signature of the auditor's firm?
u. The date of the auditor's report?
[SOP 98-3, par. 10.46]
10. If the audit of the entity's compliance with requirements applicable 
to major programs detects material instances of noncompliance with 
those requirements, does the auditors' report express a qualified or 
adverse opinion?
[SOP 98-3, par. 10.42]
11. Have scope limitations on the auditor's testing of an auditee's com­
pliance with laws, regulations, and the provisions of contracts or grant 
agreements been considered in the opinion on compliance with re­
quirements applicable to each major programs?
[SOP 98-3, pars. 10.43-10.45]
12. Have the cumulative effects of all instances of noncompliance with 
federal programs and scope limitations been considered in the opin­
ion on the financial statements?
[SOP 98-3, pars. 10.42 and 10.43]
13. Does the report not refer to a management letter with findings that are 
not required to be reported in the schedule of findings and questioned 
costs?
[SOP 98-3, par. 10.48]
14. Is the report dated the same as or later than the date of the auditors' 
report on the financial statements?
[SOP 98-3, par. 10.51]
15. If the report is dated later than the date of the auditors' reports on the 
financial statements, have appropriate subsequent events procedures 
been performed?
[SOP 98-3, par. 10.51]
16. If the audit of federal awards did not encompass the entirety of the 
auditee's operations expending federal awards, are the operations 
that are not included identified in a separate paragraph following the 
first paragraph of the report?
[SOP 98-3, par. 10.54]
17. If the report on the financial statements refers to the work of other 
auditors, has the auditor considered the need to refer to the programs 
audited by other auditors in this report on compliance and on internal 
control?
[SOP 98-3, par. 3.46]
Schedule of Findings and Questioned Costs
18. Does the report conform to the standard report illustrated in Appen­
dix E of SOP 98-3?
[SOP 98-3, App. E]
19. Is the report presented even if there are no findings to report?
[SOP 98-3, par. 10.66]
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No N/A
Yes
20. Does the report contain the following three sections:
a. A summary of the auditor's results?
b. Findings related to the financial statements that are required to be 
reported in accordance with GAS?
c. Findings and questioned costs for federal awards?
[SOP 98-3, par. 10.55]
21. Does the summary of auditor's result include:
a. The type of report the auditor issued on the financial statements 
(that is, unqualified opinion, qualified opinion, adverse opinion, 
or disclaimer of opinion)?
b. Where applicable, a statement that reportable conditions in inter­
nal control were disclosed by the audit of the financial statements 
and whether any such conditions were material weaknesses?
c. A statement on whether the audit disclosed any noncompliance 
that is material to the financial statements?
d. Where applicable, a statement that reportable conditions in inter­
nal control over major programs were disclosed by the audit and 
whether any such conditions were material weaknesses relative to 
internal control over major programs?
e. The type of report the auditor issued on compliance for major 
programs (that is, unqualified opinion, qualified opinion, adverse 
opinion, or disclaimer of opinion)?
f. A statement as to whether the audit disclosed any audit findings 
that the auditor is required to report under A-133? (See Step 23 
below.)
g. An identification of major programs?
h. The dollar threshold used to distinguish between Type A and 
Type B programs?
i. A statement as to whether the auditee qualified as a low-risk 
auditee?
[SOP 98-3, par. 10.56a]
22. Are audit findings that relate to the same issue presented as a single 
audit finding?
[SOP 98-3, par. 10.56c]
23. If audit findings relate to both the financial statements and the federal 
awards, are they reported in both sections of the schedule (one in 
summary form with a reference to the detailed finding in the other 
section)?
[SOP 98-3, par. 10.56c]
24. Are the following reported as audit findings related to federal awards: 
including:
a. Reportable conditions and material weaknesses in internal control 
over major programs?
b. Material noncompliance relating to a major program?
c. Known and likely questioned costs that are greater than $10,000 
for a major program?
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No N/A
Yes No N/A
d. Known questioned costs that are greater than $10,000 for a federal
program that is not audited as a major program? ____
e. The circumstances concerning why the report on compliance for
major programs is other than an unqualified opinion? ____
f. Known fraud affecting a federal award? (An audit finding is not 
required if the fraud was reported outside the entity as required
by GAS.) ____
g. Instances of material misrepresentation by the auditee of the status
of any prior audit findings? ____
[SOP 98-3, par. 10.63]
25. Does the audit finding detail include, as applicable:
a. A reference number? ____
b. Identification of the federal program and award, including CFDA
title and number, federal award number and year, name of federal 
agency, and name of pass-through entity?9 ____
9 When information such as the CFDA title and number or federal award number is not available, the auditor should provide the best 
information available to describe the federal award.
10 Where appropriate the instances identified should be related to the universe and the number of cases examined and be quantified 
in terms of the dollar value.
11 If the auditee's corrective action plan is available and contains the views of the responsible officials, the auditor can indicate in the 
finding that the auditee disagreed with the finding and refer to the details of the auditee's position in the plan.
c. The criteria or specific requirement upon which the audit finding
is based, including the statutory, regulatory, or other citation? ____
d. The condition found, including facts that support the deficiency
identified? ____
e. Identification of questioned costs and how they were computed? ____
f. Information to put the finding in proper perspective for judging
the prevalence and consequences of audit findings?10 11 ____
g. The possible asserted effect of the condition? ____
h. Recommendations to prevent future occurrence of the deficiency? ____
i. Views of responsible officials of the auditee when there is dis­
agreement with the audit finding, to the extent practical?11 ____
j. If the auditor disagrees with the auditees position concerning a
finding, a statement of his or her reasons for rejecting it? ____
[SOP 98-3, pars. 10.64 and 10.65]
Data Collection Form
26. Has the auditor completed Part I, item 7, and Parts II and III of the
data collection form? ____
[SOP 98-3, par. 10.72]
27. Has the auditor signed the form and dated it as of the date on which
he or she completes and signs the form? ____
[SOP 98-3, par. 10.72]
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Yes No N/A
28. Are the following areas of the data collection form properly 
addressed:
a. In Part I, question 6g of the data collection form, are the auditee
and auditor signatures dated (month, day, and year)? ____
b. In Part I, question 9 of the data collection form, is a federal agency 
identified as the cognizant or oversight agency for audit. (The
agency named should not be a pass-through agency.) ____
c. In Part III, question 5 of the data collection form, are only federal 
agencies affected by audit findings identified as needing to receive 
a copy of the reporting package (described in section 320(d) of 
Circular A-133)? (If no federal agency is required to receive a copy
of the reporting package, the auditor should mark, "None.") ____
d. In Part III, items 6 and 7, does each line item have a unique
Catalog of Federal Domestic Assistance number (or other identi­
fying number)? ____
[Federal Audit Clearinghouse, Data Collection Form, No. SF-SAC]
Program-Specific Audits
29. In a program-specific audit performed in accordance with A-133, are 
the following reports issued:12
12 If the financial statement(s) of the program only present the activity of the federal program, the auditor is not required to issue a 
separate report to meet the financial reporting requirements of GAS. This is because, in many cases, by definition the financial 
statements of the program consist only of the schedule of expenditures of federal awards. See the further discussion in paragraph 11.10 
of SOP 98-3.
a. A report on the financial statement(s) of the federal program? ____
b. A report on compliance with requirements applicable to the fed­
eral program and on the internal control over compliance in 
accordance with the program-specific audit option under Circular
A-133? ____
[SOP 98-3, pars. 11.8 and 11.9]
c. A schedule of findings and questions costs for the federal program? ____
30. Does the report on compliance and on internal control for a program- 
specific audit conform to the standard reports illustrated in Examples
6 and 6a in SOP 98-3? ____
[SOP 98-3, App. D]
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FSP Section 11,500
Illustrative Financial Statements
.01 The following illustrative financial statements demonstrate the practical applications of the reporting 
practices discussed in the June 1996 AICPA Audit and Accounting Guide Health Care Organizations with 
conforming changes as of May 1, 1999 (the Guide). The checklists and illustrative financial statements do not 
include all disclosures and presentation items promulgated. Pronouncements deemed remote for audits of 
health care providers are not included in this document. Specific types of health care organizations have been 
selected to illustrate a wide diversity of reporting practices; it is not intended that these illustrations represent 
either the only types of disclosure or the only statement formats that would be appropriate. Health care 
providers are urged to develop financial statement formats that are appropriate for their individual 
circumstances while being consistent with the accounting and reporting practices discussed in the Guide. 
This section contains illustrative financial statements for the following types of health care organizations:
• Not-for-Profit Hospital
• For-Profit Nursing Home
• Not-for-Profit Continuing Care Retirement Community
• Not-for-Profit Home Health Agency
• Not-for-Profit Health Maintenance Organization
• Not-for-Profit Ambulatory Care Organization
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The checklists and illustrative financial statements do not include all disclosures 
and presentation items promulgated.
ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NOT-FOR-PROFIT HOSPITAL
.02
Sample Not-for-Profit Hospital 
Balance Sheets
December 31, 19X7 and 19X6 
(in thousands)
See accompanying notes to financial statements.
19X7 19X6
Assets
Current assets:
Cash and cash equivalents $ 4,758 $ 5,877
Short-term investments 15,836 10,740
Assets limited as to use 970 1,300
Patient accounts receivable, net of allowance 
for doubtful accounts of $2,500 in 19X7
and $2,400 in 19X6 15,100 14,194
Other current assets 2,670 2,856
Total current assets 39,334 34,967
Assets limited as to use:
Internally designated for capital acquisition 12,000 12,500
Held by trustee 6,949 7,341
Less amount required to meet current obligations
18,949
(970)
19,841
(1,300)
Long-term investments
17,979
4,680
18,541
4,680
Long-term investments restricted for capital acquisition 320 520
Property and equipment, net 51,038 50,492
Other assets 1,695 1,370
Total assets $115,046 $110,570
Liabilities and Net Assets
Current liabilities:
Current portion of long-term debt $ 1,470 $ 1,750
Accounts payable and accrued expenses 5,818 5,382
Estimated third-party payor settlements 2,143 1,942
Other current liabilities 1,969 2,114
Total current liabilities 11,400 11,188
Long-term debt, net of current portion 23,144 24,014
Other liabilities 3,953 3,166
Total liabilities 38,497 38,368
Net assets:
Unrestricted 70,846 66,199
Temporarily restricted 2,115 2,470
Permanently restricted 3,588 3,533
Total net assets 76,549 72,202
Total liabilities and net assets $115,046 $110,570
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.03
FORMAT A
Sample Not-for-Profit Hospital
Statements of Operations
Years Ended December 31, 19X7 and 19X6
(in thousands)
See accompanying notes to financial statements.
19X7 19X6
Unrestricted revenues, gains and other support:
Net patient service revenue $85,156 $78,942
Premium revenue 11,150 10,950
Other revenue 2,601 5,212
Net assets released from restrictions used for operations 300
Total revenues, gains and other support 99,207 95,104
Expenses:
Operating expenses 88,521 80,585
Depreciation and amortization 4,782 4,280
Interest 1,752 1,825
Provision for bad debts 1,000 1,300
Other 2,000 1,300
Total expenses 98,055 89,290
Operating income 1,152 5,814
Other income:
Investment income 3,900 3,025
Excess of revenues over expenses 5,052 8,839
Change in net unrealized gains and losses on other than
trading securities 300 375
Net assets released from restrictions used for purchase of
property and equipment 200
Contributions from Sample Hospital
Foundation for property acquisitions 235 485
Transfers to parent (640) (3,000)
Increase in unrestricted net assets, before extraordinary item 5,147 6,699
Extraordinary loss from extinguishment of debt (500)
Increase in unrestricted net assets $ 4,647 $ 6,699
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Sample Not-for-Profit Hospital
Statements of Operations
Years Ended December 31, 19X7 and 19X6
(in thousands)
FORMAT B
See accompanying notes to financial statements.
19X7 19X6
Unrestricted revenues, gains and other support:
Net patient service revenue $85,156 $78,942
Premium revenue 11,150 10,950
Other, primarily investment income 6,501 8,237
Net assets released from restrictions used for operations 300
Total revenues, gains and other support 103,107 98,129
Expenses:
Salaries and benefits 53,900 49,938
Medical supplies and drugs 26,532 22,121
Insurance 8,089 8,526
Depreciation and amortization 4,782 4,280
Interest 1,752 1,825
Provision for bad debts 1,000 1,300
Other 2,000 1,300
Total expenses 98,055 89,290
Excess of revenues, gains, and other support over expenses 5,052 8,839
Change in net unrealized gains and losses on other than
trading securities 300 375
Net assets released from restrictions used for purchase of
property and equipment 200
Contributions from Sample Hospital
Foundation for property acquisitions 235 485
Transfers to parent (640) (3,000)
Increase in unrestricted net assets, before extraordinary item 5,147 6,699
Extraordinary loss from extinguishment of debt (500)
Increase in unrestricted net assets $ 4,647 $ 6,699
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Sample Not-for-Profit Hospital
Statements of Changes in Net Assets
Years Ended December 31, 19X7 and 19X6
(in thousands)
See accompanying notes to financial statements.
19X7 19X6
Unrestricted net assets:
Excess of revenues over expenses $ 5,052 $ 8,839
Net unrealized gains on investments, other than trading 
securities 300 375
Contributions from Sample Hospital Foundation for 
property acquisitions 235 485
Transfers to parent (640) (3,000)
Net assets released from restrictions used for purchase 
of property and equipment 200
Increase in unrestricted net assets before 
extraordinary item 5,147 6,699
Extraordinary loss from extinguishment of debt (500)
Increase in unrestricted net assets 4,647 6,699
Temporarily restricted net assets:
Contributions for charity care 140 996
Net realized and unrealized gains on investments 5 8
Net assets released from restrictions (500)
Increase (decrease) in temporarily restricted net assets (355) 1,004
Permanently restricted net assets:
Contributions for endowment funds 50 411
Net realized and unrealized gains on investments 5 2
Increase in permanently restricted net assets 55 413
Increase in net assets 4,347 8,116
Net assets, beginning of year 72,202 64,086
Net assets, end of year $76,549 $72,202
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Sample Not-for-Profit Hospital
Statements of Cash Flows (Indirect Method)
Years Ended December 31, 19X7 and 19X6
(in thousands)
19X7 19X6
Cash flows from operating activities:
Change in net assets $ 4,347 $ 8,116
Adjustments to reconcile change in net assets to net 
cash provided by operating activities:
Extraordinary loss from extinguishment of debt 500
Depreciation and amortization 4,782 4,280
Net realized and unrealized gains on investments,
other than trading (450) (575)
Transfers to parent 640 3,000
Provision for bad debts 1,000 1,300
Restricted contributions and investment income
received (290) (413)
(Increase) decrease in:
Patient accounts receivable (1,906) (2,036)
Trading securities 215
Other current assets 186 (2,481)
Other assets (325) (241)
Increase (decrease) in:
Accounts payable and accrued expenses 436 679
Estimated third-party payor settlements 201 305
Other current liabilities (145) (257)
Other liabilities 787 (128)
Net cash provided by operating activities 9,978 11,549
Cash flows from investing activities:
Purchase of investments (3,769) (2,150)
Capital expenditures (4,728) (5,860)
Net cash used in investing activities (8,497) (8,010)
Cash flows from financing activities:
Transfers to parent (640) (3,000)
Proceeds from restricted contributions and restricted
investment income 290 413
Payments on long-term debt (24,700) (804)
Payments on capital lease obligations (150) (100)
Proceeds from issuance of long-term debt 22,600 500
Net cash used in financing activities (2,600) (2,991)
Net (decrease) increase in cash and cash equivalents (1,119) 548
Cash and cash equivalents, beginning of year 5,877 5,329
Cash and cash equivalents, end of year $ 4,758 $ 5,877
Supplemental Disclosures of Cash Flow Information:
The Hospital entered into capital lease obligations in the amount of $600,000 for new 
equipment in 19X7.
Cash paid for interest (net of amount capitalized) in 19X7 and 19X6 was $1,780,000 
and $1,856,000, respectively.
See accompanying notes to financial statements.
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Sample Not-for-Profit Hospital 
Notes to Financial Statements 
December 31, 19X7 and 19X6
1. Description of Organization and Summary of Significant Accounting Policies
Organization. The Sample Not-for-Profit Hospital (the Hospital), located in Tulsa, Oklahoma, 
is a not-for-profit acute care hospital. The Hospital provides inpatient, outpatient and emergency 
care services for residents of northeastern Oklahoma. Admitting physicians are primarily practi­
tioners in the local area. The Hospital was incorporated in Oklahoma in 19X1 and is affiliated with 
the Sample Health System.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include certain investments in highly 
liquid debt instruments with original maturities of three months or less.
The Hospital routinely invests its surplus operating funds in money market mutual funds. These 
funds generally invest in highly liquid U.S. government and agency obligations.
Investments. Investments in equity securities with readily determinable fair values and all 
investments in debt securities are measured at fair value in the balance sheet. Investment income 
or loss (including realized gains and losses on investments, interest and dividends) is included in 
the excess of revenues over expenses unless the income or loss is restricted by donor or law. 
Unrealized gains and losses on investments are excluded from the excess of revenues over 
expenses unless the investments are trading securities.
Assets limited as to use. Assets limited as to use primarily include assets held by trustees under 
indenture agreements and designated assets set aside by the Board of Trustees for future capital 
improvements, over which the Board retains control and may at its discretion subsequently use 
for other purposes. Amounts required to meet current liabilities of the hospital have been 
reclassified in the balance sheet at December 31, 19X7 and 19X6.
Property and equipment. Property and equipment acquisitions are recorded at cost. Depreciation 
is provided over the estimated useful life of each class of depreciable asset and is computed using 
the straight-line method. Equipment under capital lease obligations is amortized on the straight- 
line method over the shorter period of the lease term or the estimated useful life of the equipment. 
Such amortization is included in depreciation and amortization in the financial statements. 
Interest cost incurred on borrowed funds during the period of construction of capital assets is 
capitalized as a component of the cost of acquiring those assets.
Gifts of long-lived assets such as land, buildings, or equipment are reported as unrestricted 
support, and are excluded from the excess of revenues over expenses, unless explicit donor 
stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit 
restrictions that specify how the assets are to be used and gifts of cash or other assets that 
must be used to acquire long-lived assets are reported as restricted support. Absent explicit 
donor stipulations about how long those long-lived assets must be maintained, expirations of 
donor restrictions are reported when the donated or acquired long-lived assets are placed in 
service.
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Temporarily and permanently restricted net assets. Temporarily restricted net assets are those 
whose use by the Hospital has been limited by donors to a specific time period or purpose. 
Permanently restricted net assets have been restricted by donors to be maintained by the Hospital 
in perpetuity.
Excess of revenues over expenses. The statement of operations includes excess of revenues over 
expenses. Changes in unrestricted net assets which are excluded from excess of revenues over 
expenses, consistent with industry practice, include unrealized gains and losses on investments 
other than trading securities, permanent transfers of assets to and from affiliates for other than goods 
and services, and contributions of long-lived assets (including assets acquired using contributions 
which by donor restriction were to be used for the purposes of acquiring such assets).
Net patient service revenue. The Hospital has agreements with third-party payors that provide 
for payments to the Hospital at amounts different from its established rates. Payment arrange­
ments include prospectively determined rates per discharge, reimbursed costs, discounted 
charges, and per diem payments. Net patient service revenue is reported at the estimated net 
realizable amounts from patients, third-party payors, and others for services rendered, including 
estimated retroactive adjustments under reimbursement agreements with third-party payors. 
Retroactive adjustments are accrued on an estimated basis in the period the related services are 
rendered and adjusted in future periods as final settlements are determined.
Premium revenue. The Hospital has agreements with various Health Maintenance Organiza­
tions (HMOs) to provide medical services to subscribing participants. Under these agreements, 
the Hospital receives monthly capitation payments based on the number of each HMO's participants, 
regardless of services actually performed by the Hospital. In addition, the HMOs make fee-for-service 
payments to the Hospital for certain covered services based upon discounted fee schedules.
Charity care. The Hospital provides care to patients who meet certain criteria under its charity care 
policy without charge or at amounts less than its established rates. Because the Hospital does not 
pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.
Donor-restricted gifts. Unconditional promises to give cash and other assets to the Hospital are 
reported at fair value at the date the promise is received. Conditional promises to give and 
indications of intentions to give are reported at fair value at the date the gift is received. The gifts 
are reported as either temporarily or permanently restricted support if they are received with 
donor stipulations that limit the use of the donated assets. When a donor restriction expires, that 
is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily 
restricted net assets are reclassified as unrestricted net assets and reported in the statement of 
operations as net assets released from restrictions. Donor-restricted contributions whose restric­
tions are met within the same year as received are reported as unrestricted contributions in the 
accompanying financial statements.
Estimated malpractice costs. The provision for estimated medical malpractice claims includes 
estimates of the ultimate costs for both reported claims and claims incurred but not reported.
Income taxes. The Hospital is a not-for-profit corporation and has been recognized as tax-ex­
empt pursuant to Sec. 501(c)(3) of the Internal Revenue Code.
2. Net Patient Service Revenue
The Hospital has agreements with third-party payors that provide for payments to the Hospital 
at amounts different from its established rates. A summary of the payment arrangements with 
major third-party payors follows:
• Medicare. Inpatient acute care services rendered to Medicare program beneficiaries are 
paid at prospectively determined rates per discharge. These rates vary according to a pa-
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tient classification system that is based on clinical, diagnostic, and other factors. Inpatient 
nonacute services, certain outpatient services, and defined capital and medical education 
costs related to Medicare beneficiaries are paid based on a cost reimbursement methodol­
ogy. The Hospital is reimbursed for cost reimbursable items at a tentative rate with final 
settlement determined after submission of annual cost reports by the Hospital and audits 
thereof by the Medicare fiscal intermediary. Beginning in 19X3, the Hospital claimed 
Medicare payments based on an interpretation of certain "disproportionate share" rules. 
The intermediary disagreed and declined to pay the excess reimbursement claimed under 
that interpretation. Through 1996, the Hospital has not included the claimed excess in net 
patient revenues pending resolution of the matter. In 19X7, the intermediary accepted the 
claims and paid the outstanding claims, including $950,000 applicable to 19X6 and $300,000 
applicable to 19X5 and prior, which has been included in 19X7 net revenues.
• Medicaid. Inpatient and outpatient services rendered to Medicaid program beneficiaries 
are reimbursed under a cost reimbursement methodology. The Hospital is reimbursed at 
a tentative rate with final settlement determined after submission of annual cost reports 
by the Hospital and audits thereof by the Medicaid fiscal intermediary.
The Hospital also has entered into payment agreements with certain commercial insurance 
carriers, health maintenance organizations, and preferred provider organizations. The basis for 
payment to the Hospital under these agreements includes prospectively determined rates per 
discharge, discounts from established charges, and prospectively determined daily rates.
3. Investments
Assets Limited as to Use
The composition of assets limited as to use at December 31, 19X7 and 19X6, is set forth in the 
following table. Investments are stated at fair value.
Other investments, stated at fair value, at December 31, 19X7 and 19X6, include:
19X7 19X6
Internally designated for capital acquisition:
Cash $ 545,000 $ 350,000
U.S. Treasury obligations 11,435,000 12,115,000
Interest receivable 20,000 35,000
12,000,000 12,500,000
Held by trustee under indenture agreement:
Cash and short-term investments 352,000 260,000
U.S. Treasury obligation 6,505,000 7,007,000
Interest receivable 92,000 74,000
6,949,000 7,341,000
$18,949,000 $19,841,000
Other Investments
19X7 19X6
Trading:
U.S. Corporate Bonds $ 1,260,000 $ 1,475,000
Other:
U.S. Treasury obligations $19,266,000 $14,233,000
Interest receivable 310,000 232,000
20,836,000 15,940,000
Less:
Long-term investments 4,680,000 4,680,000
Long-term investments restricted for capital
acquisitions 320,000 520,000
Short-term investments $15,836,000 $10,740,000
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Investment income and gains for assets limited as to use, cash equivalents, and other invest­
ments are comprised of the following for the years ending December 31, 19X7 and 19X6:
19X7 19X6
Income:
Interest income $3,585,000 $2,725,000
Realized gains on sales of securities 150,000 200,000
Unrealized gains on trading securities 165,000 100,000
$3,900,000 $3,025,000
Other Changes in Unrestricted Net Assets:
Unrealized gains on other than trading securities $ 300,000 $ 375,000
4. Property and Equipment
A summary of property and equipment at December 31, 19X7 and 19X6, follows:
Land
19X7
$ 3,000,000
19X6
$ 3,000,000
Land improvements 472,000 472,000
Buildings and improvements 46,852,000 46,636,000
Equipment 29,190,000 26,260,000
Equipment under capital lease obligations 2,851,000 2,752,000
Less accumulated depreciation and amortization
82,365,000
34,928,000
79,120,000
30,661,000
Construction in progress
47,437,000
3,601,000
48,459,000
2,033,000
Property and equipment, net $51,038,000 $50,492,000
Depreciation expense for the years ended December 31, 19X7 and 19X6 amounted to approxi­
mately $4,782,000 and $4,280,000. Accumulated amortization for equipment under capital lease 
obligations was $689,000 and $453,000 at December 31, 19X7 and 19X6, respectively. Construction 
contracts of approximately $7,885,000 exist for the remodeling of Hospital facilities. At December 
31, 19X7, the remaining commitment on these contracts approximated $4,625,000.
5. Long-Term Debt
A summary of long-term debt and capital lease obligations at December 31, 19X7 and 19X6, 
follows:
19X7 19X6
7.25 percent 19X7 Tax-Exempt Revenue Bonds, principal mat-
uring in varying annual amounts, due November 1, 20XX, 
collateralized by a pledge of the Hospital's gross receipts $21,479,000
8.50 percent 19X2 Tax-Exempt Revenue Bonds, principal 
maturing in varying annual amounts, due June 1, 19XX $22,016,000
7.75 percent mortgage loan, principal maturing in varying 
annual amounts, due January 20XX, collateralized by a 
mortgage on certain property and equipment 2,010,000 2,127,000
7.75 percent note payable, payable in monthly installments 
of $12,000, including interest, due March 19XX, unsecured 125,000 671,000
Capital lease obligations, at varying rates of imputed interest from 
6.8 percent to 9.3 percent collateralized by leased equipment 1,000,000 950,000
24,614,000 25,764,000
Less current portion 1,470,000 1,750,000
$23,144,000 $24,014,000
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Under the terms of the 19X7 and 19X2 revenue bond indentures, the Hospital is required to 
maintain certain deposits with a trustee. Such deposits are included with assets limited as to use. 
The revenue note indenture also places limits on the incurrence of additional borrowings and 
requires that the Hospital satisfy certain measures of financial performance as long as the notes 
are outstanding.
Scheduled principal repayments on long-term debt and payments on capital lease obligations 
are as follows:
$1,000,000
Year Ending Long-Term Capital Leases
December 31, Debt Obligations
19X8 $ 970,000 $ 550,000
19X9 912,000 260,000
20Y0 983,000 260,000
20Y1 1,060,000 45,000
20Y2 1,143,000 —
Thereafter 18,546,000 —
Less amount representing interest under 
capital leases obligations
$23,614,000 1,115,000
115,000
A summary of interest cost and investment income on borrowed funds held by the trustee under 
the 19X7 and 19X2 revenue bond indentures during the years ended December 31, 19X7 and 19X6, 
follows:
19X7 19X6
Interest cost:
Capitalized $ 740,000 $ 700,000
Charged to operations 1,752,000 1,825,000
Total $2,492,000 $2,525,000
Investment income:
Capitalized $ 505,000 $ 663,000
Credited to other revenue 330,000 386,000
Total $ 835,000 $1,049,000
6. Temporarily and Permanently Restricted Net Assets
Temporarily restricted net assets are available for the following purposes or periods at Decem­
ber 31, 19X7 and 19X6:
19X7 19X6
Health care services
Purchase of equipment $ 320,000 $ 520,000
Indigent care 840,000 950,000
Health education 350,000 400,000
For periods after December 31, 19X9 605,000 600,000
$2,115,000 $2,470,000
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Permanently restricted net assets at December 31, 19X7 and 19X6, are restricted to:
19X7 19X6
Investments to be held in perpetuity, the income 
from which is expendable to support health care 
services (reported as operating income) $2,973,000 $2,923,000
Endowment requiring income to be added to 
original gift until fund value is $1,500,000 615,000 610,000
$3,588,000 $3,533,000
During 19X7, net assets were released from donor restrictions by incurring expenses satisfying 
the restricted purposes of indigent care and health care education in the amounts of $250,000 and 
$50,000, respectively.
7. Medical Malpractice Claims
The Hospital purchases professional and general liability insurance to cover medical malprac­
tice claims. There are known claims and incidents that may result in the assertion of additional 
claims, as well as claims from unknown incidents that may be asserted arising from services 
provided to patients. The Hospital has employed independent actuaries to estimate the ultimate 
costs, if any, of the settlement of such claims. Accrued malpractice losses have been discounted 
at 7 percent and in management's opinion provide an adequate reserve for loss contingencies.
On March 15, 19X7, a patient filed a suit against the Hospital for malpractice during care received 
as an inpatient. The Hospital believes it has meritorious defenses against the suit; however, the 
ultimate resolution of the matter could result in a loss. The patient has claimed $16 million in 
actual damages. Under state law, punitive damages are determined at trial. The Hospital main­
tains insurance coverage for malpractice claims. The coverage does not include punitive damages 
awards. Trial is scheduled to occur within the next year.
8. Pension and Other Postretirement Benefit Plans*
The Hospital has a defined benefit pension plan covering substantially all of its employees. The 
plan benefits are based on years of service and the employees' compensation during the last five 
years of covered employment. Contributions are intended to provide not only for benefits 
attributed to service to date but also for those expected to be earned in the future.
Note: The following paragraph is encouraged but not required.
The Hospital also sponsors two defined benefit postretirement plans that cover both salaried and 
nonsalaried employees. One plan provides medical and dental benefits, and the other provides for 
the payment of life insurance premiums. The postretirement health care plan is contributory, with 
retiree contributions adjusted annually; the life insurance plan is noncontributory. The accounting for 
the health care plan anticipates future cost-sharing changes to the written plan that are consistent with 
the Hospital's expressed intent to increase retiree contributions each year to 50 percent of the excess 
of the expected general inflation rate over 6 percent. Beginning in 19X7, the Hospital adopted a funding 
policy for its postretirement health care plan similar to its funding policy for its life insurance plan—an 
amount equal to a level percentage of the employees' salaries is contributed to the plan annually. For 
19X7, that percentage was 4.25, and the aggregate contribution for both plans was $34,000.
The following table sets forth the changes in benefit obligations, changes in plan assets and 
components of net periodic benefit cost for both the pension plan and the other postretirement 
benefit plans:
SFAS 132, Employers' Disclosures About Pensions and Other Postretirement Benefits, an amendment of SFASs 87, 88, and 106, permits 
reduced disclosures for nonpublic entities. This note to the financial statements illustrates the financial statement disclosures about 
pension and postretirement benefit plans for a public entity. Readers should refer to SFAS 132 when considering disclosure require­
ments for nonpublic entities.
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Pension Benefits Other Benefits
19X7 19X6 19X7 19X6
Change in benefit obligation:
Benefit obligation at beginning of year $ 9,710 $ 9,700 $585 $500
Service cost 905 770 14 15
Interest cost
Plan participants' contributions
Actuarial gain
700
(20)
650 50
34
(7)
44
34
Benefits paid (375) (1,410) (66) (8)
Benefit obligation at end of year 10,920 9,710 610 585
Change in plan assets:
Fair value of plan assets at beginning of year 9,800 9,610 89 40
Actual return on plan assets 759 810 4 4
Employer contribution
Plan participants' contributions
866 790 39
34
19
34
Benefits paid (375) (1,410) (66) (8)
Fair value of plan assets at end of year 11,050 9,800 100 89
Funded status 130 90 (510) (496)
Unrecognized net actuarial gain (30) (40) (30) (40)
Unrecognized prior service cost
Unrecognized transition obligation
Unrecognized transition asset
50
(15)
55
(20)
16
445
19
470
Prepaid (accrued) benefit cost $ 135 $ 85 $ (79) $ (47)
Weighted-average assumptions as of December 31:
Discount rate 7.00% 7.00% 7.00% 7.00%
Expected return on plan assets
Rate of compensation increase
8.00%
6.00%
8.00%
6.00%
6.60% 6.60%
For measurement purposes, a 7 percent annual rate of increase in the per capita cost of covered
health care benefits was assumed for 19X8. The rate was assumed to decrease gradually to 5
percent over the next five years.
Pension Benefits Other Benefits
19X7 19X6 19X7 19X6
Components of net periodic benefit cost:
Service cost $905 $770 $14 $15
Interest cost 700 650 50 44
Expected return on plan assets (784) (769) (6) (3)
Amortization of prior service cost 5 7 3 2
Recognized net actuarial gain
Amortization of transition obligation
(5) (2) (15)
25
(1)
25
Amortization of transition asset (5) (1)
Net periodic benefit cost $816 $655 $71 $82
Assumed health care cost trend rates have a significant effect on the amounts reported for the 
health care plans. A one-percentage-point change in assumed health care cost trend rates would 
have the following effects:
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1-Percentage- 1-Percentage- 
Point Increase Point Decrease
Effect on total of service and interest 
cost components $13 $(11)
Effect on postretirement benefit obligation 73 (67)
9. Concentrations of Credit Risk
The Hospital grants credit without collateral to its patients, most of whom are local residents 
and are insured under third-party payor agreements. The mix of receivables from patients and 
third-party payors at December 31, 19X7 and 19X6, was as follows:
19X7 19X6
Medicare 51% 53%
Medicaid 17 14
Blue Cross 18 17
Other third-party payors 7 9
Patients 7
100%
7
100%
10. Commitments and Contingencies
Operating leases. The Hospital leases various equipment and facilities under operating leases 
expiring at various dates through April 20X2. Total rental expense in 19X7 and 19X6 for all 
operating leases was approximately $859,000 and $770,000, respectively.
The following is a schedule by year of future minimum lease payments under operating leases 
as of December 31, 19X7, that have initial or remaining lease terms in excess of one year.
Year Ending
December 31, Amount
19X8
19X9
20Y0
20Y1
20Y2
$517,000
506,000
459,000
375,000
343,000
Litigation. The Hospital is involved in litigation and regulatory investigations arising in the 
course of business. After consultation with legal counsel, management estimates that these 
matters will be resolved without material adverse effect on the Hospital's future financial position 
or results from operations.
Allowance for doubtful accounts. Beginning in 19X5, the Hospital has provided care under an 
agreement with Associated HMO. The HMO currently owes the Hospital $950,000, substantially 
all of which is overdue. The Hospital has notified the HMO that further services under the contract 
cannot be provided without payment on the outstanding balance. The HMO has assured the 
Hospital that additional funds are being obtained in order to pay the overdue balance and 
continue service under the agreement, however, if the HMO is unable to make payments, 
additional allowances for bad debts would need to be accrued.
11. Extraordinary Loss
In 19X7, the Hospital advance refunded its 19X2 Revenue Bonds in the amount of $22 million 
by issuing 19X7 Revenue Bonds. As a result of this in-substance defeasance transaction, an 
extraordinary loss totaling $500,000 was recorded. As of December 31, 19X7, $21 million of 
advance refunded bonds, which are considered extinguished, remain outstanding.
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12. Related Party Transactions
During the years ended December 31, 19X7 and 19X6, the Hospital contributed capital to Sample 
Health System, an affiliate with some board members in common with the Hospital, in the 
amounts of $640,000 and $3 million, respectively.
The Sample Hospital Foundation (the Foundation), which is controlled by Sample Health 
System, was established to solicit contributions from the general public and to support the 
Hospital. Funds are distributed to the Hospital as determined by the Foundation's Board of 
Directors. A summary of the foundation's assets, liabilities, net assets, results of operations, and 
changes in net assets follows.
December 31,
19X6 19X7
Assets, principally cash and cash equivalents $521,000 $472,000
Liabilities 11,000 10,000
Net assets 510,000 462,000
Total liabilities and net assets $521,000 $472,000
Support and revenue $269,000 $535,000
Expenses
Distributions to Sample Hospital for property acquisitions 235,000 485,000
Other 13,000 16,000
Total expenses 248,000 501,000
Excess of support and revenue over expenses 21,000 34,000
Other changes in net assets 27,000 17,000
Net assets, beginning of year 462,000 411,000
Net assets, end of year $510,000 $462,000
Liabilities include $10,000 payable at the end of each year to Sample Hospital. These amounts 
were paid after the end of each year.
13. Functional Expenses
The Hospital provides general health care services to residents within its geographic location. 
Expenses related to providing these services are as follows (in thousands):
December 31,
19X7 19X6
Health care services $86,000 $78,647
General and administrative 12,055
$98,055
10,643
$89,290
14. Fair Value of Financial Instruments
The following methods and assumptions were used by the Hospital in estimating the fair value 
of its financial instruments:
Cash and cash equivalents: The carrying amount reported in the balance sheet for cash and cash 
equivalents approximates its fair value.
Investments: Fair values, which are the amounts reported in the balance sheet, are based on quoted 
market prices, if available, or estimated using quoted market prices for similar securities.
Assets limited as to use: These assets consist primarily of cash and short-term investments and 
interest receivable. The carrying amount reported in the balance sheet is fair value.
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Accounts payable and accrued expenses: The carrying amount reported in the balance sheet for 
accounts payable and accrued expenses approximates its fair value.
Estimated third-party payor settlements: The carrying amount reported in the balance sheet for 
estimated third-party payor settlements approximates its fair value.
Long-term debt: Fair values of the Hospital's revenue notes are based on current traded value. 
The fair value of the Hospital's remaining long-term debt is estimated using discounted cash 
flow analyses, based on the Hospital's current incremental borrowing rates for similar types 
of borrowing arrangements.
The carrying amounts and fair values of the Hospital's financial instruments at December 31, 19X7 
and 19X6, are as follows (In thousands):
19X7 19X6
Carrying Carrying
Amount Fair Value Amount Fair Value
Cash and cash equivalents $ 4,758 $ 4,758 $ 5,877 $ 5,877
Short-term investments 15,836 15,836 10,740 10,740
Assets limited as to use 18,949 18,949 19,841 19,841
Long-term investments 4,680 4,680 4,680 4,680
Long-term investments restricted 
for capital acquisition 320 320 520 520
Accounts payable and 
accrued expenses 5,818 5,818 5,382 5,382
Estimated third-party 
payor settlements 2,143 2,143 1,942 1,942
Long-term debt 24,614 23,980 25,764 24,918
15. Promises to Contribute
At December 31, 19X7, the Hospital had received $1,500,000 of conditional promises to contrib­
ute to the building of a new facility for outpatient services. These contributions will be recorded 
as temporarily restricted support when received. The Hospital had no material outstanding 
unconditional promises of support at December 31, 19X7.
16. Charity Care
The amount of charges foregone for services and supplies furnished under the Hospital's charity 
care policy aggregated approximately $4,500,000 and $4,100,000 in 19X7 and 19X6, respectively.
17. Subsequent Event
On February 9, 19X8, the Hospital signed a contract in the amount of $1,050,000 for the purchase 
of certain real estate.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NURSING HOME
Sample For-Profit Nursing Home, Inc. 
Balance Sheets
December 31, 19X5 and 19X4
19X5 19X4
Assets
Current assets:
Cash and cash equivalents $ 95,000 $ 129,000
Investments 150,000
Assets limited as to use 50,000 50,000
Patient accounts receivable, net of allowance 
for doubtful accounts of $6,700 in 19X5 and
$5,300 in 19X4 162,000 152,000
Estimated third-party payor settlements 71,000 62,000
Interest receivable 7,000
Supplies 47,000 43,000
Prepaid expenses 3,000 2,000
Deferred tax asset 12,000 14,000
Total current assets 597,000 452,000
Assets limited as to use, net of amount required
for current liabilities 173,000 150,000
Property and equipment:
Land 205,000 205,000
Land improvements 37,000 32,000
Buildings 1,399,000 1,399,000
Furniture, fixtures, and equipment 228,000 189,000
1,869,000 1,825,000
Less accumulated depreciation 210,000 141,000
Property and equipment, net 1,659,000 1,684,000
Other assets 150,000 127,000
Total assets $2,579,000 $2,413,000
Liabilities and Shareholders' Equity
Current liabilities:
Current maturities of long-term debt $ 50,000 $ 50,000
Accounts payable 78,000 52,000
Accrued expenses 175,000 188,000
Deposits from patients 50,000 45,000
Other current liabilities 74,000 15,000
Total current liabilities 427,000 350,000
Deferred tax liability 6,000 14,000
Long-term debt, net of current maturities 1,700,000 1,750,000
Shareholders' equity:
Common stock, $20 par value; authorized
5,000 shares; issued and outstanding
3,500 shares 70,000 70,000
Retained earnings 376,000 229,000
Total shareholders' equity 446,000 299,000
Total liabilities and shareholders' equity $2,579,000 $2,413,000
See accompanying notes to financial statements.
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Sample For-Profit Nursing Home, Inc. 
Statements of Income and Retained Earnings 
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Revenue:
Net patient service revenue $2,163,000 $1,949,000
Other revenue 67,000 22,000
Interest on investments held by trustee 13,000 7,000
Total revenue 2,243,000 1,978,000
Expenses:
Salaries and benefits 969,000 919,000
Medical supplies and drugs 511,000 499,000
Insurance and other 216,000 176,000
Provision for bad debts 92,000 83,000
Depreciation 69,000 57,000
Interest 164,000 172,000
Total expenses 2,021,000 1,906,000
Operating income 222,000 72,000
Nonoperating income:
Other interest income 5,000
Income before provision for income taxes 227,000 72,000
Provision for income taxes 80,000 29,000
Net income 147,000 43,000
Retained earnings, beginning of year 229,000 186,000
Retained earnings, end of year $ 376,000 $ 229,000
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Sample For-Profit Nursing Home, Inc. 
Statements of Cash Flows 
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Cash flows from operating activities:
Cash received from residents and third-party payors $2,019,000 $1,796,000
Cash received from others 67,000 22,000
Cash paid to employees and suppliers (1,679,000) (1,495,000)
Interest and dividends received 10,000 10,000
Interest paid (160,000) (170,000)
Taxes paid (29,000) (30,000)
Deposits received from patients 35,000 15,000
Deposits refunded to patients (30,000) (20,000)
Net cash provided by operating activities 233,000 128,000
Cash flows from investing activities:
Purchase of investments (150,000)
Proceeds from sale of property 2,000
Capital expenditures (44,000) (79,000)
Purchase of assets limited as to use (23,000)
Net cash used in investing activities (217,000) (77,000)
Cash flows from financing activities:
Repayment of long-term debt (50,000) (50,000)
Net cash used in financing activities (50,000) (50,000)
Net increase (decrease) in cash and cash equivalents (34,000) 1,000
Cash and cash equivalents, beginning of year 129,000 128,000
Cash and cash equivalents, end of year $ 95,000 $ 129,000
Reconciliation of net income to net cash 
provided by operating activities:
Net income $ 147,000 $ 43,000
Adjustments to reconcile net income to net cash 
provided by operating activities:
Depreciation 69,000 57,000
Provision for bad debts 92,000 83,000
Loss on sale of property — 11,000
Change in deferred income taxes (6,000) (14,000)
(Increase) decrease in:
Patient accounts receivable (102,000) (41,000)
Other current assets (21,000) (15,000)
Estimated third-party payor settlements (9,000) (10,000)
Interest receivable (7,000) (3,000)
Other assets (7,000) (10,000)
Increase (decrease) in:
Accounts payable and accrued expenses 13,000 43,000
Deposits from patients 5,000 (5,000)
Other current liabilities 59,000 (11,000)
Net cash provided by operating activities $ 233,000 $ 128,000
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Sample For-Profit Nursing Home, Inc.
Notes to Financial Statements 
December 31, 19X5 and 19X4
1. Description of Organization and Summary of Significant Accounting Policies
Organization. The Sample Nursing Home, Inc. (the Company) was incorporated in New State 
in 19X1 and operates a 128-bed nursing home in Abacus, New State. A summary of the Company's 
significant accounting policies follows:
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less, excluding amounts whose use is 
limited by note indenture.
Investments. Investments in debt instruments, including assets limited as to use, are classified 
as held-to-maturity because the Company has the positive intent and ability to hold the securities 
until maturity. Held-to-maturity securities are carried at cost adjusted for amortization of premi­
ums and accretion of discounts.
Assets limited as to use. Assets deposited with a trustee under terms of the note indenture and assets 
set aside by the Board of Directors for capital improvements are classified as assets limited as to use. 
Amounts required to meet current liabilities have been reclassified in the balance sheet.
Property and equipment. Property and equipment are recorded at cost. Depreciation is calculated 
on the straight-line method over the estimated useful lives of depreciable assets.
Bond issuance costs. Costs incurred in issuing the Series 19X1 bonds are being amortized based 
on the effective interest method.
Net patient service revenue. Net patient service revenue is reported at the estimated net realizable 
amounts from residents, third-party payors, and others for service rendered.
Revenue under third-party payor agreements is subject to audit and retroactive adjustment. 
Provisions for estimated third-party payor settlements are provided in the period the related 
services are rendered. Differences between the estimated amounts accrued and interim and final 
settlements are reported in operations in the year of settlement.
Income taxes. The provisions for income taxes are based on amounts estimated to be currently 
payable and those deferred because of temporary differences between the financial statement and tax 
bases of assets and liabilities. These differences consist principally of bad debts and depreciation.
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2. Assets Limited as to Use
Assets limited as to use include:
Assets held by trustee under the Series 19X1 note indenture agreement 
at December 31, 19X5 and 19X4.
19X5 19X4
U.S. Government obligations $150,000 $130,000
Cash 24,000 21,000
Accrued interest income 2,000 2,000
Internally designated by the Board of
Directors for capital improvements
176,000 153,000
Certificate of deposit $ 45,000 $ 45,000
Accrued interest 2,000 2,000
47,000 47,000
$223,000 $200,000
3. Investments
The amortized cost and approximate fair value of held-to-maturity securities at December 31 
19X5 and 19X4, are as follows:
December 31, 19X5
Gross Gross
Amortized Unrealized Unrealized Approximate
Cost Gains (Losses) Fair Value
U.S. Treasury obligations $150,000 $11,000 $(16,000) $145,000
U.S. Government agency
obligations 83,000 (7,000) 76,000
Other debt securities 67,000 (18,000) 49,000
$300,000 $11,000 $(41,000) $270,000
December 31, 19X4
Gross Gross
Amortized Unrealized Unrealized Approximate
Cost Gains (Losses) Fair Value
U.S. Treasury obligations $103,000 $ $(10,000) $ 93,000
U.S. Government agency
obligations 27,000 2,000 29,000
$130,000 $2,000 $(10,000) $122,000
Maturities of held-to-maturity securities at December 31, 19X5, are as follows:
Amortized Approximate
Cost Fair Value
One year or less $131,000 $126,000
After one through five years 31,000 29,000
After five through ten years 68,000 62,000
After ten years 70,000 53,000
$300,000 $270,000
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4. Long-Term Debt
Long-term debt at December 31, 19X5 and 19X4, was as follows:
19X5 19X4
9.5 percent bonds payable to the City 
of Abacus, maturing $50,000 annually 
through November 1, 19YY, with a 
final maturity of $1 million on
November 1, 19YY $1,750,000 $1,800,000
Less current maturities 50,000 50,000
$1,700,000 $1,750,000
The notes are collateralized by a first-mortgage lien on all property and equipment of the 
Company and a security interest in all of its receipts. The note indenture requires the maintenance 
of certain deposits with a trustee, which are included in assets limited as to use.
Future maturities of long-term debt as of December 31, 19X5, follow:
Year ending December 31, Amount
19X6 $ 50,000
19X7 50,000
19X8 50,000
19X9 50,000
19Y0 50,000
Thereafter 1,500,000
Total $1,750,000
Income Taxes
The provisions for income taxes are as follows:
19X5 19X4
Current:
Federal $72,000 $15,000
State 2,000
Total current 74,000 15,000
Deferred:
Federal 6,000 13,000
State 1,000
Total deferred 6,000 14,000
Total provision for income taxes $80,000 $29,000
Deferred income taxes are provided for the temporary differences between the financial report­
ing basis and the tax basis of the Company's assets and liabilities.
For the years ended December 31, 19X5 and 19X4, the effective tax rate approximated the 
statutory rate of 34 percent and 40 percent, respectively.
The net current and noncurrent components of deferred income taxes recognized in the balance 
sheet at December 31,19X5 and 19X4, follows:
19X5 19X4
Net current assets $12,000 $14,000
Net noncurrent liabilities 6,000 14,000
$ 6,000 $____ 0
Management has determined that no valuation allowance related to deferred tax assets is 
necessary at December 31, 19X5 and 19X4, respectively.
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6. Concentration in State Medicaid Program
The Company has 100 of its 128 beds designated for care of patients under the state's Medicaid 
program. The current funding of that program is 90 days behind filed claims. The current state 
budget has no provision for reducing that lag and, while the proposed budget for 19X6 includes 
additional funding, there is no assurance that the final budget will include the needed additional 
funds.
7. Risks and Uncertainties Disclosures*
8. Pension and Other Postretirement Benefit Plans*
9. Fair Values of Financial Instruments*
10. Concentrations of Credit Risk*
* The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS 
FOR A CONTINUING CARE RETIREMENT COMMUNITY
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Sample Not-for-Profit Continuing Care Retirement Community 
Balance Sheets
December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Assets
Current assets:
Cash $ 375,000 $ 330,000
Assets limited as to use 265,000 170,000
Accounts receivable, net of allowance for 
doubtful accounts of $4,000 in 19X5 and
$5,000 in 19X4 187,000 197,000
Supplies 40,000 21,000
Prepaid expenses 115,000 73,000
Total current assets 982,000 791,000
Assets limited as to use, net of amount required
for current liabilities 1,865,000 1,583,000
Property and equipment, net 14,893,000 15,280,000
Deferred financing costs, net of accumulated 
amortization of $28,000 in 19X5 and
$21,000 in 19X4 83,000 90,000
Total assets $17,823,000 $17,744,000
Liabilities and Net Assets
Liabilities:
Current maturities of long-term debt $ 90,000 $ 77,000
Accounts payable 180,000 174,000
Accrued expenses 161,000 178,000
Deposits on unoccupied units 22,000 40,000
Total current liabilities 453,000 469,000
Long-term debt, less current maturities 8,871,000 8,935,000
Refundable fees 59,000 144,000
Estimated obligation to provide future 
services, in excess of amounts received
or to be received 88,000 100,000
Deferred revenue from advance fees 6,304,000 6,585,000
Total liabilities 15,775,000 16,233,000
Net assets:
Unrestricted 1,286,000 833,000
Temporarily restricted 311,000 294,000
Permanently restricted 451,000 384,000
Total net assets 2,048,000 1,511,000
Total liabilities and net assets $17,823,000 $17,744,000
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Sample Not-for-Profit Continuing Care Retirement Community
Statements of Operations
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Revenue, gains, and other support:
Resident services, including amortization
of advance fees of $935,000 in 19X5 
and $915,000 in 19X4 $3,946,000 $3,152,000
Patient revenue from nonresidents 249,000 275,000
Change in obligation to provide future services 12,000 (82,000)
Contributions 54,000 39,000
Net assets released from restrictions used for 
operations 24,000 50,000
Investment income 29,000 30,000
Other 75,000 68,000
Total revenue, gains, and other support 4,389,000 3,532,000
Expenses:
Salaries and benefits 1,708,000 1,250,000
Medical supplies and drugs 543,000 742,000
Insurance 291,000 311,000
Depreciation 452,000 447,000
Interest 967,000 955,000
Total expenses 3,961,000 3,705,000
Operating income (loss) 428,000 (173,000)
Net assets released from restriction— 
purchase of equipment 25,000 45,000
Increase (decrease) in unrestricted net assets $ 453,000 $ (128,000)
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Sample Not-for-Profit Continuing Care Retirement Community
Statements of Changes in Net Assets
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Unrestricted net assets:
Operating income (loss) $ 428,000 $ (173,000)
Net assets released from restriction—
purchase of equipment 25,000 45,000
Increase (decrease) in unrestricted net assets 453,000 (128,000)
Temporarily restricted net assets:
Contributions 40,000 15,000
Net assets released from restrictions used
for operations (24,000) (50,000)
Net assets released from restriction—
purchase of equipment (25,000) (45,000)
Investment income 26,000 15,000
Increase (decrease) in temporarily restricted
net assets 17,000 (65,000)
Permanently restricted net assets:
Contributions 67,000 52,000
Increase in permanently restricted net assets 67,000 52,000
Increase (decrease) in net assets 537,000 (141,000)
Net assets, beginning of year 1,511,000 1,652,000
Net assets, end of year $2,048,000 $1,511,000
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Sample Not-for-Profit Continuing Care Retirement Community
Statements of Cash Flows
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Cash flows from operating activities:
Cash received from residents and
third-party payors $3,252,000 $2,341,000
Advance fees received 654,000 857,000
Other receipts from operations 75,000 68,000
Investment income received 68,000 53,000
Contributions received 51,000 44,000
Cash paid to employees and suppliers (2,576,000) (2,040,000)
Interest paid (950,000) (945,000)
Net cash provided by operating activities 574,000 378,000
Cash flows from investing activities:
Purchase of property and equipment (65,000) (250,000)
Purchase of assets limited as to use (377,000) 229,000
Net cash used in investing activities (442,000) (21,000)
Cash flows from financing activities:
Permanently restricted funds received 67,000 52,000
Refunds of deposits and refundable fees (103,000) (52,000)
Proceeds from issuance of long-term debt 
Principal payments of long-term debt
26,000
(77,000) (307,000)
Net cash used in financing activities (87,000) (307,000)
Net increase in cash 45,000 50,000
Cash, beginning of year 330,000 280,000
Cash, end of year $ 375,000 $ 330,000
Reconciliation of change in net assets to 
net cash provided by operating activities:
Change in net assets $ 537,000 $ (141,000)
Adjustments to reconcile change in net assets 
to net cash provided by operating activities:
Advance fees received 654,000 857,000
Restricted net assets received (67,000) (52,000)
Amortization of advance fees (935,000) (915,000)
Loss (gain) on obligation to provide 
future services (12,000) 82,000
Depreciation 452,000 447,000
Amortization of deferred financing costs 7,000 34,000
Provision for bad debts 3,000 3,000
(Increase) decrease in:
Accounts receivable 7,000 (33,000)
Other assets (61,000) (4,000)
Increase (decrease) in:
Accounts payable and accrued expenses (11,000) 100,000
Net cash provided by operating 
activities $ 574,000 $ 378,000
115
.16
Sample Not-for-Profit Continuing Care Retirement Community
Notes to Financial Statements
December 31, 19X5 and 19X4
1. Description of Organization and Summary of Significant Accounting Policies1
1 Does not include all disclosures common to all health care entities.
Organization. The Sample Continuing Care Retirement Community (the CCRC) is a nonprofit 
organization that principally provides housing, health care, and other related services to residents 
through the operation of a retirement facility containing 249 apartments and a 78-bed health care 
facility located in Evergreen Park, Illinois. The CCRC was incorporated in Illinois in 19X1. A 
summary of significant accounting policies follows.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value 
in the balance sheet. Investment income (including realized gains and losses on investments, 
interest, and dividends) is included in operating income (loss) unless restricted by donor or law. 
Unrealized gains and losses on investments, if any, are excluded from operating income (loss).
Deferred financing costs. Deferred financing costs are amortized using the effective interest 
method over the term of the related financing agreement.
Advance fees. Fees paid by a resident upon entering into a continuing care contract, net of the 
portion thereof that is refundable to the resident, are recorded as deferred revenue and are 
amortized to income using the straight-line method over the estimated remaining life expectancy 
of the resident.
Obligation to provide future services. The CCRC annually calculates the present value of the net 
cost of future services and the use of facilities to be provided to current residents and compares 
that amount with the balance of deferred revenue from advance fees. If the present value of the 
net cost of future services and the use of facilities exceeds the deferred revenue from advance fees, 
a liability is recorded (obligation to provide future services and use of facilities) with the 
corresponding charge to income. The obligation is discounted at 9 percent, based on the expected 
long-term rate of return on government obligations.
Donor restrictions. The CCRC reports gifts of cash and other assets as restricted support if they 
are received with donor stipulations that limit the use of the donated assets. When a donor 
restriction expires (that is, when a stipulated time restriction ends or a purpose restriction is 
accomplished), temporarily restricted net assets are reclassified as unrestricted net assets and 
reported in the statement of operations as net assets released from restrictions. Donor-restricted 
contributions whose restrictions are met within the same year as received are reflected as 
unrestricted contributions in the accompanying financial statements.
The CCRC reports gifts of property and equipment (or other long-lived assets) as unrestricted 
support unless explicit donor stipulations specify how the donated assets must be used. Gifts of 
long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of 
cash or other assets that must be used to acquire long-lived assets are reported as restricted 
support. Absent explicit donor stipulations about how long those long-lived assets must be 
maintained, the CCRC reports expirations of donor restrictions when the donated or acquired 
long-lived assets are placed in service.
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Income taxes. The CCRC has been recognized by the Internal Revenue Service as a not-for-profit 
corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from 
federal income taxes pursuant to Sec. 501(a) of the IRC.
Property and equipment. Property and equipment are stated at cost. Donated property is re­
corded at its estimated fair value at the date of receipt. Depreciation is computed on the 
straight-line method based on the following estimated useful lives:
Land improvements 20 years
Buildings and improvements 40 years
Furniture and equipment 5-15 years
Operating income (loss). The statement of operations includes operating income (loss). Changes in 
unrestricted net assets which are excluded from operating income (loss), consistent with industry 
practice, include unrealized gains and losses on investments other than trading securities, 
permanent transfers of assets to and from affiliates for other than goods and services, and 
contributions of long-lived assets (including assets acquired using contributions which by donor 
restriction were to be used for the purposes of acquiring such assets).
2. Property and Equipment
A summary of property and equipment at December 31, 19X5 and 19X4, follows:
16,087,000 16,022,000
19X5 19X4
Land $ 557,000 $ 557,000
Land improvements 205,000 203,000
Buildings and improvements 14,573,000 14,564,000
Furniture and equipment 752,000 698,000
Less: accumulated depreciation (1,194,000) (742,000)
$14,893,000 $15,280,000
3. Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
Purchase of equipment
Charity care
19X5
$169,000
142,000
$311,000
29X4
$152,000
142,000
$294,000
Net assets were released from donor restrictions by incurring expenses satisfying the restricted
purposes or by occurrence of other events specified by donors:
29X5 29X4
Charity care $24,000 $50,000
Purchase of equipment $25,000 $45,000
4. Permanently Restricted Net Assets
Permanently restricted net assets are restricted to investment in perpetuity, the income from
which is expendable to support:
29X5 19X4
Charity care $168,000 $168,000
Community activities 283,000 216,000
$451,000 $384,000
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5. Long-Term Debt
Long-term debt at December 31, 19X5 and 19X4, is as follows:
19X5 19X4
10.75 percent mortgage note payable 
Notes payable to bank—unsecured
Other
$8,901,000
34,000
26,000
$8,965,000
14,000
33,000
Less current maturities
8,961,000
90,000
9,012,000
77,000
$8,871,000 $8,935,000
The mortgage note is payable in consecutive monthly installments of principal and interest of 
$85,425 to May 20XX. The note is collateralized by a first mortgage on property and equipment with 
a depreciated cost at December 31, 19X5, of $14,893,000 and by a pledge of all operating revenue.
As required by the mortgage note agreement, the CCRC established an initial debt service 
reserve fund of $1,000,000 at April 15, 19X3. All resident fees received thereafter, net of resident 
fee refunds and debt service payments not to exceed $300,000 annually in the first four years and 
$200,000 annually thereafter, are to be added to the debt service reserve fund until the total sum 
of $2,050,000 is accumulated. Since June 1, 19X4, the CCRC has been required to deliver to the 
trustee $5,500 per month to establish maintenance reserves until the aggregate of such payments 
equals a residential unit reserve and a health care center reserve of $240,000 and $90,000, 
respectively. At December 31, 19X5 and 19X4, the trustee held investments aggregating $2,130,000 
and $1,753,000, respectively. Such amount has been classified as assets limited as to use.
Scheduled annual principal maturities of long-term debt for the next five years are as follows:
Year ending December 31, Amount
19X6 $ 90,000
19X7 90,000
19X8 95,000
19X9 105,000
20Y0 105,000
6. Classification of Expenses
Program activities 
General and administrative
19X5 19X4
3,368,000
593,000
$3,961,000
3,135,000
570,000
$3,705,000
7. Assets Limited as to Use*
8. Risks and Uncertainties Disclosures*
9. Pension and Other Postretirement Benefit Plans*
10. Fair Values of Financial Instruments*
11. Concentrations of Credit Risk*
12. Investments*
* The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A HOME HEALTH AGENCY
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Sample Not-for-Profit Home Health Agency 
Balance Sheets
December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Assets
Current assets:
Cash and cash equivalents $ 74,000 $ 41,000
Investments 147,000 137,000
Accounts receivable, net of allowance for doubtful
accounts of $61,000 in 19X5 and $30,000 in 19X4 752,000 476,000
Other receivables 27,000 22,000
Total current assets 1,000,000 676,000
Investments 100,000 100,000
Equipment:
Medical and office equipment 56,000 39,000
Vehicles 50,000 37,000
Less accumulated depreciation
106,000
(45,000)
76,000
(24,000)
Equipment, net 61,000 52,000
Deferred finance charges, net of accumulated amort­
ization of $15,000 in 19X5 and $10,000 in 19X4 20,000 25,000
Total assets $1,181,000 $853,000
Liabilities and Net Assets
Current liabilities:
Current maturities of long-term debt $ 13,000 $ 13,000
Accounts payable 40,000 21,000
Accrued payroll and vacation costs 496,000 352,000
Estimated third-party payor settlements 28,000 31,000
Advances from third-party payors 70,000 66,000
Total current liabilities 647,000 483,000
Long-term debt, less current maturities 105,000 118,000
Total liabilities 752,000 601,000
Net assets:
Unrestricted 330,000 167,000
Temporarily restricted 9,000 5,000
Permanently restricted 90,000 80,000
Total net assets 429,000 252,000
Total liabilities and net assets $1,181,000 $853,000
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FORMAT A
Sample Not-for-Profit Home Health Agency 
Statements of Operations
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Revenue, gains, and other support:
Net patient service revenue $4,042,000 $2,687,000
Contributions 5,000 22,000
Net assets released from restrictions 5,000 —
Investment income 13,000 6,000
Other revenue 27,000 32,000
Total revenue, gains, and other support 4,092,000 2,747,000
Expenses:
Salaries and benefits 2,714,000 1,835,000
Medical supplies and drugs 1,042,000 675,000
Insurance and other 90,000 83,000
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Interest 16,000 19,000
Total expenses 3,929,000 2,648,000
Excess of revenue over expenses and
change in unrestricted net assets $ 163,000 $ 99,000
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FORMAT B
Sample Not-for-Profit Home Health Agency 
Statements of Operations 
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Revenue, gains, and other support:
Net patient service revenue $4,042,000 $2,687,000
Contributions 5,000 22,000
Net assets released from restrictions 5,000 —
Other revenue 27,000 32,000
Total revenue, gains, and other support 4,079,000 2,741,000
Expenses:
Salaries and benefits 2,714,000 1,835,000
Medical supplies and drugs 1,042,000 675,000
Insurance and other 90,000 83,000
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Interest 16,000 19,000
Total expenses 3,929,000 2,648,000
Operating income 150,000 93,000
Other income:
Investment income 13,000 6,000
Excess of revenue over expenses and
change in unrestricted net assets $ 163,000 $ 99,000
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Sample Not-for-Profit Home Health Agency 
Statements of Changes in Net Assets 
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Unrestricted net assets:
Excess of revenue over expenses $163,000 $ 99,000
Increase in unrestricted net assets 163,000 99,000
Temporarily restricted net assets:
Contributions 9,000 5,000
Net assets released from restrictions (5,000) —
Increase in temporarily restricted net assets 4,000 5,000
Permanently restricted net assets:
Contributions 10,000 6,000
Increase in permanently restricted net assets 10,000 6,000
Increase in net assets 177,000 110,000
Net assets, beginning of year 252,000 142,000
Net assets, end of year $429,000 $252,000
122
.21
Sample Not-for-Profit Home Health Agency 
Statements of Cash Flows 
Years Ended December 31, 19X5 and 19X4
Cash flows from operating activities:
Cash received from patients and
third-party payors 
Other receipts from operations 
Cash paid to employees and suppliers 
Interest paid
Nonoperating revenue
Net cash provided by operating activities
Cash flows from investing activities:
Purchase of equipment 
Purchase of investments
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from contributions restricted for:
Endowment
Other financing activities:
Payment of long-term debt
Net cash provided by (used in) financing activities 
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of year 
Cash and cash equivalents, end of year
19X5 19X4
$3,721,000
22,000
(3,679,000)
(11,000)
23,000
$2,542,000
32,000
(2,541,000)
(14,000)
22,000
76,000 41,000
(30,000)
(10,000)
(19,000)
(15,000)
(40,000) (34,000)
10,000 6,000
(13,000) —
(3,000) 6,000
33,000 13,000
41,000 28,000
$ 74,000 $ 41,000
Reconciliation of change in net assets to net 
cash provided by operating activities:
Change in net assets $ 177,000 $ 110,000
Adjustments to reconcile change in net assets
to net cash provided by operating activities:
Increase in permanently restricted net assets (10,000) (6,000)
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Amortization of deferred financing charges 5,000 5,000
(Increase) decrease in:
Accounts receivable (322,000) (150,000)
Other receivables (5,000) 4,000
Increase (decrease) in:
Accounts payable, accrued payroll, and
vacation costs 163,000 38,000
Estimated third-party payor settlements 1,000 4,000
Net cash provided by operating activities $ 76,000 $ 41,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Home Health Agency 
Notes to Financial Statements 
Years Ended December 31, 19X5 and 19X4
1. Description of Organization and Summary of Significant Accounting Policies
Organization. The Sample Home Health Agency (the Agency) was incorporated in 19X0 in New 
State as a not-for-profit corporation. The Agency provides health and supportive services to 
individuals at their homes, primarily in the New State area.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value 
in the balance sheet. Investment income (including realized gains and losses on investments, 
interest and dividends) is included in excess of revenues over expenses unless restricted by donor 
or law. Unrealized gains and losses on investments, if any, are excluded from excess of revenues 
over expenses.
Equipment. Equipment is recorded at cost. Depreciation is computed using the straight-line 
method over the estimated useful lives of the assets.
Deferred financing costs. Deferred financing costs are being amortized using the effective interest 
method over the term of the related financing agreement.
Donor restrictions. The Agency reports gifts of cash and other assets as restricted support if they 
are received with donor stipulations that limit the use of the donated assets. When a donor 
restriction expires, that is, when a stipulated time restriction ends or purpose restriction is 
accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and 
reported in the statement of operations as net assets released from restrictions. When long-lived 
assets are placed in service, thus satisfying purpose restrictions, the amount is included as a 
change in net assets, restricted and unrestricted. Donor-restricted contributions whose restrictions 
are met within the same year as received are reflected as unrestricted contributions in the 
accompanying financial statements.
The Agency reports gifts of equipment (or other long-lived assets) as unrestricted support unless 
explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets 
with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets 
that must be used to acquire long-lived assets are reported as restricted support. Absent explicit 
donor stipulations about how long those long-lived assets must be maintained, the Agency 
reports expirations of donor restrictions when the donated or acquired long-lived assets are 
placed in service.
Net patient service revenue. Net patient service revenue represents the estimated net realizable 
amounts from patients, third-party payors, and others for services rendered.
Charity care. The Agency has a policy of providing charity care to patients who are unable to 
pay. Such patients are identified based on financial information obtained from the patient and 
subsequent analysis. Since the Agency does not expect payment, estimated charges for charity 
care are not included in revenue.
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Income taxes. The Agency has been recognized by the Internal Revenue Service as a not-for- 
profit corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and is exempt 
from federal income taxes on related income pursuant to Sec. 501(a) of the IRC.
Excess of revenue over expenses. The statement of operations includes excess of revenue over 
expenses. Changes in unrestricted net assets which are excluded from excess of revenue over 
expenses, consistent with industry practice, include unrealized gains and losses on investments 
other than trading securities, permanent transfers of assets to and from affiliates for other than goods 
and services, and contributions of long-lived assets (including assets acquired using contributions 
which by donor restriction were to be used for the purposes of acquiring such assets).
2. Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
Charity care
Purchase of equipment
19X5
$9,000
19X4
$5,000
$5,000
Net assets were released from donor restrictions by incurring expenses satisfying the restricted
purposes or by occurrence of other events specified by donors:
19X5 19X4
Charity care expenditures $5,000 $ —
3. Permanently Restricted Net Assets
Permanently restricted net assets are restricted in perpetuity, the income from which is expend-
able to support:
19X5 19X4
Program A activities $10,000 $ —
Any activities of the Agency 80,000 80,000
$90,000 $80,000
4. Third-Party Rate Adjustments and Revenue
Approximately 38 percent in 19X5 and 37 percent in 19X4 of net patient service revenue was 
derived under federal and state third-party reimbursement programs. These revenues are based, 
in part, on cost reimbursement principles and are subject to audit and retroactive adjustment by 
the respective third-party fiscal intermediaries. In the opinion of management, retroactive adjust­
ments, if any, would not be material to the financial position or results of operations of the Agency.
5. Internally-Designated Assets
The Board of Directors has designated investments aggregating $100,000 to be used for future major 
capital improvements. Those assets are classified in the balance sheet as long-term investments.
6. Long-Term Debt
Long-term debt at December 31, 19X5 and 19X4, is as follows:
19X5 19X4
Note payable to bank, interest at 15 percent, 
payable in monthly installments of $2,200 per 
month, including interest, collateralized by 
equipment with a depreciated cost of $42,000 $118,000 $131,000
Less current maturities 13,000 13,000
$105,000 $118,000
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Scheduled maturities of long-term debt at December 31, 19X5, are as follows:
Year ending December 31, Amount
19X6 $ 13,000
19X7 13,000
19X8 13,000
19X9 13,000
20Y0 13,000
Thereafter 53,000
Total $118,000
(The preparer of the financial statements may wish to include a brief description of the types of programs.)
Classification of Expenses
Total
Program General and 
AdministrativeA B C
Expenses incurred for the
year ended December 31,
19X5, were for:
Salaries and benefits $2,714,000 $1,363,000 $699,000 $363,000 $289,000
Medical supplies and drugs 1,042,000 511,000 246,000 285,000
Insurance and other 90,000 58,000 32,000
Provision for bad debts 46,000 16,000 30,000
Depreciation 21,000 5,000 16,000
Interest 16,000 10,000 3,000 3,000
Total expenses $3,929,000 $1,963,000 $978,000 $648,000 $340,000
Expenses incurred for the
year ended December 31,
19X4, were for:
Salaries and benefits $1,835,000 $ 915,000 $463,000 $216,000 $241,000
Medical supplies and drugs 675,000 335,000 211,000 129,000
Insurance and other 83,000 64,000 19,000
Provision for bad debts 21,000 21,000
Depreciation 15,000 6,000 9,000
Interest 19,000 12,000 5,000 2,000
Total expenses $2,648,000 $1,353,000 $679,000 $345,000 $271,000
8. Charity Care
Charity care represented approximately 3 percent and 4 percent of visits in 19X5 and 19X4, 
respectively.
9. Risks and Uncertainties Disclosures*
10. Pension and Other Postretirement Benefit Plans*
11. Fair Value of Financial Statements*
12. Concentrations of Credit Risk*
13. Investments*
* The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
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Sample Not-for-Profit Health Maintenance Organization 
Balance Sheets
June 30, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Assets
Current assets:
Cash and cash equivalents $2,937,000 $1,021,000
Premiums receivable, net of allowance for 
doubtful accounts of $36,000 in 19X5 
and $42,000 in 19X4 358,000 407,000
Other receivables 263,000 261,000
Supplies 190,000 184,000
Prepaid expenses 197,000 99,000
Total current assets 3,945,000 1,972,000
Property and equipment, net 5,756,000 5,626,000
State guaranty fund deposit 150,000 150,000
Debt issuance costs, net of accumulated 
amortization of $42,000 in 19X5 and 
$39,000 in 19X4 18,000 21,000
Total assets $9,869,000 $7,769,000
Liabilities and Net Assets
Current liabilities:
Unsecured 12 percent note payable to a bank $ — $ 44,000
Current maturities of long-term debt 241,000 109,000
Accounts payable—medical services 2,245,000 1,471,000
Other accounts payable and accrued expenses 829,000 661,000
Unearned premium revenue 141,000 202,000
Total current liabilities 3,456,000 2,487,000
Long-term debt, less current maturities 4,295,000 2,382,000
Total liabilities 7,751,000 4,869,000
Net assets—unrestricted 2,118,000 2,900,000
Total liabilities and net assets $9,869,000 $7,769,000
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Sample Not-for-Profit Health Maintenance Organization
Statements of Operations and Changes in Net Assets
Years Ended June 30, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Revenue:
Premiums earned $27,682,000 $22,500,000
Coinsurance 689,000 500,000
Interest and other income 242,000 100,000
Total revenue 28,613,000 23,100,000
Expenses:
Salaries and benefits 16,154,000 13,328,000
Medical supplies and drugs 8,507,000 5,988,000
Insurance 3,963,000 2,463,000
Provision for bad debts 19,000 20,000
Depreciation 367,000 336,000
Interest 385,000 375,000
Total expenses 29,395,000 22,510,000
Operating income (loss) (782,000) 590,000
Net assets, beginning of year 2,900,000 2,310,000
Net assets, end of year $ 2,118,000 $ 2,900,000
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Sample Not-for-Profit Health Maintenance Organization
Statements of Cash Flows
Years Ended June 30, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Cash flows from operating activities:
Cash received from premiums,
stop-loss insurance recoveries, 
and coinsurance $28,969,000 $24,410,000
Cash paid to employees and to
providers of health care services (28,405,000) (22,818,000)
Interest and other income received 230,000 90,000
Interest paid (382,000) (372,000)
Net cash provided by operating activities
Cash flows from investing activities:
412,000 1,310,000
Capital expenditures (497,000) (121,000)
Net cash used in investing activities
Cash flows from financing activities:
(497,000) (121,000)
Proceeds from long-term debt 2,300,000 —
Principal payments on long-term debt (255,000) (1,000,000)
Principal payments on note payable (44,000) —
Net cash provided by (used in)
financing activities 2,001,000 (1,000,000)
Net increase in cash and cash equivalents 1,916,000 189,000
Cash and cash equivalents, beginning of year 1,021,000 832,000
Cash and cash equivalents, end of year $ 2,937,000 $ 1,021,000
Reconciliation of change in net assets to net cash
provided by operating activities:
Change in net assets
Adjustments to reconcile change in net assets to
$ (782,000) $ 590,000
net cash provided by operating activities: 
Depreciation and amortization 370,000 339,000
Provision for bad debts 19,000 20,000
(Increase) decrease in:
Premiums receivables 30,000 64,000
Other current assets 230,000 (93,000)
Increase (decrease) in:
Accounts payable—medical services 774,000 335,000
Other accounts payable and accrued expenses (168,000) (60,000)
Unearned premium revenue (61,000) 115,000
Net cash provided by operating activities $ 412,000 $ 1,310,000
129
.25
,26
Sample Not-for-Profit Health Maintenance Organization 
Notes to Financial Statements 
June 30, 19X5 and 19X4
1. Organization
The Sample Health Maintenance Organization (the HMO) was incorporated in 19X0 in New 
State as a not-for-profit corporation for the purpose of providing comprehensive health care 
services on a prepaid basis and for the purpose of establishing and operating organized health 
maintenance and health care delivery systems.
The HMO has been determined to be a qualified health maintenance organization under Title 
XIII of the Public Health Service Act.
2. Summary of Significant Accounting Policies
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less.
Supplies. Inventories of drugs and other supplies are stated at the lower of cost (first-in, 
first-out) or market.
Property and equipment. Property and equipment are recorded at cost. Maintenance and repairs 
are charged to expense, and betterments are capitalized. Property and equipment costing approxi­
mately $700,000 was financed by health maintenance organization initial development grants 
received in 19X1 and 19X2 from the U.S. Department of Health and Human Services (HHS). This 
property will be owned by the HMO as long as the equipment and facilities are used for projects 
related to the objectives of the Public Health Service Act.
Depreciation is computed using the straight-line method over the estimated useful lives of the 
related assets as follows:
Building 40 years
Improvements 20-25 years
Data processing and laboratory
equipment and automobiles 3-7 years
Medical equipment 10 years
Office equipment 5-10 years
Amortization of debt issuance costs. Debt issuance costs are deferred and amortized using the 
effective interest method over the term of the related debt.
Health care service cost recognition. The HMO contracts with various health care providers for 
the provision of certain medical care services to its members. The HMO compensates these 
providers on a capitation basis. As part of a cost control incentive program, the HMO retains up 
to 20 percent of the capitation as a risk-sharing fund. In the event of hospital utilization in excess 
of budget, those providers bear the risk to the extent of 15 percent of the capitation fee. Operating 
expenses include all amounts incurred by the HMO under the aforementioned contracts.
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The cost of other health care services provided or contracted for is accrued in the period in which 
it is provided to a member based in part on estimates, including an accrual for medical services 
provided but not reported to the HMO.
Premiums revenue. Membership contracts are on a yearly basis subject to cancellation by the 
employer group or the HMO upon 30 days written notice. Premiums are due monthly and are 
recognized as revenue during the period in which the HMO is obligated to provide services to 
members.
Reinsurance (stop-loss insurance). Reinsurance premiums are reported as health care costs, and 
reinsurance recoveries are reported as a reduction of related health care costs.
Federal income tax. The HMO is exempt from federal income taxes under Sec. 501(c)(4) of the 
Internal Revenue Code; accordingly, no provision for federal income taxes has been made in the 
accompanying financial statements.
3. Property and Equipment
Property and equipment at June 30, 19X5 and 19X4, consists of the following:
19X5 19X4
Land $ 300,000 $ 300,000
Buildings and improvements 5,473,000 5,459,000
Furniture and equipment 1,786,000 1,303,000
7,559,000 7,062,000
Less accumulated depreciation (1,803,000) (1,436,000)
$5,756,000 $5,626,000
4. Long-Term Debt
Long-term debt is collateralized by assets with a depreciated cost of $4,943,000. A summary of 
long-term debt at June 30, 19X5 and 19X4, follows.
29X5 29X4
HHS loan, interest at 7.5 percent,
payable in monthly installments
of $50,000, including interest $2,020,000 $ 111,000
HHS loan, interest at 9.25 percent,
payable in monthly installments
of $10,000, including interest 1,658,000 1,694,000
Secured equipment loans, payable
in monthly installments of $15,000,
including interest 858,000 686,000
4,536,000 2,491,000
Less current maturities 241,000 109,000
$4,295,000 $2,382,000
Scheduled principal payments on long-term debt are as follows:
Year ending December 31, Amount
19X6 $ 241,000
19X7 259,000
19X8 280,000
19X9 800,000
20Y0 2,956,000
$4,536,000
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5. State Guarantee Fund Deposit
In August 19X4 the state in which the HMO is domiciled enacted legislation specifically 
governing HMOs. Under this legislation, the corporation is required to maintain a deposit of 
$150,000 with the director of the division of insurance of the state.
6. Employee Retirement Plan
The HMO has a contributory defined contribution retirement plan covering substantially all 
employees. Expense determined in accordance with the plan formula (4 percent to 10 percent of 
eligible covered compensation) was $354,000 and $275,000 for the years ended June 30, 19X5 and 
19X4, respectively.
7. Stop-Loss Insurance
The HMO entered into a stop-loss insurance agreement with an insurance company to limit its 
losses on individual claims. Under the terms of this agreement, the insurance company will 
reimburse the HMO approximately 25 percent of the cost of each member's annual hospital 
services, in excess of a $1,000 deductible, up to a lifetime limitation of $500,000 per member. In 
the event the HMO ceases operations, (a) plan benefits will continue for members who are 
confined in an acute care hospital on the date of insolvency until their discharge, and (b) plan 
benefits will continue for any other member until the end of the contract period for which 
premiums have been paid.
Stop-loss insurance premiums of approximately $700,000 and $500,000 are included in insurance 
expense (Note 9) in 19X5 and 19X4, respectively. Approximately $600,000 and $400,000 in stop-loss 
insurance recoveries are deducted from insurance expense in 19X5 and 19X4, respectively.
Included in other receivables is approximately $50,000 recoverable from insurers.
8. Malpractice Claims
Malpractice claims have been asserted against the HMO by various claimants. The claims are in 
various stages of processing, and some may ultimately be brought to trial. In the opinion of counsel, 
the outcome of these actions will not have a significant effect on the financial position or the operating 
income of the HMO. Incidents occurring through June 30, 19X5, may result in the assertion of 
additional claims. Other claims may be asserted arising from past services provided. Management 
believes that these claims, if asserted, would be settled within the limits of insurance coverage.
9. Classification of Expenses
19X5 19X4
Program activities 26,921,000 20,909,000
General and administrative 2,474,000
$29,395,000
1,601,000
$22,510,000
10. Risks and Uncertainties Disclosures*
11. Pension and Other Postretirement Benefit Plans*
12. Fair Value of Financial Instruments*
13. Concentrations of Credit Risk*
* The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
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FOR AN AMBULATORY CARE ORGANIZATION
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Sample Not-for-Profit Ambulatory Care, Inc. 
Balance Sheets
December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Assets
Current assets:
Cash $ 65,000 $ 76,000
Patient accounts receivable, net of allowance for 
doubtful accounts of $15,000 in 19X5 and
$5,000 in 19X4 290,000 278,000
Estimated retroactive adjustments—third-party payors 19,000 32,000
Accounts receivable—other 13,000 8,000
Supplies 21,000 18,000
Prepaid expenses and deposits 5,000 9,000
Total current assets 413,000 421,000
Property and equipment, at cost:
Land 100,000 100,000
Land improvements 322,000 322,000
Buildings 682,000 682,000
Equipment 1,390,000 1,389,000
Less accumulated depreciation
2,494,000
217,000
2,493,000
100,000
Property and equipment, net 2,277,000 2,393,000
Other assets:
Advances receivable 14,000 5,000
Total assets $2,704,000 $2,819,000
Liabilities and Net Assets
Current liabilities:
Notes payable $ 138,000 $ 144,000
Accounts payable 52,000 87,000
Accrued payroll, benefits, and taxes 33,000 22,000
Estimated retroactive adjustments—third-party payors 30,000 24,000
Financing advance from third-party payors — 1,000
Total current liabilities 253,000 278,000
Net assets—unrestricted 2,451,000 2,541,000
Total liabilities and net assets $2,704,000 $2,819,000
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Sample Not-for-Profit Ambulatory Care, Inc.
Statements of Operations and Changes in Net Assets
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Revenue and gains:
Net patient service revenue $ 860,000 $ 357,000
Other 29,000 15,000
Total revenue and gains 889,000 372,000
Expenses:
Salaries and benefits 485,000 243,000
Medical supplies and drugs 189,000 66,000
Insurance 154,000 98,000
Provision for bad debts 14,000 4,000
Depreciation 117,000 100,000
Interest 20,000 18,000
Total expenses 979,000 529,000
Operating loss (90,000) (157,000)
Net assets, beginning of year 2,541,000 2,698,000
Net assets, end of year $2,451,000 $2,541,000
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Sample Not-for-Profit Ambulatory Care, Inc. 
Statements of Cash Flows 
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Cash flows from operating activities:
Cash received from patients and third-party payors $866,000 $ 368,000
Cash received from others 21,000 6,000
Interest received 3,000 11,000
Interest paid (15,000) (16,000)
Cash paid to employees and suppliers (870,000) (432,000)
Net cash provided by (used in) operating activities 5,000 (63,000)
Cash flows from investing activities:
Purchase of equipment (1,000) (4,000)
Advances made to XYZ Affiliate (9,000) (5,000)
Net cash used in investing activities (10,000) (9,000)
Cash flows from financing activities:
Proceeds from notes payable 144,000
Payments on notes payable (6,000) —
Net cash provided by (used in) financing activities (6,000) 144,000
Net increase (decrease) in cash (11,000) 72,000
Cash, beginning of year 76,000 4,000
Cash, end of year $ 65,000 $ 76,000
Reconciliation of change in net assets 
to net cash provided by (used in) 
operating activities:
Change in net assets $(90,000) $(157,000)
Adjustments to reconcile change in net 
assets to net cash provided by (used in) 
operating activities:
Depreciation 117,000 100,000
Provision for bad debts 14,000 4,000
(Increase) decrease in:
Patient accounts receivable (12,000) (19,000)
Other current assets 1,000 (2,000)
Increase (decrease) in:
Accounts payable and accrued payroll,
benefits, and taxes (24,000) 10,000
Other current liabilities (1,000) 1,000
Net cash provided by (used in) 
operating activities $ 5,000 $ (63,000)
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Sample Not-for-Profit Ambulatory Care, Inc. 
Notes to Financial Statements 
December 31, 19X5 and 19X4
1. Description of Organization and Summary of Significant Accounting Policies
Organization. Ambulatory Care, Inc. was incorporated on September 7, 19X3, in New State, to 
operate an ambulatory care health facility to treat or prevent injury and disease, to provide funds 
or to expend funds to further the treatment or prevention of injury or disease, and to develop and 
participate in activities designed to promote the general health of the community.
Three area hospitals—ABC Hospital and Health Center, DEF Hospital, and GHI Hospital—en­
tered into a members' agreement to develop this ambulatory care center. In accordance with this 
agreement, each hospital contributed capital of $947,000 to Ambulatory Care, Inc. Ambulatory 
Care, Inc. began operations in October 19X3.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Supplies. Supplies are stated at the lower of cost (first-in, first-out) or net realizable value.
Depreciation. Depreciation of property and equipment is computed on the straight-line method 
over the estimated lives of depreciable assets.
Third-party contractual adjustments. Retroactively calculated third-party contractual adjust­
ments are accrued on an estimated basis in the period the related services are rendered. Net patient 
service revenue is adjusted as required in subsequent periods based on final settlements.
Net patient service revenue. Patient service revenue is reported at the estimated net realizable 
amounts from patients, third-party payors, and others for services rendered.
Charity care. Ambulatory Care, Inc. has a policy of providing charity care to patients who are 
unable to pay. Such patients are identified and related charges are estimated, based on financial 
information obtained from the patient and subsequent analysis. Since management does not 
expect payment for charity care, the estimated charges are excluded from revenue.
Income taxes. Ambulatory Care, Inc. has been recognized by the Internal Revenue Service as a 
not-for-profit corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and 
is exempt from federal income taxes on related income pursuant to Sec. 501(a) of the IRC.
2. Advances Receivable
In May 19X4, Ambulatory Care, Inc. entered into a five-year agreement with XYZ Affiliates 
(XYZ). Under this agreement, XYZ is to provide emergency medical services as well as charge 
and bill each patient treated at Ambulatory Care, Inc. Ambulatory Care, Inc. has guaranteed that XYZ 
will collect at least $18,000 per month during the term of this agreement. In any month in which XYZ 
does not collect the minimum guarantee, Ambulatory Care, Inc. advances funds to XYZ to cover the 
deficiency. Such advances are to be repaid to the extent XYZ's net cash collections exceed the minimum 
guarantee amount. Management estimates that the advances will be fully recovered in 19X8.
3. Related-Party Transactions
During 19X3, Ambulatory Care, Inc. entered into a contract with one of the member hospitals 
(the managing hospital) for the management of the business and affairs of Ambulatory Care, Inc.
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Under this agreement, Ambulatory Care, Inc. pays $4,000 per month to the managing hospital. 
The agreement with the managing hospital was to remain in effect through December 31, 19X5, 
but has been extended on a month-to-month basis.
In addition, during 19X4 each hospital loaned $48,000 to Ambulatory Care, Inc. in the form of 
promissory notes at an interest rate of prime rate plus 1 percent (effective rates of 10 percent and 
9 percent in 19X5 and 19X4, respectively). Of the total $144,000 liability, $48,000 is payable on 
demand after November 28, 19X5, to one member hospital, with the remaining portion ($96,000) 
payable on demand after December 8, 19X5, to the other two member hospitals. During 19X5, 
Ambulatory Care, Inc. paid $2,000 to each member hospital, thereby reducing the obligation to 
$138,000.
4. Revenue From Contracting Agencies
Ambulatory Care, Inc. participates as a provider of health care services to Blue Cross, Medicare, 
and County Indigent Plan patients. Reimbursement for covered services is based on tentative 
payment rates. Final reimbursement is determined after submission of annual cost reports and 
audits thereof by the fiscal intermediaries. Provisions for estimated reimbursement adjustments 
are reported in the financial statements in the period that the services are rendered.
5. Charity Care
Ambulatory Care, Inc. has a policy of providing charity care to indigent patients in emergency 
situations. These services, which are excluded from revenues, amounted to $27,000 and $13,000 
in 19X5 and 19X4, respectively, when measured at Ambulatory Care, Inc.'s established rates.
6. Classification of Expenses
Program
Total A B C
general ana 
Administrative
Expenses incurred for the
year ended December 31,
19X5, were for:
Salaries and benefits $485,000 $216,000 $102,000 $121,000 $46,000
Medical supplies and drugs 189,000 98,000 43,000 48,000 —
Insurance 154,000 79,000 45,000 14,000 16,000
Provision for bad debts 14,000 9,000 — 5,000 —
Depreciation 117,000 100,000 — 17,000 —
Interest 20,000 9,000 — — 11,000
Total expenses $979,000 $511,000 $190,000 $205,000 $73,000
Expenses incurred for the
year ended December 31,
19X4, were for:
Salaries and benefits $243,000 $111,000 $ 46,000 $ 57,000 $29,000
Medical supplies and drugs 66,000 31,000 15,000 20,000 —
Insurance 98,000 45,000 19,000 26,000 8,000
Provision for bad debts 4,000 — 4,000 — —
Depreciation 100,000 56,000 — 44,000 —
Interest 18,000 7,000 — — 11,000
Total expenses $529,000 $250,000 $ 84,000 $147,000 $48,000
(The preparer of the financial statements may wish to include a brief description of the types of 
programs.)
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7. Risks and Uncertainties Disclosures*
8. Pension and Other Postretirement Benefit Plans*
9. Fair Value of Financial Instruments*
10. Concentrations of Credit Risk*
The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
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Comment Letter
We welcome any comments and suggestions you have regarding this Checklist. Please send this 
completed form to: AICPA, Accounting and Auditing Publications, Harborside Financial Center, 201 
Plaza Three, Jersey City, NJ, 07311-3881. Thank you.
Checklist Title:_______________________________________________________________________________
Comments and Suggestions:
TECHNICAL HOTLINE
The AICPA Technical Hotline answers 
inquiries about specific audit or accounting problems.
Call Toll Free 
(888) 777-7077
This service is free to AICPA members.
www.aicpa.org 008761
